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A diabetes tipo 2 é um dos distúrbios metabólicos mais comuns no mundo. 
Globalmente, está previsto um aumento da sua prevalência, assim como um 
aumento do risco de desenvolver complicações associadas. Uma dessas 
complicações é a nefropatia diabética, definida pelo aumento progressivo de 
proteinúria e um declínio gradual da função renal. Aproximadamente 25% a 
30% dos indivíduos com diabetes tipo 2 desenvolvem esta complicação. No 
entanto, os mecanismos genéticos associados permanecem por esclarecer. 
Posto isto, o objetivo deste estudo é contribuir para a identificação dos 
mecanismos envolvidos no desenvolvimento e progressão desta 
complicação, através da identificação de variantes genéticas relevantes, em 
indivíduos com diabetes tipo 2 na população portuguesa. 
Para isso, os exomas de 36 portugueses com diabetes tipo 2 foram 
sequenciados na plataforma Ion Proton
TM
. Desses individuos, 19 não 
apresentavam nefropatia diabética, tendo sido incluídos no grupo de 
controlo, e os restantes 17 individuos, com a complicação diagnosticada, 
formaram o grupo dos casos. Uma análise estatística foi depois realizada 
para identificar, com base nas diferenças genéticas entre os dois grupos, 
variantes comuns, assim como genes que acumulam variantes raras 
candidatas, que podem explicar o risco acrescido ou diminuído para 
desenvolver a complicação.  
Na pesquisa das variantes comuns, as variantes rs1051303 e o rs1131620 no 
gene LTBP4, a variante rs660339 no UCP2, a variante rs2589156 no gene 
RPTOR, a variante rs2304483 no SLC12A3 e, por fim, a variante 
rs10169718 presente no gene ARPC2, foram, de todas aquelas consideradas 
estatisticamente significativas (p-value ≤ 0,05), as mais relevantes para a 
patogénese da nefropatia diabética. O rs1051303 e o rs1131620, assim como 
o rs660339 e o rs2589156, têm um efeito protetor, enquanto o rs2304483 e o 
rs10169718 foram considerados de risco, estando associados a indivíduos 
que sofrem da complicação referida. Pela abordagem utilizada para 
identificar as variantes raras, o gene STAB1, que acumula 9 variantes, e o 
gene CUX1, que acumula 2, foram, de todos os genes com significado 
estatístico (p-value ≤ 0,05), aqueles que se evidenciaram como sendo 
biologicamente relevantes. Ambos os genes foram considerados protetores, 
já que as suas variantes raras acumuladas estavam presentes 
maioritariamente nos indivíduos que não apresentam esta complicação 
renal. 
Este estudo providencia uma análise inicial das evidências genéticas 
associadas ao desenvolvimento e progressão da nefropatia diabética, 
podendo os seus reultados contribuir para uma melhor compreensão dos 
mecanismos genéticos que estão por detrás do seu surgimento.    
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Type 2 diabetes is one of the most common metabolic disorders in the 
world. Globally, the prevalence of this disorder is predicted to increase, 
along with the risk of developing diabetic related complications. One of 
those complications is diabetic nephropathy, defined by a progressive 
increase in proteinuria and a gradual decline in renal function. 
Approximately 25% to 30% of type 2 diabetic individuals develop this 
complication. However, its underlying genetic mechanisms remain unclear. 
Thus, the aim of this study is to contribute to the discovery of the genetic 
mechanisms involved in the development and progression of diabetic 
nephropathy, through the identification of relevant genetic variants in 
Portuguese type 2 diabetic individuals.  
The exomes of 36 Portuguese type 2 diabetic individuals were sequenced on 
the Ion Proton
TM
 Sequencer. From those individuals, 19 did not present 
diabetic nephropathy, being included in the control group, while the 17 
individuals that presented the diabetic complication formed the case group. 
A statistical analysis was then performed to identify candidate common 
genetic variants, as well as genes accumulating rare variants that could be 
associated with diabetic nephropathy.    
From the search for common variants in the study population, the 
statistically significant (p-value ≤ 0.05) variants rs1051303 and rs1131620 
in the LTBP4 gene, rs660339 in UCP2, rs2589156 in RPTOR, rs2304483 in 
the SLC12A3 gene and rs10169718 present in ARPC2, were considered as 
the most biologically relevant to the pathogenesis of diabetic nephropathy. 
The variants rs1051303 and rs1131620, as well as the variants rs660339 and 
rs2589156 were associated with protective effects in the development of the 
complication, while rs2304483 and rs10169718 were considered risk 
variants, being present in individuals with diagnosed diabetic nephropathy. 
In the rare variants approach, the genes with statistical significance (p-value 
≤ 0.05) found, the STAB1 gene, accumulating 9 rare variants, and the CUX1 
gene, accumulating 2 rare variants, were identified as the most relevant. 
Both genes were considered protective, with the accumulated rare variants 
mainly present in the group without the renal complication. 
The present study provides an initial analysis of the genetic evidence 
associated with the development and progression of diabetic nephropathy, 
and the results obtained may contribute to a deeper understanding of the 
genetic mechanisms associated with this diabetic complication.  
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1. Diabetes Mellitus 
 
Diabetes Mellitus (DM), often simply called diabetes, is a metabolic syndrome 
characterized by abnormally high blood glucose levels (hyperglycemia). The most 
common forms of diabetes are type 1 diabetes (T1D) and type 2 diabetes (T2D). T2D is the 
most prevalent form of diabetes affecting 90% of the diabetic population (1,2). Both types 
of diabetes can lead to hyperglycemia, excessive urine production, compensatory thirst and 
increased fluid intake, among others (1).  
Diabetes is diagnosed according to the World Health Organization (WHO) 1999 
recommendations (3) (Table 1). Hyperglycemia is measured by the blood glucose level 
after a minimum 8 hours fasting and 2 hours upon glucose load (75 grams (g)). The 
glucose concentration measured will determine if a person has pre-diabetes, defined as 
impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), or DM (4).   
 
Table 1. Diabetes diagnostic criteria and other categories of hyperglycemia (adapted from (4)). 
 Glucose concentration in venous plasma 
(mmol/L) 
Diabetes Mellitus 
 
Fasting ≥ 7.0 or 2 hour post-glucose load ≥ 11.1 
 
Impaired glucose tolerance 
 
Fasting (if measured) ˂ 7.0 and 2 hour post-
glucose load ≥ 7.8 and ˂ 11.1 
 
Impaired fasting glucose 
 
Fasting ≥ 6.1 and ˂ 7.0 and 2 hour post-glucose 
load (if measured) ˂ 7.8 
 
mmol/L: millimoles per liter. 
Glucose load – 75 g glucose orally 
 
1.1. Type 2 Diabetes 
 
Type 2 diabetes is one of the most common metabolic disorders in the world (5). 
Globally the prevalence of diabetes has been increasing at an alarming rate in the last 15 
years, being estimated that 381,800,000 people worldwide (8.3%) currently have this 
disorder. This number is expected to rise to 591,900,000 people, implying that there will be 
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a 55% increase in diabetes by 2035 (5). The estimates for the number of people with 
diabetes in Portugal are presented in Table 2. 
 
Table 2. Prevalence and estimated number of people with diabetes (20-79 years) for 2013 and 2035 
in Portugal (adapted from (5)).  
Prevalence 
adjusted to the 
national 
population (%) 
Prevalence 
adjusted to the 
world 
population (%) 
Diabetes cases 
(20-79 years) in 
1000s 
Mean annual 
increment 
(000s) 
Proportional 
change in number 
of people with 
diabetes from 2013 
to 2035 (%) 
 
2013 
 
2035 2013 2035 2013 2035 
9 19.5 
 
13.0 
 
15.8 9.6 9.8 1032 1233 
 
This increase in prevalence can be due to a variety of factors that influence the risk of 
developing T2D (6). As a multifactorial disease, T2D is caused by the interaction of 
genetic susceptibility and environmental factors causing hyperglycemia, the hallmark of 
T2D (Figure 1) (6,7). The main environmental factors that contribute to the development 
of this disorder are a sedentary lifestyle and increased caloric intake that are responsible for 
most of the weight excess and obesity (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of the interaction between the risk factors underlying the development of T2D 
(adapted from (9)). FFA: Free fatty acids.  
 
2. Pathophysiology of Type 2 Diabetes 
 
From a pathophysiological standpoint, T2D is characterized by increased levels of 
blood glucose due to impairment in insulin action and/or insulin secretion (10). Insulin, the 
main hormone that regulates glucose uptake from the blood into most cells, is synthesized 
in the pancreatic β-cells (1). The pancreas is an organ constituted by about 1,000,000 islets 
of Langerhans, each with approximately 1,000 β-cells. These islets are highly organized 
aggregates of β-cells (production and release of insulin), α-cells (production and release of 
glucagon), δ-cells (production and release of somatostatin) and pancreatic polypeptide (PP) 
cells (production and release of the pancreatic polypeptide) (11,12,13). The islets receive a 
rich systemic vascular supply (approximately 10% of the blood supply) through the splenic 
and superior mesenteric arteries, which allows the β-cells to sense changes in plasma 
glucose concentration and release insulin to match the metabolic demand (12,14). 
Therefore, the development of T2D is characterized by a combination of insulin 
resistance and β-cell dysfunction, which result from a complex interaction between 
predisposing genetic factors and precipitating environmental ones (9,15).  
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2.1. Genetic and environmental factors 
 
The role of the genetic component in T2D is well documented (9). The risk of 
developing this disorder increases when relatives have the disease; 15% to 25% of first-
degree relatives of T2D patients develop IGT or diabetes (16). Moreover, there is also a 
40% chance of developing T2D for those who have an affected parent (higher if it is the 
mother rather than the father) and 70% chance if both parents are diabetics (17). In 
addition, a genetic predisposition to T2D is also supported by the observation that 
differences in disease prevalence rates exist among populations, even after migration of 
entire ethnic groups to another country, and thus independent from the environmental 
influences. On the other hand, the role of the environmental factors in T2D susceptibility is 
equally well known, being the spread of the western way of life in developing countries an 
explanation for the disease epidemic explosion (9).  
Over the past few years various methods, such as linkage analysis, candidate gene 
association, genotyping for genetic markers, meta-analysis and genome-wide association 
studies (GWAS), were used to highlight the role of genetic factors in the development of 
T2D (9). More than 60 genetic variants, more specifically single nucleotide 
polymorphisms (SNPs), have been associated with this disorder (9,18,19). A list of the 
susceptibility genes associated with T2D is available in Appendix A – Table A1. However, 
some of these variants are non-coding, thus becoming a challenge to analyze their 
functional impact. It is estimated that the genetic variants identified so far only explain 
about 10% of T2D heritability (9,19,20). 
Most of the variants identified so far are directly related to insulin secretion (β-cell 
function) and not insulin action in tissues sensitive to insulin, suggesting that most of the 
risk associated with T2D relates to genetic defects in pancreatic β-cells (9,20). One of the 
mechanisms responsible for β-cell dysfunction and resulting insulin secretion deficiency is 
the exposure to an adverse intrauterine environment and consequent low birth weight. This 
adversity affects fetal development by modifying gene expression of both pluripotent cells, 
that are rapidly replicating, and terminally differentiated cells, which replicate poorly. 
However, whether the effects of exposure to an altered intrauterine milieu extend into 
adulthood depends on whether the cells are undergoing differentiation, proliferation and/or 
functional maturation at the time of that exposure. There are several examples where 
human exposure to an abnormal intrauterine milieu leads to abnormalities in glucose 
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homeostasis and ultimately T2D. For example, an epidemiological study from 
Hertfordshire, in the United Kingdom, found that men who were the smallest at birth (< 2.5 
kilograms (kg)) were seven times more likely to have glucose intolerance or T2D than 
those who were heaviest at birth. Moreover, a study demonstrated that perinatal nutrient 
restriction leads to silencing histone modifications in the skeletal muscle, which in turn 
directly contributes to a decrease in the expression of the SLC2A4 gene. This gene encodes 
the glucose transporter type 4 (GLUT4) and a decrease in its expression creates a 
metabolic knockdown of this important regulator of peripheral glucose transport and 
insulin resistance, contributing to the adult T2D phenotype. Therefore, maternal nutrition 
can change the stable expression of genes in the offspring potentially through epigenetic 
modifications occurring in utero. Those modifications of the genome provide a mechanism 
that allows the stable propagation of gene expression from one generation of cells to the 
next, through histone modifications and deoxyribonucleic acid (DNA) methylation (21).  
The nucleosome is composed of DNA wrapped around an octameric complex that 
consists of two molecules of each one of the four histones: H2A, H2B, H3 and H4. The N-
termini of histones can be modified by several processes, being the most common ones 
acetylation and methylation of lysine residues in this terminal of H3 and H4. Increased 
acetylation induces transcription activation, whereas decreased acetylation is usually 
associated with transcription repression. On the other hand, methylation of histones is 
related to both transcription repression and activation. The other mechanism through which 
epigenetic information is inherited is DNA methylation (21). Methylation is a key 
epigenetic feature of DNA that plays an important role in chromosomal integrity and the 
regulation of gene expression with different methylation profiles now being associated 
with several complex diseases (22). In this mechanism, a cytosine base is modified by 
DNA methyltransferase at its C5 position. In addition to targeted DNA methylation 
changes in response to external stimuli, random DNA methylation changes also occur 
during aging in several tissues and are associated with increased oxidative stress. Such 
changes in the DNA methylation patterns can affect the expression of multiple genes. An 
example of that is the methylation within the promoter of the PDX1 gene, a pancreatic 
homeobox transcription factor, induced by overexpression of a DNA methyltransferase. 
This methylation resulted in an effected gene expression, demonstrating that genes 
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essential to the pancreatic β-cell development, such as the PDX1 gene, are susceptible to 
epigenetic modifications (21). 
Exposure to oxidative stress can directly mediate both DNA methylation and chromatin 
remodeling in multiple diseases and thus could be suggested as a mechanism by which 
aberrant epigenetic programming leads to T2D (21). Furthermore, there is growing 
evidence that suggests that DNA methylation differences are associated with complex 
diseases and that understanding the role of developmental programming of genes crucial to 
the development of T2D might unveil a critical window during which epigenetic 
therapeutic agents could be used as a means to prevent the later development of the 
disease. Therefore, epigenetic modification provides a dynamic link between each 
individual’s genetic background and relevant environmental exposures, ultimately 
affecting the expression of key genes linked to the development of T2D, including genes 
critical for pancreatic development, β-cell function, peripheral glucose uptake and insulin 
resistance (21,22).  
Genetic variants present in other genes were also associated with impaired insulin 
secretion. For instance, in the TCF7L2 gene, a transcription factor, and in the CDKAL1 
gene, a cyclin-dependent kinase 5 (CDK5) regulatory subunit, genetic variants were 
associated with reduced fasting insulin, which indicates β-cell dysfunction (23). Other 
genes associated with increased T2D risk are KCNJ11 gene, which protein products take 
place in the formation of adenosine triphosphate (ATP)-sensitive potassium 
channel/sulfonylurea receptor of the pancreatic β-cells and the SLC2A2 gene. This latter 
gene encodes the glucose transporter type 2 (GLUT2), which is expressed in the pancreatic 
β-cells, liver and kidney, and functions as a glucose sensor to maintain glucose 
homeostasis. Furthermore, a polymorphism in the gene that encodes the insulin receptor 
substrate 1 (IRS-1) was also associated with T2D. This polymorphism causes a defect in 
the binding of the p85 subunit of the phosphatidylinositol 3-kinase (PI3K), which leads to 
a decrease in insulin secretion in response to glucose and sulfonylureas (9).  
The mechanisms responsible for impaired insulin action in tissues sensitive to insulin 
include obesity; the secretion of circulating factors by adipocytes, particularly of free fatty 
acids (FFA); mitochondrial dysfunction as a consequence of oxidative stress and 
inflammation (9). The modern lifestyle has been a major contributor for the increased 
prevalence of obesity. This factor, combined with advancing age, forms the most potent 
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risk factors for T2D (24). An increased caloric intake and a sedentary lifestyle, two 
conditions common in populations with a higher standard of living and a more westernized 
lifestyle, are responsible for most of the excess weight and obesity in the modern adult’s 
life (9). Obesity is a state of low grade inflammation and constitutes a key risk factor for 
T2D, as it desensitizes glucose recipient organs to the action of insulin (25). Therefore, 
obesity predisposes to insulin resistance, which represents the initial step in the natural 
history of T2D (9). For example, it has been calculated that a lean, insulin sensitive adult 
may need as little as 0.5 units of insulin to dispose of an oral load of 75 g of glucose over 2 
hours, while an obese, insulin resistant, glucose intolerant subject may require 45 units to 
perform the same task (11). Genetic variants in the gene associated with obesity, the FTO 
gene, appear to influence predisposition to T2D through a positive effect on body mass 
index and obesity (9). This gene is associated with higher fasting insulin, which is 
consistent with a primary defect in insulin action (9,23). Moreover, also the KLF14 and 
PPARG genes appear to have primary effects in insulin action, but, unlike the FTO gene, 
those effects are not driven by obesity (9). 
The insulin-stimulated glucose uptake in adipocytes depends mostly on the transporter 
GLUT4. The downregulation of this transporter expression in adipose tissue can be found 
in obesity and T2D, and is commonly associated with insulin resistance (Figure 2) (10).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of the GLUT4 downregulation in adipose tissue (adapted from (9)). GLUT4: 
glucose transporter type 4; INSR: insulin receptor.  
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However, given that the skeletal muscle is the major site for glucose disposal, the 
development of hyperglycemia associated with obesity and T2D, cannot be only explained 
by the decreased glucose uptake in the adipose tissue due to the downregulation of GLUT4 
in adipocytes. Therefore, the secretion of circulating factors that mediate cross-organ 
communication (“crosstalk”) by adipocytes is suggested for explaining T2D pathogenesis. 
Those factors, such as adiponectin, resistin, leptin, visfatin, retinol-binding protein 4 
(RBP4) and the cytokines, interleukin-6 (IL-6) and tumor necrosis factor α (TNFα), may 
alter insulin action (10). Furthermore, the reduced glucose uptake in adipocytes accelerates 
lipolysis and raises the level of FFA, which also contributes to the altered insulin action 
(10,26).  
Over the past few years, an increasing number of studies have linked lipid accumulation 
in the skeletal muscle to reduced insulin sensitivity in type 2 diabetic individuals (27). The 
disparity between the uptake of fatty acids and their oxidation induce the accumulation of 
triacylglycerol and fatty acid metabolites such as fatty acyl-coenzyme A (acyl-CoA), 
diacylglycerol and ceramide in the skeletal muscle. This accumulation leads to an elevation 
in circulating FFA, which inhibit insulin action via activation of serine/threonine kinases 
and phosphorylation of serine residues of the IRS-1 (1,27). The phosphorylation reduces 
tyrosine phosphorylation of IRS-1 in response to insulin, and thus signaling downstream of 
IRS-1 (10). Therefore, the increase of FFA is associated with a decrease in insulin 
signaling and glucose disposal rates (1). In addition to FFA, also the TNFα secreted by 
adipocytes, stimulates phosphorylation of the serine residues of IRS-1 (10). Furthermore, 
there is growing evidence that the oxidative capacity of the skeletal muscle, which is 
mostly dependent on mitochondrial function, is directly correlated with insulin sensitivity, 
being the impaired ability to oxidize fatty acids associated with insulin resistance. A 
reduction in the number, as well as changes in the morphology of mitochondria, has been 
observed in the skeletal muscle of type 2 diabetic patients. This suggests that excessive 
FFA could alter mitochondrial functions, leading to an increased production of reactive 
oxygen species (ROS), and consequently oxidative stress. Therefore, mitochondrial 
dysfunction is a consequence of the ROS production induced by hyperglycemia and 
increased FFA in the skeletal muscle. The full effects of that FFA excess on mitochondrial 
biogenesis and functions have not been investigated in detail. Moreover, because increased 
ROS levels can also play an important role in altered insulin secretion by the pancreas, 
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oxidative stress contributes to both insulin resistance as well as pancreatic β-cell 
dysfunction (27). The role of the recently identified T2D-associated SREBF1 gene in the 
susceptibility for this disorder is still unclear, however, it is known that this gene is 
involved in the transcriptional regulation of lipid homeostasis (9).  
The concept that obesity and elevated cytokine production results in an inflammatory 
state that can cause of insulin resistance has emerged. Inflammatory pathways can be 
initiated by both extracellular mediators or by intracellular stresses. The extracellular 
mediators include cytokines and lipids while the intracellular stresses can be endoplasmic 
reticulum (ER) stress or excess ROS production by mitochondria. The increased glucose 
metabolism can lead to a rise in the mitochondrial production of ROS. This production is 
also elevated in obesity (10). Furthermore, the adipose tissue is a major source of 
inflammation with the infiltration of macrophages as the primary source of cytokines in 
obese individuals (25). This contributes to an enhanced activation of the inflammatory 
pathways (10). The obesity-induced macrophages infiltration is represented in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Macrophage infiltration into adipose tissue induced by obesity (adapted from (28)). (A) 
adipose tissue in a lean state, most resident macrophages are M2 macrophages that contribute to 
insulin sensitivity by secreting IL-10, (B) hyperphagia and lack of exercise cause hypertrophy of 
adipocytes, which induces the secretion of MCP-1 to the circulation, leading to the recruitment of 
circulating monocytes to adipose tissues. Those monocytes differentiate into activated M1 
macrophages and secrete proinflammatory cytokines such as TNFα, IL-6 and MCP-1, therefore, 
contributing to inflammation in adipose tissue and a decrease in the adiponectin levels. That results 
in insulin resistance. IL-6: interleukin-6; IL-10: interleukin-10; MCP-1: monocyte chemotactic 
protein-1; TNFα: tumor necrosis factor α. 
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Therefore, both the adipose tissue and the macrophages within that tissue serve in both 
endocrine and paracrine fashion to promote inflammation and decrease insulin sensitivity. 
The inhibition of signaling downstream of IRS-1 is thought to be the primary mechanism 
through which this inflammatory state causes insulin resistance (10). 
A better understanding of the genetics in the T2D pathophysiology will allow the 
translation of the genetic information to the clinical practice, and the identification of new 
opportunities for treatment, diagnosis and monitoring. However, the information available 
so far does not provide sufficient evidence to support the use of genetic screening for the 
prediction of T2D (18,20). 
 
2.2. Insulin resistance and β-cell dysfunction 
 
Functionally, β-cells are the most important endocrine cells, having as the main product 
the hormone insulin (11). The biosynthesis of this hormone is controlled by multiple 
factors, being glucose metabolism the main one (14). Pancreatic β-cells are electrically 
excitable and use changes in the membrane potential to stimulate or inhibit insulin 
secretion (12). The objective of this β-cell electrical activity is to elevate the intracellular 
concentration of calcium ([Ca
2+
]i) promoting exocytosis of insulin granules by merging to 
the plasma membranes and releasing insulin (12,14). After a meal, elevated glucose levels 
trigger a signaling cascade in the pancreatic islet β-cells to release insulin. This process 
was described as an 8 step process (Figure 4) (29). 
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Figure 4. Glucose stimulated insulin release from the pancreatic β-cells (taken from (29)). ADP: 
adenosine diphosphate; ATP: adenosine triphosphate; Ca
2+
: calcium ion; [Ca
2+
]i: intracellular 
calcium concentration; GLUT2: glucose transporter type 2; KATP: adenosine triphosphate-
dependent potassium channels; PM: plasma membrane; SNAP 23/25: synaptosomal-associated 
protein 23/25 kilodalton; VAMP2: vesicle-associated membrane protein 2; VDCC: voltage-
dependent calcium channels. 
 
Glucose-stimulated insulin secretion from the β-cells is mediated by the soluble N-
ethylmaleimide-sensitive factor activating protein receptor (SNARE) complex proteins, 
syntaxin 1 and 4, synaptosomal-associated protein 23 kilodaltons (kDa) (SNAP23) and 
synaptosomal-associated protein 25 kDa (SNAP25) and lastly, vesicle-associated 
membrane protein 2 (VAMP2). In step 1, glucose entries β-cells through the constitutively 
active plasma membrane (PM) localized GLUT2 transporter. Following, the glucose 
suffers phosphorylation by glucokinase to generate glucose-6-phosphate. This latter is 
subsequently metabolized via mitochondrial oxidative phosphorylation. This 
metabolization increases the intracellular ATP: adenosine diphosphate (ADP) ratio (step 
2). Elevated β-cell ATP levels induce closure of the ATP-dependent potassium channels 
(KATP) (step 3). This closure results in PM depolarization (step 4) and an influx of calcium 
ions (Ca
2+
) through the voltage-dependent calcium channels (VDCC) (step 5) to yield a 
raise in [Ca
2+
]i (step 6). The increase in [Ca2+]i signals SNARE complex formation (step 
7) which, through a largely uncharacterized series of events, mediate vesicle fusion to 
facilitate insulin release from the granules (step 8). The precise mechanism by which Ca
2+
 
triggers granule fusion remains unclear (29).   
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In a normal situation, insulin secretion from the β-cells occurs in a pulsatile fashion in 
synchronization with Ca
2+
 influxes (29). This secretion possesses a biphasic pattern with a 
momentary first phase (about 10 minutes) and a sustained second one (14). The first phase 
occurs within 5-10 minutes following β-cell stimulation, which happens after a spike in 
blood glucose concentration (for example after a meal). These cells are stimulated to 
release insulin in large bursts (ultradian oscillations) to maximize the efficiency of glucose 
clearance to the target tissues and suppress the endogenous glucose production, which 
occurs primarily in the liver (15,29,30). In the second phase, insulin is released every 11 to 
14 minutes to keep a normal regulation of endogenous glucose production (31). This phase 
is less robust than the first phase, but can be sustained for several hours if elevated blood 
glucose levels persist. These phases of secretion are thought to use separate pools of 
insulin-containing granules. The insulin secreted in the first phase appears to arise from 
PM pre-docked granules, termed the readily releasable pool (RRP), while the insulin 
secreted in the second phase is believed to involve release from a granule pool deeper 
within the cell, the storage-granule pool. This latter pool presumably replenishes the RRP. 
In addition to this, the insulin release phases also differ in their required SNARE complex 
proteins. The first phase insulin release uses syntaxin 1A, syntaxin 4, SNAP25 or SNAP23, 
and VAMP2, whereas secretion in the second phase involves syntaxin 4, SNAP25 or 
SNAP23, and VAMP2, but specifically not syntaxin 1A (29). Usually after the blood 
glucose level lowers, the secretion of insulin also diminishes, and glucagon is released to 
stimulate the conversion of the stored glycogen into glucose. The release of glucagon 
usually happens after a fasting period (1). 
The plasma insulin concentrations are dependent on insulin secretion from the 
pancreatic β-cells and hepatic and renal clearance, and can be influenced by several factors 
such as size and composition of meals and changes in insulin sensitivity of the target 
tissue. Whole-body insulin clearance occurs mostly through hepatic degradation since the 
kidneys only contribute with about 20% of the clearance. This process is regulated by the 
insulin concentration through a saturable process (11).  
In general, insulin resistance is defined as impaired insulin-mediated glucose clearance 
into target tissues, especially the skeletal muscle (15). As insulin resistance emerges, there 
is a failure of adequate insulin-mediated glucose clearance from the skeletal muscle 
combined with a reduction in the suppression of hepatic glucose production, which leads to 
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hyperglycemia (32). Besides this, renal and hepatic failures lead to a reduced organ 
clearance of insulin, also contributing to the hyperglycemia caused by insulin resistance. 
Furthermore, this hyperglycemia is also responsible for an increase in insulin secretion 
from the β-cells as a compensatory response, which ultimately causes hyperinsulinemia 
(11,32). Hyperinsulinemia occurs at an early stage of pancreatic β-cell dysfunction, 
followed by β-cell failure (33).  
The main theories associated with β-cell failure involve the exposure of β-cells to 
glucose (glucotoxicity) and FFA (lipotoxicity). Although the mechanisms are not fully 
understood, it is known that chronic exposure to glucose leads to an increase in cytosolic 
Ca
2+
 that induce β-cell destruction and a long exposure of the islets to FFA leads to a 
decrease in insulin secretion. Moreover, the IRS-1 and insulin receptor substrate 2 (IRS-2) 
are important to β-cell function and survival, being the insulin receptor signaling cascade 
crucial for regulation of islets cell differentiation and function (14,34).  
One of the major defects that can be observed in β-cell failure and that impairs insulin 
secretion is the disruption of the pulsatile patterns of insulin release in the early course of 
the disease (31). This, in combination with the loss of insulin secretion burst after an acute 
rise in glucose concentration, causes glucose intolerance (32). Defects in proinsulin 
processing at the β-cell/islet level were also found, although the underlying mechanism is 
yet unidentified (35). Another change that some but not all studies report is the decrease in 
β-cell relative mass. The underlying mechanism for this reduction has been suggested as 
increased β-cell apoptosis since it is the only mechanism altered and both new islet 
formation and β-cell replication are normal in individuals with T2D. It has been found that 
there is a 35% to 39% decrease in β-cell mass in T2D patients compared to non-diabetic 
individuals (35,36). Although there are many proposed mechanisms for β-cell dysfunction, 
none of them is widely accepted. What is already known is that β-cell dysfunction causes a 
rise in the blood glucose levels, leading to impaired glucose tolerance and/or impaired 
fasting glucose, and consequently T2D (37).  
The relationship between insulin resistance and β-cell dysfunction is relevant due to the 
feedback that links them both. Insulin resistance signals back to the pancreatic β-cells to 
increase the insulin output to maintain normal glucose tolerance (11). Currently, it is 
considered that T2D is a dual defect disease (38).  
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3. Complications associated with Type 2 Diabetes 
 
Due to the slow onset of symptoms in T2D, the condition can remain undetected for 
several years. During that time, increased levels of untreated blood glucose can cause the 
development of irreversible complications (39). These complications appear due to injuries 
in the vasculature, being classified as either microvascular (nephropathy, retinopathy and 
neuropathy) or macrovascular (development of atherosclerosis that affects vital organs 
such as the heart and brain, causing cardiovascular and cerebrovascular disease) 
(39,40,41). Both injuries cause elevated disability and healthcare costs and are responsible 
for most of the morbidity and mortality associated with diabetes (24). 
Currently, even though it is known that hyperglycemia induces damage to the particular 
cell subtypes, such as the mesangial cells in the renal glomerulus, the capillary endothelial 
cells in the retina and the neurons and Schwann cells in the peripheral nerves, little is 
known about the mechanisms underlying these damages (24,40). The activation of key 
metabolic and hemodynamic pathways by hyperglycemia can lead to the development of 
diabetic complications since each of those pathways can generate toxic and reactive 
metabolites that can then alter several key signaling intracellular pathways. Thus, several 
hypotheses for the responsible mechanisms have been proposed (summarized in Figure 5) 
(40).   
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Overview of the metabolic pathways involved in the pathogenesis of complications 
associated with T2D (adapted from (40)). AGE: advanced glycation end-product; DAG: 
diacylglycerol; PKC: protein kinase C; ROS: reactive oxygen species.   
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The main hypothesis considers the increased flux to the aldose reductase (AR) or polyol 
pathways due to elevated intracellular glucose concentration. The activation of AR (highly 
expressed in the lens compared to other tissues) and polyol pathways increase nicotinamide 
adenine dinucleotide phosphate (NADPH) consumption and decrease the production of 
glutathione (GSH). This latter is an important antioxidant mechanism in the cell, leaving 
the cells with an increased susceptibility to oxidative stress (40). Other mechanisms 
involved are the increased advanced glycation end-products (AGEs) formation; the 
overproduction of ROS by both enzymatic and non-enzymatic processes, being its major 
source the mitochondria and the NADPH oxidase complex; the increased hexosamine 
pathway flux and activation of protein kinase C (PKC) pathway (40,42). The increase in 
oxidative stress that leads to the overproduction of ROS also increases superoxide and 
reduce nitric oxide levels. The excess of superoxide during oxidative stress partially cause 
an increase in diacylglycerol (DAG), an activator of the PKC pathway, and methylglyoxal 
(MG), the main intracellular AGE precursor. The activation of the PKC pathway causes 
changes in the blood flow and increases the vascular permeability, ultimately causing 
vascular damage in the kidney, nerves and retina (40).  
 
4. Diabetic Nephropathy 
 
Approximately 25% to 30% of patients with T2D develop diabetic nephropathy, being 
this prevalence predicted to increase in the decades ahead (43,44). The kidneys regulate 
electrolyte, water and acid-base balance, being, therefore, indispensable for the 
maintenance of body homeostasis. These functions are carried out by the collective action 
of approximately 1,000,000 nephrons in each kidney, each consisting of a glomerulus and 
a system of renal tubules. The glomerulus is responsible for the filtration process while the 
tubular system regulates selective reabsorption and secretion, dictating the final 
composition of urine. Normally, the kidneys ensure almost protein-free and ultra-filtrated 
urine, however, in disease conditions, a variety of plasma proteins get excreted in the urine 
(45). The structure of the nephron is represented in Figure 6. 
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Figure 6. Kidney nephron structure (adapted from (46)). 
 
Diabetic nephropathy is defined by a progressive increase in proteinuria (˃ 500 
milligrams (mg)/24 hours), the leakage of valuable plasma proteins, mainly albumin, into 
the urine, and a gradual decline in renal function, being the leading cause of chronic kidney 
disease and end-stage renal disease (ESRD) (43,47,48,49). Diabetic nephropathy has been 
categorized into two different phases, microalbuminuria and macroalbuminuria, based on 
the values of urinary albumin excretion (UAE) (47). The UAE values are also used to 
make the clinical diagnosis of diabetic nephropathy instead of an invasive renal biopsy 
(50). When a patient has microalbuminuria (30-299 mg/24 hours), it is a sign of early 
diabetic nephropathy, also called incipient diabetic nephropathy. If not treated, it can 
evolve to macroalbuminuria (˃ 300 mg/24 hours), also known as overt or clinical diabetic 
nephropathy and a sign of the complication progression (51). Besides the renal damage 
caused by this microvascular complication, diabetic nephropathy can also be associated 
with increased cardiovascular mortality. Most of the patients die due to cardiovascular 
causes before even progressing to renal failure (52,53).  
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4.1. Risk factors and disease pathophysiology 
 
The main risk factors that lead to the initiation and progression of nephropathy are 
hyperglycemia, dyslipidemia (54), systemic hypertension (55) and dietary factors such as 
the amount and source of protein (56). Besides this, other microvascular complications, 
such as diabetic retinopathy, can be a predictor for the development of diabetic 
nephropathy since both of these complications share common risk factors like the lack of a 
proper glycemic control, elevated blood pressure and dyslipidemia (54). Furthermore, 
since about 7% of T2D patients already present microalbuminuria at the time of disease 
diagnosis (47) and due to the possibility of patients with microalbuminuria developing 
macroalbuminuria, which can ultimately lead to ESRD, microalbuminuria can also be 
considered a risk factor for diabetic nephropathy progression (51,57). These risk factors 
only explain 30% to 50% of the variation in the progression of this complication, being 
thought that other factors such as genetic factors may contribute to determining 
susceptibility to diabetic nephropathy (40,50). However, it is still difficult to clearly define 
a genetic component in diabetic nephropathy, since the studies performed so far have not 
been successful in identifying genes that consistently show an association with the disease 
(49,58). 
The natural history of diabetic nephropathy is characterized by a prolonged period of 
clinical silence during which subtle renal changes emerge. For this reason, when the 
clinical diagnosis of the complication is made, significant kidney damage (structural and/or 
functional) has already developed (50,59). Structurally, kidney abnormalities include 
hypertrophy of the kidney, tubular atrophy, and, more importantly, extracellular matrix 
(ECM) accumulation and dysfunction and/or loss of podocytes, the two main changes that 
occur in diabetic nephropathy (44,48,60,61,62). Regarding functional modifications, there 
is an increase in the glomerular filtration rate (GFR) (glomerular hyperfiltration) along 
with a raise in the glomerular capillary hydraulic pressure (PGC), followed by systemic 
hypertension, a gradual decline in the GFR over the period of several years that only 
manifests when structural renal lesions become far advanced, and eventual loss of renal 
function (59,62,63,64). The different factors that play a role in the pathophysiology of 
diabetic nephropathy and lead to renal damage are presented in Figure 7. 
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Figure 7. Overview of  the hemodynamic and metabolic factors that influence the pathophysiology 
of diabetic nephropathy (adapted from (65)). Obesity and hyperglycemia alter vasoactive regulators 
of the afferent and efferent arterioles, leading to increased PGC, hyperperfusion, and hyperfiltration. 
These early renal hemodynamic changes, combined with systemic hypertension, result in 
glomerular damage, which contributes to the development and progression of diabetic nephropathy. 
Additionally, chronic hyperglycemia and dyslipidemia induce mitochondrial superoxide 
production, and consequently elevation of ROS, leading to oxidative stress. This activates several 
pathways that also lead to the development and progression of diabetic nephropathy. Collectively, 
these factors in the diabetic milieu are responsible for inducing glomerular damage, histologically 
characterized by mesangial expansion, thickening of the glomerular basement membrane and 
podocytopathy. AGE: advanced glycation end-product; Ang II: angiotensin II; ANP: atrial 
natriuretic peptide; COX: cyclooxygenase; ET-1: endothelin-1; GBM: glomerular basement 
membrane; IL-1: interleukin-1; IL-6: interleukin-6; NO: nitric oxide; PGC: glomerular capillary 
hydraulic pressure; ROS: reactive oxygen species; TGF: transforming growth factor; TNF: tumor 
necrosis factor; VEGF: vascular endothelial growth factor. 
 
The development of these renal abnormalities in diabetic nephropathy was categorized 
into a series of stages (Table 3), however, most of the time, it is difficult to document those 
different stages in a diabetic patient due to the use of confounding factors, such as systemic 
hypertension medication, which ultimately alters the natural course of diabetic 
nephropathy (62,66). 
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Table 3. Stages of diabetic nephropathy in type 2 diabetic individuals (adapted from (62,66)). 
 
Stage 
 
Stage characteristics Chronology 
 
1 – Early hyperfunction 
and hypertrophy 
 
Glomerular hyperfiltration Present at the time of diagnosis 
2 – Silent Stage 
 
Thickening of the glomerular 
basement membrane and 
mesangial matrix expansion 
 
First 5 years 
 
3 – Incipient diabetic 
nephropathy 
 
Microalbuminuria 6-15 years 
 
4 – Overt diabetic 
nephropathy 
 
Macroalbuminuria 15-25 years 
 
5 – Uremic 
 
ESRD 25-30 years 
ESRD: End-stage renal disease. 
 
These changes, both structural and functional, can be detected by direct or indirect 
methods. Directly, alterations in the kidney can be found by histological alterations in the 
renal biopsy, whether indirectly, changes can be discovered by a rise in UAE, 
modifications in the urine sediment or differences identified with imaging techniques (43).  
 
4.1.1. Extracellular matrix accumulation 
 
The mesangial cells occupy a central position in the renal glomerulus, forming the 
glomerulus central stalk (67,68). These cells generate and are embed in their own ECM, 
known only as the mesangial matrix. Along with their matrix, mesangial cells are part of a 
functional unit interacting closely with endothelial cells and podocytes, meaning that 
alterations in one type of cell can produce changes in the others (68). The mesangial cells 
resemble vascular smooth muscle cells in phenotype and responsiveness to different 
stimuli, being responsible for providing structural support for the glomerular capillary 
loops (68,69). Due to that smooth muscle similarity, these cells possess contractile 
properties (68). Therefore, they can play a role in glomerular contraction, having the ability 
to contract or relax in response to some vasoactive agents. That ability allows them to 
modify glomerular filtration locally, through modulation of the ultrafiltration coefficient 
and capillary filtration surface area, thus helping to regulate GFR (67,69). The filtration 
 21 
 
surface area can be regulated by a constriction of the capillary loops that results in the 
reduction of the capillary diameter and consequently alters the intraglomerular capillary 
flow (68,69). Besides the functions associated with its smooth muscle cell characteristics, 
mesangial cells are also capable of some other functions (67). They can generate and 
control the turnover of the mesangial matrix and serve as a source and target of growth 
factors. Therefore, mesangial cells and their matrix can be involved in the pathophysiology 
of some glomerular diseases (68).  
The composition and amount of mesangial matrix are tightly controlled in health but 
can be markedly altered during disease. An abnormal production of the cytokines 
regulating the various matrix components emanating from mesangial cells, particularly 
transforming growth factor β (TGF-β), are responsible for the mesangial matrix expansion 
as well as glomerular basement membrane thickening that are associated with diabetic 
nephropathy (68,69). The glomerular basement membrane changes are a result of the 
interplay between metabolic and hemodynamic factors in the renal microcirculation. As a 
rule, the thickening of the glomerular basement membrane occurs soon after the onset of 
T2D and gradually increases as diabetic nephropathy clinically manifests (70). The 
structure of a normal glomerulus is presented in Figure 8. 
 
   
 
 
 
 
 
 
Figure 8. Structure of the renal glomerulus (adapted from (71)). GBM: glomerular basement 
membrane. 
 
Extracellular matrix remodeling depends on the balance between the synthesis of ECM 
proteins and their degradation, a process controlled by a complex cytokine network in 
which the TGF-β has a major role (72). The main process during ECM remodeling is 
cleavage of the matrix components, which is important for regulating ECM abundance, 
composition and structure, as well as for releasing biologically active molecules, such as 
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growth factors. The ECM can be cleaved by different families of proteases, being matrix 
metalloproteinases (MMPs) the main ones. Most MMPs are secreted as zymogens and are 
subsequently activated in the extracellular space. Their activation primarily occurs via 
proteolytic cleavage, by serine proteases or other MMPs, or via the modification of the 
thiol group by oxidation, for example through ROS. Furthermore, they are produced as 
either soluble or cell membrane-anchored proteases and cleave ECM components with 
wide substrate specificities (73). On the basis of substrate specificity, sequence homology 
and domain organization, MMPs have been classified into six groups: collagenases 
(MMP1, MMP8, MMP13 and MMP18), gelatinases (MMP2 and MMP9), stromelysins 
(MMP3, MMP10 and MMP11), matrilysins (MMP7 and MMP26), membrane-type MMPs 
(MT-MMPs) (MMP14, MMP15, MMP16, MMP17, MMP24 and MMP25) and other 
MMPs (MMP12, MMP19, MMP20, MMP21, MMP23, MMP27 and MMP28), which are 
not classified in any of the other categories. Moreover, MT-MMPs can be divided into type 
I transmembrane proteins and glycosylphosphatidylinositol (GPI)-anchored proteins (74). 
Collectively, the MMPs can degrade all the ECM proteins (73).  
Under normal physiological conditions, the activity of MMPs is low, but tightly 
regulated at the level of transcription, activation of the precursor zymogens, interaction 
with specific ECM components and inhibition by endogenous inhibitors (73,74). During 
repair or remodeling processes, this activity increases. The ECM proteolysis also requires 
tight regulation to avoid excessive tissue degradation, being the activity of endogenous 
inhibitors that inactivate MMPs important for tissue integrity. The tissue inhibitor of 
metalloproteinases (TIMPs) family consists of four members (TIMP1–TIMP4) that 
reversibly inhibit the activity of MMPs. The ratios MMP:TIMP determine the overall 
proteolytic activity, and each TIMP displays preferential MMP-binding specificity (73). 
Therefore, both increased, as well as decreased MMP activity may result in dysregulated 
ECM remodeling that leads to a variety of diseases, such as cancer, atherosclerosis, 
nephritis, tissue ulcers and fibrosis (73,74). 
In a hyperglycemic state, MMP gene expression can be regulated via various 
transcription factors, such as activator protein-1 (AP-1) and nuclear factor kappa B (NF-
kB), or depending upon the tissue levels of growth factor cytokines, such as TGF-β and 
connective tissue growth factor (CTGF). In the past years, extensive investigatory efforts 
have been made to understand the role of MMPs in a variety of kidney diseases, including 
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diabetic nephropathy. However, their role in kidney pathology seems to be still very much 
confounding (75).   
In mammalians, TGF-β has three different isoforms, TGF-β1, TGF-β2 and TGF-β3, of 
which TGF-β1 is the most potent promoter of ECM accumulation (44). This isoform is 
secreted as latent complexes, which are then stored in the ECM to provide stability to its 
active form and a constant activable source (76).  
In the kidney, the mesangial cells secret TGF-β1 in a latent dimeric complex form, 
containing in the C-terminal the mature TGF-β and in its N-terminal the inactive domain 
TGF-β latency-associated peptide (LAP) (77,78). The two polypeptide chains of inactive 
TGF-β associate to form a disulfide-bonded dimer and LAP remains associated with that 
dimer by non-covalent interactions, which results in the formation of what is known as the 
small latent complex. In this small complex, LAP becomes covalently linked to one of the 
four latent TGF-β binding proteins (LTBPs), forming the large latent complex. The LTBP 
has an ECM-binding region that allows targeting into the mesangial ECM (Figure 9) (78). 
 
Figure 9. Formation of the large latent complex (adapted from (78)). LAP: latency-associated 
peptide; LTBP: latent TGF-β binding protein; TGF-β: transforming growth factor β.  
 
 This large latent complex is then subjected to proteolysis by multiple proteinases of the 
serine protease family, being released from LTBP and consequently from the mesangial 
ECM, resulting in a soluble complex localized at the podocyte surface (77,78). This 
complex is completely activated by the disruption of the non-covalent interaction between 
TGF-β and LAP, enabling this growth factor to bind its signaling receptors (78).  
The renin-angiotensin-aldosterone system (RAAS) plays an important role in diabetic 
nephropathy. Its activity is augmented in individuals where this complication is present. In 
response to hyperglycemia, angiotensin II, the active octapeptide derived from 
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angiotensinogen in the RAAS, is increased, being this response mediated, in part, by ROS 
(44,79). The overproduction of ROS can be part of a positive feedback loop responsible for 
perpetuating the RAAS activity in diabetic nephropathy. Angiotensin II contributes to ROS 
production by activating NADPH oxidase in the vascular smooth muscle cells and 
mesangial cells. At the same time, ROS activates the NF-kB, which mediates further 
angiotensinogen activation and consequently increases angiotensin II (44,77). This latter, 
along with hyperglycemia, is responsible for the ECM accumulation, mainly by 
stimulating the synthesis of ECM proteins through an enhanced TGF-β1 production in 
mesangial cells (44). TGF-β1 gene expression is stimulated through two AP-1 binding sites 
in the promoter region of the growth factor gene. These binding sites, designated box A 
and box B, regulate the promoter activity and an increased binding activity of the AP-1 
transcription factor complex components, transcription factors JunD and c-FOS, 
predominantly to the box B, results in increased TGF-β1 promoter region activity and 
consequently enhanced TGF-β1 expression (44,80,81). 
The overexpression of TGF-β1 leads to an imbalance in the ECM metabolism, since its 
action mechanisms include both increased ECM synthesis by stimulating the production of 
ECM proteins and inhibition of ECM degradation by inhibiting the synthesis of MMPs, 
stimulating the production of the MMPs inhibitors, TIMPs, and also by inhibiting the 
synthesis of collagenases, the enzymes responsible for collagen degradation 
(44,60,61,72,79). These matrix-related actions of TGF-β1 are mediated by the Smad 
proteins, a family of intracellular signal transducers that act downstream of receptors for 
the TGF-β family members (44,82). Members of the TGF-β family, which include TGF-
βs, activins and bone morphogenetic proteins (BMPs), bind to type II and type I 
serine/threonine kinase receptors (83,84). The type II receptor kinases are active and, upon 
ligand binding, the type II receptors activate type I receptor kinases through 
phosphorylation of the juxtamembrane domain. These type I receptor kinases then activate 
intracellular substrates like the Smad proteins (84). Smads can be divided into three 
subclasses, the receptor-regulated Smads (R-Smads), which are anchored to the cell 
membrane through membrane-bound proteins, including Smad-anchor for receptor 
activation (SARA), the common-partner Smads (Co-Smads), which assemble into 
heteromeric complexes with the R-Smads, and the inhibitory Smads (I-Smads), which 
function as antagonists of R-Smads and Co-Smads. The R-Smads directly interact with and 
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become phosphorylated by type I receptors, then forming complexes with Co-Smads and 
migrating into the nucleus, where they regulate the transcription of target genes by 
interacting with various DNA binding proteins or by recruitment of transcriptional co-
activators or co-repressors (Figure 10). In mammals, TGF-βs/activin-specific R-Smads, 
Smad2 and Smad3, are phosphorylated by type I receptor kinase and form a heteromeric 
complex with Smad4, the only Co-Smad in mammals. The complex is translocated into the 
nucleus, where it regulates the transcription of the target genes (83,84,85).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Signaling by TGF-β through serine/threonine kinase receptors and Smad proteins 
(adapted from (84)). Co-Smad: common-partner Smads; I-Smad: inhibitory Smads; R-I: type I 
receptor; R-II: type II receptor; R-Smad: receptor-regulated Smads.  
 
The R-Smads also include Smad1, Smad5 and Smad8, that are BMP-specific Smads 
and the Smad6 and Smad7 are I-Smads (84,85). In a similar way to the R-Smads, the I-
Smads interact with type I receptors kinases and compete with the Co-Smads for complex 
formation with the R-Smads. Smad7 is a potent inhibitor of TGF-β signaling, being its 
expression directly induced by effects of the Smad3 and Smad4 on its promoter, and the 
Smad6 preferentially inhibits BMP signaling (84). Although the main signaling pathway of 
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TGF-β is the Smad signaling pathway, activation of the p38 mitogen-activated protein 
kinases (MAPK) signaling pathway may also occur (44).  
Therefore, and due to the action mechanisms associated with TGF-β1 previously 
mentioned, the overexpression of this growth factor results in ECM accumulation in the 
renal tubulointerstitium, the mesangium and the basement membrane of the glomerulus 
due to excessive deposition of either proteins that are normally present in these structures, 
or proteins that are not present in the normal tissue, or both (Table 4) (44). 
  
Table 4. Proteins that are normally present in the mesangium and glomerular basement membrane 
and changes in the accumulation of those proteins in diabetic nephropathy (adapted from (44)).  
 Protein Normal/Diabetic Nephropathy 
M
es
a
n
g
iu
m
 
 
 
Collagen I  
 
 
Only detected in advanced glomerulosclerosis 
 
 
Collagen III  
 
 
Only detected in advanced glomerulosclerosis 
Collagen IV 
Chains α1(IV) and α2(IV) expressed in normal mesangium/ Increased 
in diabetic nephropathy 
Collagen V 
Minor component in normal mesangium/ Increased in diabetic 
nephropathy 
Collagen VI 
Present in normal mesangium/ In diabetic nephropathy has the same 
distribution as α1(IV) in normal mesangium 
 
 
Fibronectin 
 
 
Present in normal mesangium/ Increased in diabetic nephropathy 
Laminin 
Minor component in normal mesangium/ Increased in diabetic 
nephropathy 
 
SLR 
Proteoglycans* 
 
Present in normal mesangium/ Only detected in advanced 
glomerulosclerosis 
G
lo
m
er
u
la
r 
b
a
se
m
en
t 
m
em
b
ra
n
e 
Collagen IV 
Chains α3(IV) and α4(IV) present in normal glomerular basement 
membrane/ Increased in diabetic nephropathy;  
Chains α1(IV) and α2(IV) are minor components in normal glomerular 
basement membrane/ Decreased in diabetic nephropathy 
 
Entactin 
(Nidogen)  
 
Present in normal glomerular basement membrane/ Increased in 
diabetic nephropathy 
Laminin 
Present in normal glomerular basement membrane/ May be increased 
in early diabetic nephropathy followed by a decrease 
 
Heparan Sulfate 
Proteoglycan 
 
Present in normal glomerular basement membrane/ Decreased in 
diabetic nephropathy 
SLR Proteoglycans: small leucine-rich proteoglycans.  
*Includes decorin, biglycan, lumican and fibromodulin 
 
Protein deposition leads to mesangial expansion and glomerular basement membrane 
thickening, eventually leading to glomerulosclerosis and tubulointerstitial fibrosis (44). 
The comparison between a normal glomerulus and a diabetic one is presented in Figure 11. 
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Figure 11. Diabetic nephropathy associated glomerular changes (adapted from (71)). GBM: 
glomerular basement membrane.  
 
The TGF-β1 active form, localized in the podocytes, has a very short half-life in 
plasma, making it unlikely for TGF-β1 to transverse the glomerular basement membrane to 
promote mesangial expansion (77). Instead, TGF-β1 induces the production of CTGF, via 
Smad binding elements and a unique TGF-β response element in the CTGF promoter, to 
mediate TGF-β1 stimulated ECM accumulation in the mesangial cells of the mesangium 
(44,77). The mesangial expansion, due to abnormal ECM metabolism in mesangial cells, 
reduces the capillary surface area available for glomerular filtration, contributing to the 
progressive loss of renal function. This structural change in the kidney is frequently 
associated with the development of diffuse glomerulosclerosis, characterized by a 
distributed mesangial expansion, or nodular glomerulosclerosis, which happens when there 
are areas of marked mesangial expansion, forming roundish and fibrillar zones with 
palisade arrangement of the nuclei, the Kimmelstiel-Wilson nodes (58,86,87). 
Furthermore, the mesangial expansion also correlates with tubulointerstitial fibrosis, a 
disease much less well studied than glomerulosclerosis. Even though the mechanisms of 
tubulointerstitial fibrosis are not clear, it is known that progressive loss of renal function 
associates with the worsening of the fibrosis (44). The thickening of the glomerular 
basement membrane, a consequence of the excessive production of the membrane matrix 
components by the podocytes and endothelial cells, results in modifications of the charge-
selective properties of this structure, consequently contributing to proteinuria (49,87). 
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4.1.2. Dysfunction and/or loss of podocytes 
 
Some of the changes that occur in the kidney of individuals with diabetic nephropathy 
lead to proteinuria, being this event associated mainly with modifications in the glomerular 
filtration barrier (86). This barrier is highly permeable to water and small molecules but 
maintains very low permeability to macromolecules, being these characteristics dependent 
on its unique three-layer structure (88). The glomerular filtration barrier is, therefore, 
composed of the fenestrated glomerular endothelium, the glomerular basement membrane, 
and the glomerular visceral epithelial cells, widely known as podocytes (Figure 12) 
(45,86,89). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Architecture of the glomerular filtration barrier in the kidney glomerulus (taken from 
(45)). 
 
The first layer encountered in the glomerular filtration barrier starting from the 
glomerular capillary lumen, is the fenestrated glomerular endothelium (Figure 13). This 
endothelium consists of endothelial cells characterized by fenestrations, round or ovoid 
transcellular holes through the cytoplasm with 60-80 nanometers (nm) of diameter (88,90). 
Until recently, it was thought that the fenestrated endothelium contributed little to the 
selective permeability of the glomerular filtration barrier (88). However, it is now known 
that the endothelium is covered with glycocalyx, a negatively charged hydrated mesh of 
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cell-surface anchored proteoglycans, adsorbed proteins and glycosaminoglycans in 
dynamic equilibrium with the circulating plasma. The glycocalyx forms a significant 
permeability barrier, making it possible for the fenestrated endothelium to present some 
restriction to the passage of plasma proteins (86,88,90).  
Separating the fenestrated endothelium from the podocytes is the second layer of the 
glomerular filtration barrier, the glomerular basement membrane (Figure 13). This 
structure provides support for the glomerular capillaries and represents the ECM 
component of the glomerular filtration barrier. As part of this barrier, the glomerular 
basement membrane is considered to be a “crude prefilter” that functions as a size and 
charge-selective filtration barrier, since macromolecules as well as negatively charged 
molecules are impaired from crossing it. While the size-selectivity is related to the porosity 
of the membrane conferred by the laminin and collagen IV, the major components of the 
glomerular basement membrane, in concert with the remaining membrane components, the 
charge-selectivity of this structure can be attributed to agrin, the major heparin sulfate 
proteoglycan present in the membrane. Agrin has sulfated glycosaminoglycan side chains 
that confer to it a highly negative charge, being, therefore, responsible for the anionic sites 
present within the basement membrane (49,86).  
Lastly, the podocytes are the final layer of the glomerular filtration barrier, functioning 
as the ultimate size-selectivity barrier and only permitting permeability to molecules 
smaller than albumin (Figure 13) (87). They are highly specialized epithelial cells that 
cover the urinary side of the glomerular basement membrane (45). The podocytes are 
comprised of a cell body and cytoplasmic extensions called major processes, which are 
divided into actin-rich foot processes that interdigitate and cover the capillary walls of the 
glomerulus (45,91). The podocyte foot processes are a contractile system similar to that 
seen in pericytes, and, while podocyte major processes are constituted by microtubules and 
intermediate filaments, the foot processes present a complex mesh of actin filament 
bundles with a dense network of F-actin and myosin. These actin filament bundles form 
arches between the foot processes of the same podocyte, constituting the actin 
cytoskeleton. The cytoskeleton is connected to the underlying glomerular basement 
membrane via the α3β1 integrin and α- and β-dystroglycans, consequently anchoring the 
foot processes to this membrane and maintaining the podocyte integrity, a requirement for 
a fully functional glomerular filtration barrier (45,87,92,93). At the interdigitation site, the 
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foot processes from neighboring podocytes are connected to each other by an intercellular 
adherent junction, the slit diaphragm, which is located just above the glomerular basement 
membrane (48,91). The slit diaphragm consists of several proteins that, besides forming 
the protein complex that contributes to its structure, also connect the diaphragm to the actin 
cytoskeleton, which ultimately determines the structural maintenance of the slit diaphragm, 
and enable it to do its function as the structure responsible for the podocytes size-selective 
permeability (Figure 13) (45,89,93).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Protein components of the podocyte slit diaphragm (adapted from (89)). CD2AP: CD2-
associated protein; FAT1: FAT atypical cadherin 1; FAT2: FAT atypical cadherin 2; Neph1: 
nephrin-like protein 1; Neph2: nephrin-like protein 2; P-cadherin: placental cadherin; ZO-1: zonula 
occludens-1.  
 
Nephrin is a large transmembrane molecule, being its N-linked glycosylation critical for 
the plasma membrane localization of this molecule. Its predicted structure and biochemical 
properties suggest that nephrin may form dimers across the filtration slit, meaning that 
nephrin molecules from adjacent foot processes are thought to interact with one another in 
the middle of the slit diaphragm to form a central density that functions as a filtering 
 31 
 
structure, since it contains 30-40 nm wide pores, the filtration slits (77,89,93). The proteins 
nephrin-like protein 1 (Neph1) and nephrin-like protein 2 (Neph2) are structurally related 
to nephrin, forming heterodimers with it that can transduce signals from the podocyte slit 
diaphragm that lead to actin filament polymerization, and, therefore, contributing to the 
stabilization of the diaphragm (89,92). The podocin, a membrane protein from the stomatin 
family, is located solely in the slit diaphragm region and, like other stomatin family 
members, recruits its complex partners to cholesterol-enriched membrane domains in the 
slit diaphragm (lipid rafts - specialized membrane domains enriched in cholesterol, 
glycosphingolipids and GPI-anchored proteins critical for the dynamic functional 
organization of the slit diaphragm), thereby creating a cluster that can act as a unique 
signaling platform. Podocin associates via its C-terminus with nephrin and neph1, forming 
the nephrin-neph1-podocin receptor complex. This complex interacts with proteins 
associated with the actin cytoskeleton, like CD2-associated protein (CD2AP), signaling to 
regulate cytoskeleton dynamics and morphology, as well as actin remodeling (89,92,93). 
The placental cadherin (P-cadherin), as well as FAT atypical cadherin 1 (FAT1) and FAT 
atypical cadherin 2 (FAT2) proteins, are widely expressed cadherin superfamily proteins 
that provide structural support to the slit diaphragm (93). Other proteins such as CD2AP 
protein is localized at the intracellular insertion site of the slit diaphragm and interacts with 
nephrin, functioning as an adaptor that connects this protein to the actin cytoskeleton. 
While CD2AP does not appear to be necessary for podocyte development, it is essential for 
maintaining podocyte structure, since an efficient association between the slit diaphragm 
and the actin cytoskeleton is required for the stabilization of the diaphragm (89,92,93). The 
protein zonula occludens-1 (ZO-1), similarly to CD2AP, is also localized at the 
intracellular insertion site of the diaphragm and interacts with actin filaments, but its 
precise role in the protein complex is still unknown (89,93). The last protein involved with 
the actin cytoskeleton is α-actinin-4. This protein is an actin filament cross-linking protein 
that cross-links F-actin filaments in the foot processes, contributing to the normal assembly 
or disassembly of actin filaments in podocytes (45,87,89). Besides this, α-actinin-4 also 
interacts with components of the integrin complex at the glomerular basement membrane, 
more specifically the α3β1 integrin, making the connection between the foot processes and 
the glomerular basement membrane (93).  
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The glomerular filtration barrier functions as a whole, meaning that disruption of any of 
the layers affects the overall permeability of the barrier, which can result in proteinuria 
(88). The role of each component of the glomerular filtration barrier in the development of 
proteinuria in diabetic nephropathy has been subjected to much debate. The dysfunction of 
the fenestrated glomerular endothelium as well as the thickening of the glomerular 
basement membrane, which, as mentioned before, leads to the loss of its charge-selective 
properties, have been proposed to explain partly the pathogenesis of proteinuria (45). The 
glomerular basement membrane charge-selectivity is, as previously mentioned, a property 
attributed to agrin, a heparin sulfate proteoglycan, and its loss can be explained by the 
presence of hyperglycemia as well as the increase in angiotensin II. The presence of 
hyperglycemia suppresses the production of the agrin core protein while angiotensin II, in 
addition to decreasing the synthesis of the agrin core protein, also diminishes the sulfation 
of its side chains, causing it to lose its negative charge (86). However, this loss of charge-
selective only occurs late in the course of diabetic nephropathy, sometimes long after the 
development of microalbuminuria, which suggests that other glomerular filtration barrier 
components may have a more pivotal role in the pathogenesis of proteinuria in diabetic 
nephropathy (45,86). These observations along with the data collected over the past decade 
has highlighted the crucial role of podocytes in the glomerular filtration barrier, more 
specifically, the crucial role of the podocytes slit diaphragm in the filtering process, being 
the integrity of the slit diaphragm what ultimately determinates the permeability properties 
of the glomerular filtration barrier (45,86,94).  
Podocytes are old cell types, being expected that their features have been extensively 
shaped by natural selection. Their complex structure and their unique position as “floating” 
cells fixed to the glomerular basement membrane only by their foot processes are 
somehow indispensable for their function (95). In diabetic nephropathy early podocyte 
damage occurs, resulting in podocyte dysfunction, and causing the podocytes to undergo 
tremendous changes in their shape without losing its viability (86,95). The most general 
change is the loss of the interdigitating foot process pattern, usually called foot process 
effacement. This effacement is a consequence of the retraction, widening or shortening of 
the foot processes of each podocyte, being associated with the leakage of macromolecules, 
such as albumin, through the glomerular filtration barrier (87,95). The foot process 
effacement can be caused by interference with the slit diaphragm protein complex, 
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interference with the glomerular basement membrane or with its interaction with the 
podocyte or it can also be caused by abnormalities in the actin cytoskeleton, being this 
phenomenon separated into two stages (87,93,95). Within the first stage, foot processes 
undergo tremendous changes in shape, losing their regular interdigitating pattern and 
retracting into short irregularly shaped cells, causing the slit diaphragms to be lost or 
displaced from their usual position at the base of the processes. The second phase includes 
retraction of the foot processes into the primary podocyte foot processes, leading to broad 
flattened disc-like projections covering the glomerular basement membrane (95). In 
addition to this, decreased expression of some proteins associated with the slit diaphragm, 
such as nephrin, P-cadherin, and ZO-1, impairs the integrity of this structure, correlating 
with the development of foot process effacement and changes in podocyte permeability. 
Furthermore, besides a diminished expression, nephrin localization in the podocyte foot 
processes is also altered in individuals with diabetic nephropathy, which also contributes to 
the impairment of the slit diaphragm integrity and the development of foot process 
effacement (45,87). Therefore, foot process effacement is not a simple pathological 
derangement of normal podocyte architecture, but it seems to represent a regulated change 
in the podocyte that can be considered as a reestablishment of a more typical epithelial cell 
structure. The detailed mechanisms associated with this phenomenon are still poorly 
understood (95). 
In diabetic nephropathy, the number of podocytes is reduced (podocytopenia), being 
this reduction correlated with disease progression (86). Usually, podocyte reduced numbers 
reflect the imbalance between podocyte proliferation and podocyte loss (87). The 
podocytes exit the cell-cycle and remain terminally differentiated, lacking a proliferative 
mechanism in response to injury (45,87,93). Meanwhile, the exact etiology of podocyte 
loss remains unclear, but two different mechanisms can be suggested for it: apoptosis and 
detachment (86). Apoptosis is regarded as a mechanism by which podocytes are lost. 
Apoptosis of podocytes occurs under very specific conditions that can develop during 
diabetic nephropathy progression, such as the overexpression of TGF-β1 (95). This growth 
factor induces apoptosis through Smad pathways, specifically Smad7, and via p38 MAPK 
(45,77,87,93). Even though the full mechanisms are still not clear, it is known that Smad7 
is responsible for podocyte apoptosis by inhibiting the nuclear translocation and 
transcriptional activity of a survivor cell factor, the NF-kB (45,86). The podocytes unique 
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situation by being “floating” cells only connected to the glomerular basement membrane 
by their foot processes and being exposed to the flow of filtrate, makes them highly 
susceptible to detachment. In diseases where there are changes in the composition of the 
glomerular basement membrane, such as diabetic nephropathy, a weaker adhesion of 
podocytes to this membrane is expected to occur, due to both the changes in the glomerular 
basement membrane itself as well as changes in the proteins that connect these two 
structures. The main mechanism associated with the detachment process is interference 
with components of the integrin complex, more specifically with α3β1 integrin (95). The 
overexpression of the growth factor TGF-β1, in addition to inducing podocyte apoptosis, 
also contributes to a reduction in α3β1 integrin expression, the integrin responsible for 
establishing the connection between the foot processes and the glomerular basement 
membrane (77). Therefore, an impaired podocyte adhesion to the underlying glomerular 
basement membrane may result from a downregulation of α3β1 integrin (77,86). Besides 
α3β1 integrin, it is also thought that changes in dystroglycan expression contribute for 
podocyte detachment. However, those changes under diabetic conditions have not been 
fully explored yet (87). Furthermore, podocyte detachment may occur in conjunction with 
apoptosis or podocytes can detach as viable cells (86,95). As a consequence of the 
detachment, detached podocytes are present in the urinary sediment of individuals with 
kidney diseases, being the majority of those detached podocytes still viable, with a well-
formed nucleus with a normal chromatin pattern and a cytoplasm with well-preserved 
organelles. For that reason, it is thought that the majority of podocytes that go through 
detachment are still viable, and, during that process undergo changes in their shape, being 
foot process effacement frequently present. Therefore, foot process effacement appears to 
precede podocyte detachment (95). 
With the increased loss of podocytes and their limited proliferative capacity, a critical 
proportion of the podocyte population of the glomerulus is lost, being the remaining 
podocytes unable to compensate for the lost ones, resulting in an impaired glomerular 
filtration function (45,77). These factors, along with the mesangial expansion, result in the 
development of glomerulosclerosis (45,77,93). This development occurs firstly because of 
podocyte loss, since the inability to replace the lost podocytes result in a localized “bare” 
or denuded glomerular basement membrane at that site. The lack of tensile support 
normally provided by podocytes is lost in the denuded area of the basement membrane, 
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which leads to the outward bulging of the capillary loop due to capillary hydrostatic 
pressures. This expanding capillary loop causes the glomerular basement membrane to 
come into contact with the Bowman’s capsule, resulting in synechia formation (86,93). 
Finally, subendothelial hyalinosis develops in the affected capillary, and progressive 
scarring ensues (87,93).  
In addition to the effects already mentioned, the overexpression of TGF-β1 also 
stimulates the expression of vascular endothelial growth factor (VEGF) in podocytes 
(58,86). This factor acts through VEGF receptors (VEGFR)-1 to 3 and comprises isoforms 
from VEGF-A to VEGF-E, being its strong permeability properties associated with 
increasing permeability of the glomerular filtration barrier to plasma proteins (86,90). 
Podocytes not only produce this factor but are acted upon by it through the VEGFR-1. The 
VEGFA stimulates the podocyte production of the chain α3 (IV) of the collagen IV, a 
major component of the glomerular basement membrane, having, therefore, a role in the 
regulation of this membrane composition by podocytes and contributing to the thickening 
of the glomerular basement membrane (86). Furthermore, VEGF-A also moves across the 
glomerular basement membrane and connects to VEGFR-2 on the fenestrated glomerular 
endothelium, being critical for the maintenance of the endothelium, since it is a key 
inducer of its fenestrations (58,88,90). Ultimately, this factor induces endothelial nitric 
oxide production, thereby promoting the vasodilation and glomerular hyperfiltration that 
are typical of early diabetic nephropathy (58,86). 
 
4.2. Disease management and treatment 
 
Although there is no definitive cure, adequate treatment like a strict glycemic control, 
early treatment of systemic hypertension, dietary protein restriction, and lipid-lowering 
therapy can delay the progression of nephropathy (96). Patients that present this 
complication show a progressive decline in glomerular function and, the treatment of 
systemic hypertension in these individuals slows down the rate of renal function loss (97). 
The most effective way for delaying its progression is the blockade of the RAAS using 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers 
(ARBs). This treatment, in addition to interrupting the RAAS at different levels, also 
lowers the blood pressure and provides renoprotective effects, possibly because of the 
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decrease in glomerular capillary hydraulic pressure due to the removal of the 
vasoconstrictor effect of angiotensin II in the efferent arteriole (58,97,98,99). 
 
5. Genetic models of complex diseases 
 
Many human complex diseases and related traits are believed to be influenced by 
several genetic and environmental factors, but until recently, the identification of genetic 
variants that contribute to these complex diseases has been slow (100). In recent years, 
GWAS have been extensively used to uncover the genetic architecture of common 
complex diseases. This method is based on the “common disease, common variant” 
hypothesis, where allelic variants present in more than 5% of the population are 
responsible for the development of the disease. However, part of the genetic contribution 
to complex traits remains unexplained since most common variants individually or in 
combination, only confer small increments in disease risk and only explain a small 
proportion of disease heritability (the portion of phenotypic variance in a population 
explained by additive genetic factors), creating the so-called missing heritability problem 
(100,101). 
Several explanations have been suggested to explain the missing heritability, including 
a larger number of small effect variants, the rare variants, yet to be found. The rare variants 
possess a cumulative strong biological effect and are not detected by the available 
methods, since they only focus on variants present in 5% or more of the population, the 
structural variants are poorly captured by the existing arrays and there is a current low 
power to detect gene-by-gene and gene-by-environment interactions (100,102). Much of 
the speculation about the current missing heritability focuses on the possible contribution 
of rare variants since these variants could have substantial effect sizes without 
demonstrating clear Mendelian segregation and could explain additional disease risk or 
trait variability. Besides this, also the evolutionary theory predicts that deleterious alleles 
are likely to be rare as a result of purifying selection, and indeed, variants that cause loss of 
function and, therefore, prevent the generation of functional proteins, are especially rare 
(100,101). 
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Given that little has been explained about most complex diseases despite the 
identification of hundreds of associated genetic variants, the search for the missing 
heritability can provide a potentially important path towards further discoveries (100). 
 
6. Methodologies to obtain genetic information of complex diseases 
 
As previously stated, it is now known that complex diseases are, in part, determined by 
genetic factors, which resulted in increased interest in identifying the genetic basis of those 
diseases (19). For that reason, during the past few years several methods were used to 
study and identify genes that could be associated with complex diseases (9).  
 
6.1. Genome-Wide Association Studies 
 
The genome-wide association studies, known as GWAS, have discovered multiple 
genetic variants that can be associated with an ever increasing number of diseases (103). 
This method is based on linkage disequilibrium (adjacent polymorphisms are correlated 
with each other due to their co-segregation from one generation to the next) and advanced 
genotyping techniques (microarrays through which many tag SNPs can be typed in a single 
array) (40). This technique is used to find connections between genes and diseases across a 
population since it uses a database with over a 1,000,000 known common variants. 
Therefore, this methodology, although it requires large sample sizes to detect effects of 
common variants (minor allele frequency (MAF) ˃ 5%) with genome-wide significance, 
can simultaneously analyze several variations, helping to identify dozens of new 
associations between genes and diseases (9,40,104).  
GWAS has allowed to deepened our understanding of disease etiology in multiple 
directions because, first, it has led to the identification of a vast number of disease-
associated genomic loci/genetic variants and secondly, the associated loci/variants 
discovered from GWAS could serve as risk predictors for some diseases, provided large 
enough GWAS discovery sample size. An example of this can be seen in the study of 
Crohn’s disease, an inflammatory bowel disease with a prevalence of 0.32% in Europe and 
North America. GWAS identified 163 loci at genome-wide significance level, which 
collectively explain 13.6% of this disease phenotypic variance. Moreover, valuable insight 
can be learned about the genetic etiology of many diseases due to the analysis of the 
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variance contribution of SNPs from certain genomic regions and pathways. However, 
GWAS still presents problems such as the difficulty in interpreting its results partly 
because of our limited understanding of the genomic function, especially the non-coding 
regions in which a considerable number of genetic variants been identified, and because of 
the correlation structure among neighboring variants, often referred to as linkage 
disequilibrium (102).  
Even though the systematic identification of rare variants associated with complex 
diseases is not yet done, several of those variants have already been identified as 
conferring risk for disease development (for example in autism, mental retardation, 
epilepsy and schizophrenia). It is clear that the common variants found by GWAS have 
little success in implicating specific genes in specific diseases, which ultimately reduces 
their importance in several applications such as drug development (104). Due to the 
limitations of GWAS and to investigate the rare genetic variants that are not captured by 
this method, whole-genome and whole-exome sequencing began being used as a substitute 
for the screening of genes (103,104).  
 
6.2. Whole-Exome Sequencing 
 
Whole-exome sequencing (WES) is the method by which only the coding regions of the 
genome (1-2%), the exome, are sequenced, enabling the detection of the majority of 
important pathogenic variants (101,105,106). This method targets the consensus coding 
sequence (of the collaborative consensus coding sequence (CCDS) Project) (107), which is 
approximately 30,000,000 bases, only differing the targeted regions depending on the 
service provider (101). This technique has been, therefore, proposed to provide a new 
strategy to study the missing heritability (108). In recent years, the emergence of exome 
sequencing has led to a change in the approach to identify new causal mutations and genes 
(103). The current ability for interpretation of the functional consequences of sequence 
variation outside the coding regions (introns) is limited, and exome sequencing became an 
efficient strategy for identification of rare functional variants (101,109). Additionally, 
WES has recently begun being explored as a diagnostic tool for genetic diseases (103). 
The utility of exome sequencing as a diagnostic tool is becoming evident for disorders 
characterized by genetic heterogeneity. Diseases characterized by locus heterogeneity can 
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result from a causal mutation on one of several candidate genes, which results in the need 
for each one of those genes to be screened in its entirety by polymerase chain reaction 
(PCR) and Sanger sequencing, a laborious and expensive process. On the same way, also 
phenotypic heterogeneity interferes with the accuracy of the assessment of clinical 
manifestations, resulting in a potentially incorrect or ambiguous diagnosis. As a result, 
only the more probable causal genes are prioritized for screening. An example of this is in 
disorders caused by mutations in several candidate genes such as retinitis pigmentosa and 
Charcot-Marie-Tooth disease, for which the diagnostic strategy involves gene by gene 
screening. (103). In response to this limitation, the exome sequencing began to be used as a 
diagnostic tool and its advantages are evident comparing to the traditional approach 
(103,110). For cases that are not explained by mutations in known loci, the distinction 
between the diagnostic tool and the discovery one is a little blurred. A definitive genetic 
diagnosis is not made based only on the new found mutation; screening in additional cases 
is required, and the discovery of the new mutation in those cases from different families is 
the only confirmation of causality (103). 
In exome sequencing, the workflow is divided into three phases: sample preparation and 
sequencing, primary data processing and secondary data processing (Figure 14).  
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Figure 14. Exome sequencing workflow since genomic DNA extraction to biological interpretation 
and identification of the causal mutation (adapted from (103)). 1000GP: 1000 genome project; 
BWA: burrows-wheeler aligner; dbSNP: single nucleotide polymorphism database; DNA: 
deoxyribonucleic acid. 
 
The library preparation uses genomic DNA and involves several steps like DNA 
fragmentation and adapter ligation. Exon capture and enrichment are usually done using 
commercial kits before proceeding to exome sequencing with one of the high-throughput 
next-generation sequencing (NGS) platforms (steps performed according to the 
manufacturer’s recommended protocols). According to the platform used, there is a 
minimum value of coverage considered sufficient for the correct calling of variants. In 
recent years, several technical approaches have been developed to enrich selectively for the 
protein-coding regions of the genome using modified multiplex PCR, capture by 
circularization or capture by hybridization in solution or on an oligonucleotide array. After 
sequencing, the data obtained is processed to raw sequence reads, which are then aligned to 
a reference genome. Finally, variant calling and filtering is done using quality control 
criteria followed by variant annotation to obtain information such as genomic position and 
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functional effect, and after, those variants are analyzed to find the causal mutation 
(103,111).  
Despite all the advantages, in practice, various improvements in WES are yet to be 
introduced. Most importantly, WES almost entirely misses structural variation, only small 
(1-25 nucleotides) insertions and deletions can reliably be detected and, if causal variations 
are in exons not targeted, such as novel exons in known and novel genes, they will not be 
identified. Another major challenge is to analyze and manage the large amounts of 
sequencing data generated since exome sequencing usually generates much more than 
10,000 genetic variants that have to be filtered to identify only the causal mutations. Also, 
since the success of WES depends on the capture of all known exons (approximately 
200,000) followed by an adequate depth of sequencing, the methods for exome capture, 
even though suitable, can be improved (103,104,106).  
Because for many applications it is not necessary the sequencing of entire genomes and 
the most disease-causing variants are in the coding regions (approximately 85% in 
Mendelian diseases), WES is a cost-effective alternative to GWAS or even whole-genome 
sequencing (WGS), since this latter still presents challenges concerning technical, 
analytical and economic issues (103,104,105). At the present, the introduction of NGS has 
allowed fast and relatively inexpensive sequencing of thousands of genes at a time through 
WES (19). Therefore, with the affordability with WES and with the advances in NGS 
technologies, researchers are gaining the genomics tools to discover associations between 
coding variants and complex diseases and directly test the hypothesis that rare variants 
may be associated with increased risk of developing complex diseases (19). 
Regarding ethics, the unmasking of genetic details has always been intertwined with 
some complex ethical implications (111). With the increasing capability of sequencing 
genomes, new ethical issues were raised (105). For certain diseases where the causal 
mutations are already known, the information on whether the individual under study has or 
not the mutation is available but, when that is not the case, should the researchers have the 
obligation to screen for other variants besides the ones related to the disorder being 
investigated? Several positions are in discussion, being one of them that researchers do not 
have the obligation to screen for other variants besides the ones related to the disorder 
being investigated, because, among other things, that obligation would damage the 
researcher ability to focus on the particular disease being studied. Meanwhile, the 
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international research and clinical community are still discussing the ethical implications 
of the information availability (112). 
 
6.2.1. Next-Generation Sequencing 
 
Different methods to sequence DNA were developed in the 1970s. Sanger and 
colleagues developed the use of chain-terminating dideoxynucleotide analogs that caused 
base-specific termination of primed DNA synthesis (113). In an alternative approach, 
Maxam and Gilbert suggested a method in which labeled DNA fragments were subjected 
to chemical cleavage at specific bases and the reaction products were separated by gel 
electrophoresis (114). Since the method developed by Sanger and colleagues, commonly 
referred to as Sanger sequencing, had less handling of toxic chemicals and radioisotopes 
than the Maxam and Gilbert’s technique, it became the obvious choice for DNA 
sequencing and clinical application involving the analysis of single genes with limited 
polymorphisms (105,111). Later, Sanger sequencing was improved to provide an increased 
throughput that led to laboratory automation and process parallelization (105). This 
progress eventually  made it possible to complete the first human genome sequence in 
2004 (115) even though it also made clear the need for faster and higher throughput and 
cheaper technologies (105).  
To overcome the limitations of the Sanger method (considered first-generation 
technology), NGS technologies were developed and commercialized. Those techniques 
sequence by either creating micro-reactors and/or attaching the DNA molecules to be 
sequenced to solid surfaces or beads, which results in millions of reactions happening in 
parallel (105,116). This technology is, therefore, a high-throughput, massively parallel 
technology (106). Therefore, the appearance of NGS satisfied the growing demand for 
low-cost sequencing technology producing massive parallel nucleotide sequencing but it 
also created demands on the bioinformatics tools for data analysis and management 
(105,117). With this, part of the increase in throughput in NGS is due to advances in data 
handling (105). The number of reads produced by NGS revolutionized genomics research, 
however, a drawback to the use of these technologies is the relatively short reads (35-500 
base-pairs (bp), depending on the platform) compared with the traditional sequencing 
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(1,000-1,200 bp), which ultimately made genome assembly more difficult and required 
new alignment algorithms (105,118,119). 
The NGS technologies present major improvements compared with the Sanger 
sequencing. First, the DNA sequencing libraries are clonally amplified in vitro instead of 
requiring bacterial cloning of DNA fragments; secondly, DNA is sequenced by synthesis 
rather than chain termination chemistry; thirdly, instead of hundreds, thousands to millions 
of sequencing reactions are produced in parallel, and finally, the sequencing output is 
detected directly without needing an electrophoresis. These technological improvements 
contribute to the growing interest in the use of NGS as a diagnostic tool (105) as well as in 
other fields (Figure 15) (119). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The several NGS applications and the different methods used for which field (taken 
from (119)). ChIP-Seq: chromatin immunoprecipitation sequencing; DNA: deoxyribonucleic acid; 
MeDIP-Seq: methylated DNA immunoprecipitation; miRNA: micro ribonucleic acid; mRNA: 
messenger ribonucleic acid; RNA: ribonucleic acid.  
 
Now, despite the benefits of NGS technologies, a number of technical challenges 
appeared, such as the storage of information since the technology generates massive 
volumes of data, and the bioinformatic analysis since the generated DNA sequences have 
to be aligned to a reference genome, and the short reads may result in difficulties with the 
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assembling of the generated sequence. Also, both NGS and bioinformatic tools are unable 
to identify accurately certain genetic variations, such as copy number variations (CNV), 
inversions, translocations and nucleotide repeat expansions; DNA regions enriched with 
guanine-cytosine (GC) content that tend to have low coverage. Finally, all NGS platforms 
have sequencing errors particularly towards the end of the read (106,117,120). 
The first NGS technology to be released was the 454 Life Sciences (now Roche) in 
2005. This technology uses a pyrosequencing method and currently generates about 
1,000,000 reads of 1,000 bp. In 2006, the Illumina Genome Analyzer platform was also 
released followed by the Sequencing by Oligo Ligation Detection (SOLiD) by Applied 
Biosystems (now a part of Life Technologies
TM
) in 2007. Even though both of these 
sequencers generated a greater number of reads than 454 (30,000,000 and 100,000,000 
reads, respectively), the length of the reads was only 35 bp long. In 2010, Ion Torrent (now 
a part of Life Technologies
TM
) commercialized the Personal Genome Machine (PGM). 
This system was developed by Jonathan Rothberg, the founder of the 454, and it resembles 
the 454 system. The major difference between the 454 and PGM is that the latter uses 
semiconductor technology for nucleotide incorporation detection, not relying on the optical 
detection using fluorescence and camera scanning. As a result, PGM has a higher speed, 
lower cost and smaller instrument size than 454. Later, from the same company of PGM, 
Ion Proton emerged (105,121).  
Other NGS platforms developed that did not dominate the market were the Qiagen-
intelligent bio-systems sequencing-by-synthesis, Polony sequencing and a single molecule 
detection system (Helicos BioSciences). This latter method, since the template DNA is not 
amplified before sequencing, is at the interface between NGS and third-generation 
sequencing technologies (105). Ideally, third-generation sequencing combines all the 
advantages of NGS with longer read length and decreases in the computational power 
required to assemble genomes (105,111). The Pacific Biosciences RS (PacBio) platform, a 
third-generation sequencing technology from Pacific Biosciences, is the first sequencing 
technology to offer long read lengths (average of 2-3 kilobase (kb)) without GC bias or 
systematic errors (122). This technology consists of a process in which a DNA polymerase 
molecule, bound to a DNA template, is attached to the bottom of a well. Each polymerase 
synthesizes the second strand DNA in the presence of γ-phosphate fluorescently labeled 
nucleotides and, as each base is incorporated, a distinct fluorescence is detected in real 
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time (real time sequencing). Besides this, the Pacific Biosciences RS platform offers an 
amplification-free workflow (123).    
 
6.2.1.1. Ion Proton 
 
Ion Proton is used mainly for sequencing exomes and ribonucleic acid sequencing 
(RNA-Seq) (121). The basic concept of this sequencer is to perform sequencing-by-
synthesis, with electrochemical detection. One of the main products of DNA synthesis is 
the release of a hydrogen ion (H
+
) from the 3’ OH incorporation site on the strand being 
synthesize, and a sensor capable of detecting this product (124).  
In Ion Proton, DNA molecules are connected, at both ends of each fragment, to adaptors 
that contain the necessary elements for immobilization on a solid surface and sequencing. 
The DNA fragments bound to the adaptors are then captured on the surface of beads. The 
complex DNA fragment-bead is isolated in an individual water-in-oil emulsion (emulsion 
polymerase chain reaction (ePCR)) that also contains PCR reagents, and subsequent 
thermal cycling produces about 1,000,000 copies of each DNA fragment present on the 
surface of each bead (Figure 16). Only little input of DNA (a few micrograms at most) is 
needed to produce the library (105,118,125).     
Figure 16. Basic concept of emulsion PCR (adapted from (125)). DNA: deoxyribonucleic acid; 
PCR: polymerase chain reaction.  
 
The main issues with library preparation are the introduction of quantitative biases and 
the loss of material. For this purpose, and because PCR is the major source of bias, 
comparisons between PCR polymerases have been performed, and the enzymes that 
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introduce less noise have been identified. Regarding the loss of material, DNA 
fragmentation, end-repair, and adaptor ligation have been combined into a single reaction 
and gel and column purification steps have been replaced by magnetic beads (105).   
After the amplification process, these single molecules are sequenced (125). In the Ion 
Proton platform, the release of the ion H
+
 causes a variation in pH, and that change is 
detected by a transistor. A practical transistor for sensing pH variation is the pH-sensitive 
field effect transistor (pHFET), used in solid-state pH meters. This transistor opened the 
general field of ion sensitive field effect transistor sensors, known as ISFET. The ISFET 
senses a variety of ionic concentrations being used to serve as a pHFET in Ion Proton. In a 
simple way, the detection process occurs because the H
+
 concentration creates a positive 
voltage near the gate region of the transistor and, as a result, the current flowing through 
the transistor changes (Figure 17A). A ISFET sensor is deposited at the bottom of a 
microwell, and a bead carrying the sample DNA fragment, amplified by ePCR, to be 
sequenced is placed on top of the ISFET. Each bead normally carries hundreds of 
thousands of copies of the same DNA fragment to amplify the chemical signal produced by 
the sequencing reaction and the well acts as a retainer of the bead and helps to localize and 
retain the H
+
 released when the incorporation occurs (Figure 17B). To achieve the massive 
parallelism, an array of millions of the transistor sensors are formed on a chip (124).   
 
Figure 17. Basic concept of how a transistor works (A) and how that transistor is incorporated into 
a microwell to detection for the sequencing process (B) (adapted from (124)). H
+
: hydrogen ion.  
 
For the sequencing process itself, the DNA fragments that are single stranded and 
connected to the primers are loaded with polymerase and the sequencing process occurs by 
sequentially flowing in different nucleotide (adenine (A), cytosine (C), guanine (G) and 
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thymine (T)) solutions (solution of native deoxyadenosine triphosphate (dATP), 
deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP) and 
deoxythymidine triphosphate (dTTP)) and monitoring for an incorporation signal via the 
sensor. The flowing in of the nucleotide solutions can result in incorporation or no 
incorporation. If the nucleotide solution does not result in incorporation, the sensor 
response will be only to whatever change in pH is present in the ambient solution flowing 
in, which ideally would be none since all solutions should have a matched pH. If, on the 
other hand, the incorporation occurs (for example if it has been used a solution of dATP 
and the next base on the template is a T), H
+
 ions will be released due to the polymerase 
activity when incorporating a base and a signal emerges. In this way, the flowing of 
nucleotide solutions in a repeatedly sequential manner (A, C, G, T, A, C, G, T,...) results in 
a sensor signal each time a base is incorporated. Between each trial flow, a wash flow is 
performed to eliminate the previous trial nucleotide solution before moving on to the next 
one (124).  
 
 
6.2.2. Bioinformatics Analysis 
 
After sequencing, the initial data analysis pipeline consists of raw data collection and 
signal processing, followed by base calling, which results in a FASTQ file (Figure 18) 
(124,126).  
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Figure 18. Overview of the data analysis process, which consists of: (A) data acquisition that 
requires high bandwidth data capture, transfer and reduction hardware solutions; (B) signal 
processing required for the removal of background pH variation and fit the incorporation model to 
the data; (C) base calling that consists of processing the sequencing signal to nucleotides; (D) 
alignment of the reads produced to a reference sequence and (D) variant calling that is when the 
differences between the samples and the reference genome are analyzed, and it is based on the 
coverage provided by the reads at each locus (taken from (124)).  
 
After the base calling, the remainder of the bioinformatics analysis consists of mapping 
(Figure 18 – Read Alignment), variant calling and lastly annotation. The mapping step 
consists in the alignment of each short read to a position on a reference genome (in this 
case, the human genome), using software that will assess the likely starting point of each 
read within the reference genome. This step is hindered by the large volume of short reads 
generated by NGS, unique versus non-unique mapping and the variation in base quality. 
Beside this, the mapping is a critical step since any errors in this step will be carried 
through the rest of the analysis (126). The resulting sequence alignment is stored in a 
sequence alignment/map (SAM) or binary alignment/map (BAM) file (127). There are 
software available that differ in accuracy and speed that can be used to perform sequencing 
read alignment (126). In the case of Ion Proton, the platform provides the Torrent MAPper 
(TMAP) aligner to perform this step (124).  
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The next step in the pipeline is variant calling. This process usually refers to finding 
SNPs and small insertions/deletions (indels) and consists in the comparison of the aligned 
sequences to the reference genome to determine which positions deviate from the known 
position (126,128). These variants may have a functional impact, resulting in diseases or 
may simply be genetic variants with no functional effect (126). There are a few challenges 
regarding this step like the presence of indels, which represents a major source of false 
positive single nucleotide variant (SNV) identifications; errors from the library preparation 
due to PCR artifacts and variable GC content in the reads and finally, variable quality 
scores, being that  most of the higher error rates are found at the end of reads (129). The 
variant call format (VCF) is the standard generic format where all the sequence variations 
are recorded (130). In Ion Proton, a specific variant calling software, the torrent variant 
caller (TVC) is provided (124).  
The last step of the pipeline is annotation, the step in which all the known information 
about each variant that was detected is gathered. The annotation may reveal, among other 
things, if the variant is already known, if it has a functional impact or not and if that impact 
has already been predicted, if the function or activity of the specific gene is known and 
even if an identified disease is already associated with that variant in that gene. The result 
of this step is a small list of well-annotated variants that can explain a certain biological 
phenomenon (126). In this last step, different prediction programs are used to predict the 
effects of functional SNP. One of those is the polymorphism phenotyping v2 (PolyPhen-2) 
server, which is responsible for automated functional annotation of coding SNPs, 
predicting the damaging effects of genetic variants (131,132,133). For that, PolyPhen uses 
sequence conservation, structure and Universal Protein KnowledgeBase (UniProtKB) 
annotation (133). PolyPhen-2 possesses two databases, HumDiv (HDIV) and HumVar 
(HVAR). While HDIV should be used when accessing rare alleles at loci potentially 
involved in complex diseases, dense mapping of regions identified by GWAS and analysis 
of natural selection from sequence data, the HVAR should be used for diagnosis of 
Mendelian diseases, which requires distinguishing mutations with drastic effects from all 
the remaining human variation (132). Another prediction software is the sorting intolerant 
from tolerant (SIFT), which is based on the principles of protein evolution. This software is 
a multi-step algorithm that uses a sequence homology-based approach to classify amino 
acids substitutions, meaning that SIFT uses sequence homology to predict whether an 
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amino acid substitution will affect protein function and hence, potentially alter the 
phenotype (133,134). In this software, the scores are calculated using position-specific 
(hydrophobic conserved, highly conserved and unconserved) scoring matrices (133). 
Lastly, the other prediction tool used is the combined annotation dependent depletion 
(CADD). In this approach, CADD measures the deleteriousness of SNVs, a property that 
strongly correlates with both molecular functionality and pathogenicity, into a single score. 
This means that the basis of CADD is to quantitatively predict the deleteriousness, 
pathogenicity and molecular functionality, both protein-altering and regulatory, in a variety 
of experimental and disease contexts. This tool combines the generality of conservation-
based metrics with the specificity of subset-relevant functional metrics (e.g. PolyPhen-2) 
(135).  
 
7. Objectives 
 
With the continued increase in the prevalence of T2D, the risk for the development of 
related complications, such as diabetic nephropathy, also increases. Currently, the 
underlying genetic mechanisms for the development of this complication remain unclear, 
and it is believed that SNPs in several genes distributed across the genome may be causal 
for the development and progression of the complication. Thus, the main objective of this 
work is to contribute to uncover the genetic mechanisms associated with the development 
of diabetic nephropathy. For that, this work intends to: 
 
i. Identify common and rare genetic variants present in the exomes of 36 type 2 
diabetic individuals with and without diabetic nephropathy using different 
statistical approaches;  
ii. Search, in the results obtained for the 36 type 2 diabetic individuals, the 
presence of genes and genetic variants already associated with diabetic 
nephropathy identified based on the literature;  
iii. Validate the biologically relevant genetic variants found in the studied 
population; 
iv. Establish a phenotype-genotype correlation between the genetic variants present 
in the exomes of the individuals in the study and the presence or absence of 
diabetic nephropathy. 
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This study will, therefore, identify the relevant common and rare genetic variants and 
genes associated with diabetic nephropathy in Portuguese type 2 diabetic patients, and 
highlight if there is a particular mechanism involved in disease pathophysiology within the 
Portuguese population. The genetic variants and genes uncovered in this study can be used 
in following studies to contribute to a deeper understanding of the genetic mechanisms 
associated with diabetic nephropathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2| Materials and Methods 
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1. Characterization of the population under study  
 
This study was performed in a 36 Portuguese patients group, comprising 20 men and 16 
women between the ages of 45 and 77 years old with diagnosed T2D. These patients were 
divided, based on their phenotypes, into a control group formed by 19 individuals with 
T2D and without diabetic nephropathy and a case group consisting of 17 individuals with 
T2D that presented the diabetic complication. The peripheral blood samples collected from 
the diabetic individuals that participated in this study were obtained from the 
Endocrinology Unit of the Coimbra Hospital and University Center. The diabetic 
nephropathy diagnosis on the subjects was made by a physician from the same institution. 
Informed written consent was obtained from all participants before the study.  
Case and control groups were characterized by age, disease duration, glycated 
hemoglobin (HbA1c) levels and sex, using the International Business Machines 
Corporation (IBM) Statistical Package for the Social Sciences (SPSS) software, version 
20.0 (International Business Machines Corporation, Armonk, New York, United States of 
America). For the qualitative covariate, sex, a chi-square (χ2) test was performed while, for 
the quantitative covariates, age, disease duration, and HbA1c, a t-test was conducted.  
 
2. Whole-Exome Sequencing 
 
2.1. DNA extraction and Quality Control 
  
 
The DNA extraction process from the peripheral blood samples was performed using an 
extraction kit, the DNeasy Blood & Tissue Kit (QIAGEN
®
, Hilden, Germany). The 
workflow of this kit is presented in Figure 19.  
Figure 19. Workflow of the DNA extraction process using the DNeasy Blood & Tissue Kit 
(adapted from (136)). DNA: deoxyribonucleic acid.  
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The DNA samples are first lysed using a lysis buffer containing a detergent, which is 
responsible for the disruption of the cell and nuclear membranes, and proteinase K, to 
digest the protein components. Subsequently, ethanol is added to precipitate the DNA and 
the purification process begins. The lysate is loaded onto a DNeasy Mini spin column and 
then centrifuged, causing the DNA to bind selectively to the DNeasy membrane and the 
contaminants to pass through. The buffering conditions are adjusted to provide optimal 
DNA binding conditions. The remaining contaminants and enzyme inhibitors are then 
removed in two wash steps and the DNA is eluted in 100 microliters (μL) of the elution 
buffer.    
Following the extraction, the DNA was quantified, and its purity was assessed by 
spectrophotometry, applying two μL of each DNA sample to the NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, United States of America). 
This technology allows the determination of nucleic acids concentration, both single 
stranded as well as double stranded, based on the Beer-Lambert law ([DNA] (nanograms 
per microliter (ng/μL)) = A260 x 50 micrograms per milliliter (μg/mL) x dilution factor, 
where A260 represents the absorbance at 260 nm, the maximum peak of absorbance for 
nucleic acids). The purity of the samples or the presence of contaminants such as proteins, 
phenols, and RNA, among others, was determined by the ratios 260nm/280nm and 
260nm/230nm. A 260nm/280nm ratio between 1.7 and 1.9 is generally accepted as pure 
DNA, while in the 260nm/230nm ratio, expected values are commonly in the range of 2.0-
2.2. The samples that had contamination (ratios lower than the referred values) were 
subjected to a standard purification with isopropanol. 
After the purifying steps, the integrity of the samples was evaluated by performing an 
electrophoresis on a 1% (weight/volume (w/v)) agarose gel with tris-acetate-
ethylenediamine tetraacetic acid (TAE) buffer, in which 50 nanograms (ng) of DNA were 
run along with the molecular marker NZYDNA Ladder III (NZYTech, Lisbon, Portugal). 
A current of 90 volts (V) for 30 minutes was applied and the gel, stained with ethidium 
bromide, was visualized under ultraviolet light with the Molecular Imager Gel Doc XR 
System (Bio-Rad Laboratories, Hercules, California, United States of America).  
Finally, another quantification protocol was performed, using for the sample preparation 
the Qubit
® 
dsDNA HS Assay Kit (Invitrogen
TM
, Life Technologies
TM
, Eugene, Oregon, 
United States of America) and for the quantification itself, the Qubit
®
 2.0 Fluorometer 
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(Invitrogen
TM
, Life Technologies
TM
, Carlsbad, California, United States of America). This 
technology uses fluorescent probes that connect specifically to DNA to quantify the 
sample. A more precise value of DNA concentration is obtained than the one obtained with 
NanoDrop
®
 and without the possible contaminants. A DNA sample concentration higher 
than 10 ng/μL was considered acceptable. 
All of the procedures described above, as well as the kits used, were performed 
accordingly to the manufacturer instructions.  
 
2.2. Sequencing process 
 
The first step in the sequencing process consists of an exome library preparation for 
each DNA sample. The Ion Ampliseq
TM
 Library Kit 2.0 (Life Technologies
TM
, Carlsbad, 
California, United States of America) was used. For each sample, a multiplex PCR reaction 
with 294,000 pairs of primers distributed across 12 pools of primers allowed the 
amplification of the genome coding regions (exome), being this step designed to create 
overlapping amplicons, to cover all the target regions. The kit master mix was distributed 
across 12 wells, followed by 75 ng of DNA from a single sample per well (Figure 20).   
 
 
 
 
 
 
 
 
Figure 20. Example of the plate used in the library preparation for exome sequencing (adapted 
from (137)). 
 
After this process, the samples underwent a multiplex PCR in which all the exons were 
amplified, followed by the combination of the amplicons by sample into a single plate 
well, where FuPa reagent was added to digest partially primer sequences. Subsequently, 
each DNA fragment was ligated to adapters with barcodes using the Ion Xpress
TM
 Barcode 
Adapters 1-16 Kit (Life Technologies
TM
, Carlsbad, California, United States of America), 
allowing the distinction between fragments from two different DNA samples. This permits 
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the sequencing of different DNA samples at the same time (Figure 21). Lastly, the exome 
library preparation ends with the purification of the amplified library by adding magnetic 
beads, the Agencourt
® 
AMPure
®
 XP (Beckman Coulter Inc., Brea, California, United 
States of America), that connect to the DNA fragments with the adapters and elute the 
unamplified fragments as well as the digested primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Exome library preparation using the Ion AmpliseqTM Library Kit 2.0 (adapted from 
(137)). DNA: deoxyribonucleic acid; PCR: polymerase chain reaction.   
 
The next step was to assess the exome library profile through evaluation of the DNA 
fragment size and to verify if primer-dimers were present. The library size profile was 
determined with the High Sensitivity DNA Kit (Agilent Technologies
®
, Waldbronn, 
Germany) in the Agilent 2100 Bioanalyzer and the software 2100 expert (Agilent 
Technologies
®
, Santa Clara, California, United States of America). The concentration of 
each exome library was determined by real-time PCR with the Ion Library TaqMan
®
 
Quantitation Kit (Applied Biosystems
®
, Life Technologies
TM
, Austin, Texas, United States 
of America) in a 7500 Fast Real-Time PCR System and the results analyzed with the 7500 
Software v2.0 (Applied Biosystems
®
, Life Technologies
TM
, Singapore). Proper dilutions 
that resulted in an exome library concentration of approximately 100 picomolar (pM) were 
prepared for template amplification and exome sequencing on the Ion Proton platform.  
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The following stage in the sequencing process is the clonal amplification of each DNA 
fragment by ePCRs, to generate enough copies of the sequencing template. In the ePCR 
first step, the adapters connected to the DNA fragment are matched with the 
complementary oligonucleotides connected to the Ion Sphere
TM
 particles (ISPs). After, 
each ISP connected to the DNA fragment is isolated in an individual water-in-oil emulsion 
containing the necessary reagents for the amplification process to occur. Each ePCR 
combined two exome libraries. Following the ePCR, the water-in-oil emulsions are broken 
allowing the recovery of the ISPs. This entire procedure was carried out on the Ion 
OneTouch
TM
 2 System (Life Technologies
TM
, Carlsbad, California, United States of 
America) using the Ion PI
TM
 Template OT2 200 Kit v2 (Life Technologies
TM
, Carlsbad, 
California, United States of America). 
After the ISPs recovery, an aliquot was saved to perform a quality control test. Each ISP 
contains multiple copies of the same DNA fragment, being those fragments bound to the 
ISP on one side and biotinylated on the other side. During enrichment, the biotinylated side 
is bound to magnetic beads that are coated with streptavidin, allowing to retain the 
template-positive ISPs (ISPs that have amplified DNA) and wash away all empty ISPs that 
do not contain any DNA fragment. After the enrichment, another aliquot was saved. The 
quality control test was performed with both aliquots, before and after enrichment, to 
determine the percentage of enriched ISPs in the total ISPs. This test was carried out on the 
Qubit
®
 2.0 Fluorometer (Invitrogen
TM
, Life Technologies
TM
, Carlsbad, California, United 
States of America) using the Ion Sphere
TM
 Quality Control Kit (Life Technologies
TM
, 
Carlsbad, California, United States of America). Lastly, a chip was loaded with the 
enriched ISPs using the Ion PI
TM
 Chip Kit v2 (Life Technologies
TM
, Carlsbad, California, 
United States of America) as well as the Ion PI
TM
 Sequencing 200 Kit v2 (Life 
Technologies
TM
, Carlsbad, California, United States of America), and the sequencing 
process was executed in the Ion Proton
TM
 Sequencer (Life Technologies
TM
, Carlsbad, 
California, United States of America). Each chip was loaded with two exome libraries, the 
process being repeated for 18 sequencing runs in a total of 36 DNA samples/exomes.    
All of the procedures, as well as the kits described above, were performed accordingly 
to the manufacturer’s instructions.     
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2.3. Bioinformatics Analysis 
 
Following the completion of a sequencing run, the Torrent Suite
TM
 Software (Life 
Technologies
TM
, Carlsbad, California, United States of America) processed the raw data 
obtained. This software contains all the necessary software components to execute signal 
processing, base calling, read alignment (mapping) and variant calling (Chapter 1| 
Introduction – Figure 18) and is already installed on the ProtonTM Torrent Server (Life 
Technologies
TM
, Carlsbad, California, United States of America).  
For each of the 36 sequenced exomes, the adapter sequences, as well as the low-quality 
bases were trimmed using the Torrent Suite
TM
 Software (Life Technologies
TM
, Carlsbad, 
California, United States of America). The resulting reads were then mapped to the human 
reference genome hg19, using the TMAP version 4.0.6 (Life Technologies
TM
, Carlsbad, 
California, United States of America), and the aligned sequence stored in a BAM file.   
For a sample identification control, the number of reads mapped to the Y chromosome 
were counted using SAMtools, a library, and software package for manipulating 
alignments in SAM or BAM files (127), and divided by the number of total mapped reads 
thereby creating a ratio to determine sample sex. Therefore, this test determined, based on 
the sequencing results, the sex of each sequenced exome, and compared this “informatics 
determined sex” to the sex of each individual in the study. 
The next step in this pipeline is the variant calling, a step where the positions in which 
the aligned sequence deviates from the reference sequence, creating genetic variants, are 
identified. This step was performed by running the TVC plugin version 4.0 (Life 
Technologies
TM
, Carlsbad, California, United States of America) with the optimized 
parameters for exome sequencing recommended for the Ion AmpliSeq™ Exome Kit (Life 
Technologies
TM
, Carlsbad, California, United States of America), being the genetic 
variants recorded into a VCF file. The genotypes were then recalled based on the altered 
allele frequency, using for that an in-house script. Therefore, altered homozygous 
genotypes were assigned for altered allele frequencies higher than 0.8 and the 
heterozygous genotypes were assigned for frequencies between 0.2 and 0.8. The 
homozygous positions equal to the reference genome were further evaluated using an in-
house script since no information about these genotypes is reported in the generated VCF. 
The in-house script stipulated that when the altered allele frequencies were lower than 
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0.05, the genotype was considered homozygous equal to the reference, but, if the altered 
allele frequencies were higher than 0.05, then the genotype was considered undetermined. 
Furthermore, the genetic variants with less than 10x depth of coverage were discarded. The 
remaining variants from the 36 exomes were considered and integrated altogether using 
VCFtools, an open-source software package for analyzing and manipulating VCF files 
(130). 
The last step in the bioinformatics analysis is the annotation. This is the step in which 
all the known information about each genetic variant detected in the 36 exomes is 
gathered. For this process, the Variant Effect Predictor (VEP) software, responsible for 
predicting the impact of genetic variants in genes, transcripts and protein sequences (138), 
was used, being the transcripts used by this software obtained from the version GRCh37 
from Ensembl (139). The VEP results were then used by the Genome Mining (GEMINI) 
framework (140) to annotate the genetic variants against a comprehensive set of genomic 
annotation files, which includes the Single Nucleotide Polymorphism Database (dbSNP) 
(141), the Encyclopedia of DNA Elements (ENCODE) (142), the Clinical Variation 
database (ClinVar) (143), the 1000 Genomes Project (1000G) (144), the Exome 
Sequencing Project (ESP) (145), the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(146), the Genomic Evolutionary Rate Profiling (GERP) (147), and lastly the Human 
Protein Reference Database (HPRD) (148). Finally, GEMINI saved all information from 
the impact and annotation prediction in a database for further analysis. Furthermore, to 
detect relatedness between samples, pair-wise genetic distance tests were performed by the 
GEMINI framework. 
 
3. Common Variants Approach 
 
3.1. Statistical Analysis 
 
The common variants approach was used to test for an association between diabetic 
nephropathy and several single common genetic variants. It consisted in the prioritization 
of the common variants using the χ2 test or the Fisher exact test to detect the ones that had 
significant genotype differences between cases and controls (univariate analysis). The 
analysis was performed in the IBM SPSS software, version 20.0 (International Business 
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Machines Corporation, Armonk, New York, United States of America). Only variants that 
passed the Hardy-Weinberg equilibrium (HWE) (p-value > 0.05) were considered. From 
the obtained genetic variants, the ones with a p-value ≤ 0.05 and a call rate ≥ 0.9 were then 
tested in a binary logistic regression model for adjustment to factors like age, disease 
duration, HbA1c, and sex, being statistically significant results considered for a p-value ≤ 
0.05. As the number of statistically significant genetic variants obtained was high, several 
filters were applied to prioritize these variants. Therefore, the variants present in the 3’ or 
5’-untranslated regions (UTR), those intronic, the ones upstream or downstream of the 
gene, as well as the synonymous variants, had to have a CADD (135) ˃ 15 and be in 
conserved regions. Missense variants had to have at least one of the prediction programs 
(PolyPhen-2 (132), SIFT (134), and CADD) indicating that the variant was pathogenic or 
the variant had to be in a conserved region.  
Moreover, each one of the common variants that passed the filters was studied for its 
gene function and expression, as well as for any known disease association, to detect the 
most biologically relevant to the pathogenesis of diabetic nephropathy. The gene function 
was evaluated through GeneCards
®
: The Human Gene Database (www.genecards.org) 
(149) and HumanMine (www.humanmine.org) (150), the gene expression was evaluated 
through neXtProt (www.nextprot.org) (151) and also HumanMine, and the variants 
association to any known disease was studied based on the information contained in the 
Human Gene Mutation Database (HGMD) (www.hgmd.cf.ac.uk) (152) and ClinVar 
(www.ncbi.nlm.nih.gov/clinvar) (143). Furthermore, Google (www.google.pt) and 
PubMed (www.ncbi.nlm.nih.gov/pubmed) were also used to perform a more generalized 
search for the genes in which the genetic variants were present and to search for the 
variants. 
Lastly, for the biologically relevant genetic variants found, its functional impact was 
assessed based on information provided by VEP and then used by the GEMINI framework, 
as well as information obtained from UniProtKB (www.uniprot.org) (153).            
 
3.2. Candidate Genes 
 
In order to compile a list of candidate genes and respective common variants already 
associated with diabetic nephropathy from previous studies, a search was made using 
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Google (www.google.pt), PubMed (www.ncbi.nlm.nih.gov/pubmed), HGMD 
(www.hgmd.cf.ac.uk) (152) and ClinVar (www.ncbi.nlm.nih.gov/clinvar) (143). The 
research was restricted to candidate genes and their common variants associated with 
diabetic nephropathy only in European type 2 diabetic individuals, being this list then 
compared with the results obtained from the statistical analysis of common variants in the 
36 exomes used in this study.  
 
3.3. Validation 
 
Several methods were used to validate the common variants found in the 36 exomes 
studied. The first validation method was performed with the objective of verifying if the 
variants found were real or simply an error of the sequencing technology. For that, the 
BAM file containing the aligned sequence of each exome was manually verified for the 
positions of the genetic variants present in that same exome. The second validation method 
consisted in genotyping 4 of the 36 exomes used in this study by Illumina microarray with 
the HumanOmniExpressExome (Illumina
®
, San Diego, California, United States of 
America) at ATLAS Biolabs GmbH in Berlin, Germany. Besides the 4 of the 36 exomes in 
study, others exomes also sequenced by the Ion Proton
TM
 Sequencer (Life Technologies
TM
, 
Carlsbad, California, United States of America) were genotyped by this method, which 
allowed the validation of the results obtained by this sequencing technology.  
 
4. Rare Variants Approach 
 
4.1. Statistical Analysis 
 
The rare variants approach was used to test for an accumulation of rare variants in genes 
by a gene-wise burden test. GEMINI (140) was used to select the rare variants that passed 
the HWE (p-value > 0.05) and those with a call rate ≥ 0.9, a MAF ≤ 0.01 in 1000G (144) 
and/or ESP (145) and a MAF ≤ 0.05 in the study population. Variants had to be non-
synonymous or present in splice site regions. The rare variants that passed the filters were 
then prioritized through a binary (cases vs. controls) gene-wise burden test, the emmaxVT 
test, using the Efficient and Parallelizable Association Container Toolbox (EPACTS) 
(154). Statistically significant results were considered for a p-value ≤ 0.05. 
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From the resulting list, and in a similar manner to the common variants approach, each 
one of the statistically significant genes with accumulated rare variants was studied for its 
function and expression, as well as for any known disease association from the rare 
variants present in that gene, in order to detect the most biologically relevant genes to the 
development of diabetic nephropathy. The gene function was evaluated through 
GeneCards
®
: The Human Gene Database (www.genecards.org) (149) and HumanMine 
(www.humanmine.org) (150), the gene expression was evaluated through neXtProt 
(www.nextprot.org) (151) and also HumanMine, and the association of the rare variants 
present in a particular gene to any known disease was studied based on the information 
contained in the HGMD (www.hgmd.cf.ac.uk) (152) and ClinVar 
(www.ncbi.nlm.nih.gov/clinvar) (143). Furthermore, to perform a more generalized search 
for the genes, Google (www.google.pt) and PubMed (www.ncbi.nlm.nih.gov/pubmed) 
were also used. 
Lastly, for the genes considered as biologically relevant, their accumulated rare variants 
functional impact was assessed based on information provided by VEP and then used by 
the GEMINI framework, as well as information obtained from UniProtKB 
(www.uniprot.org) (153).  
 
4.2. Validation 
 
To validate the genes obtained by the statistical analysis, several validation methods 
were used. The first method, as it was for the common variants, was performed with the 
objective of verifying if the rare variants accumulated in the genes found were real or an 
error of the sequencing technology, using for that the BAM file of each exome to manually 
verify the positions of the rare genetic variants present in that same exome. The second 
validation method consisted in the determination of each rare variant MAF in the 
sequenced exomes of 19 healthy (without T2D and without diabetic nephropathy) 
individuals unrelated to this study. Thirdly, some rare variants, like what happen with the 
common variants, were validated through genotyping 4 of the 36 exomes used in this study 
by the Illumina microarray with the HumanOmniExpressExome (Illumina
®
, San Diego, 
California, United States of America). This validation method was performed by ATLAS 
Biolabs GmbH in Berlin, Germany.  
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The rare variants that were not validated by this latter method were subjected to allele-
specific oligonucleotide polymerase chain reaction (ASO-PCR). To test the presence of a 
SNP by this method, each primer, either forward or reverse, was designed to be 
complementary and specific for only one allele, one primer was specific for the reference 
allele and the other primer was specific for the altered allele of the DNA being tested, 
having both primers to have the same direction (both forward or both reverse). The 
remaining primer is a common one to both the allele-specific primers. Furthermore, a pair 
of control primers was also added in each PCR reaction to ensure that all amplification 
conditions were met. The primers were designed in the Oligo Explorer software, version 
1.2 (Gene Link
TM
, Hawthorne, New York, United States of America) and are listed in 
Table 5. For each ASO-PCR reaction, the conditions had to be optimized using 
BIOTAQ
TM
 DNA Polymerase (Bioline, London, United Kingdom), deoxynucleotides 
(dNTPs) (BIORON, Ludwigshafen, Germany) and, for some of the rare variants, betaine 
solution (VWR, Denmark), being the reaction final volume 10.1 μL. The used reagents 
conditions are presented in Table 6. The amplification process was performed by 
MyCycler
TM
 Thermal Cycler (Bio-Rad Laboratories, Hercules, California, United States of 
America) under the conditions presented in Table 7. Lastly, the results were visualized by 
performing an electrophoresis on a 1.5% (w/v) agarose gel with TAE buffer, in which, 
besides the samples, a molecular marker, the NZYDNA Ladder I (NZYTech, Lisbon, 
Portugal). A current of 90 V was applied for 40 minutes to the agarose gel. The gel was 
stained with ethidium bromide and visualized under ultraviolet light with the Molecular 
Imager Gel Doc XR System (Bio-Rad Laboratories, Hercules, California, United States of 
America). Negative controls were performed, along with a wild-type (homozygous equal 
to the reference) and a heterozygous sample, for each reaction, using the same conditions. 
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Table 5. Information regarding the primers used for validation by ASO-PCR. 
 
 
Gene 
 
rs ID or 
Chr: end 
position 
Primer name 
Primer sequence  
(5’>>3’) 
Frag. 
size 
(bp) 
Control primer 
name 
Control primer sequence  
(5’>>3’) 
Control 
frag. 
size 
(bp) 
Optimized 
Ta (ºC) 
S
T
A
B
1
 
rs371042844 
STAB1_NF_F_C 
STAB1_NF_F_T 
STAB1_NF_R 
CCATCCTGGAGGTAAGCTC 
CCATCCTGGAGGTAAGCTT 
CCACAGCCTCATTGCTTGG 
370 
ITGA1_DR_F 
ITGA1_DR_R 
CTCAGGAGAAAGCAGTTGTG 
CACCCATCCAACATGAAGAC 
537 66 
rs41292856 
STAB1_NF1_F_N 
STAB1_NF1_R_A_N 
STAB1_NF1_R_G_N 
CTTCTCCATCTTCTACCAATG 
GTTCACCACATACCCCACT 
GTTCACCACATACCCCACC 
639 
PRKCQ_DR_F 
PRKCQ_DR_R 
GTGCTCTGTCCTCCTTATAC 
GGTATTCGTCTTGGCATCTC 
355 64 
rs149944392 
STAB1_NF2_F 
STAB1_NF2_R_G 
STAB1_NF2_R_A 
GCTTCAGTGATCTGAGTCAG 
GCCATCCCCGCTGTAACC 
GCCATCCCCGCTGTAACT 
433 
ITGA1_DR_F 
ITGA1_DR_R 
CTCAGGAGAAAGCAGTTGTG 
CACCCATCCAACATGAAGAC 
537 64 
rs199636230 
STAB1_NF3_F_C 
STAB1_NF3_F_T 
STAB1_NF3_R 
CAACCATGACTCCACTTGCTC 
CAACCATGACTCCACTTGCTT 
CTCCAGCCCACAGATGCTG 
488 
PRKCQ_DR_F 
PRKCQ_DR_R 
GTGCTCTGTCCTCCTTATAC 
GGTATTCGTCTTGGCATCTC 
355 67 
rs143836348 
STAB1_NF4_F 
STAB1_NF4_R_T 
STAB1_NF4_R_C 
CTTCTCTGCCTTCCAGGTAG 
GCCACACTTCTTCACTTCCA 
GCCACACTTCTTCACTTCCG 
239 
ITGA1_DR_F 
ITGA1_DR_R 
CTCAGGAGAAAGCAGTTGTG 
CACCCATCCAACATGAAGAC 
537 66 
Chr 3: 
52546850 
STAB1_NF5_F_N 
STAB1_NF5_R_G_N 
STAB1_NF5_R_A_N 
CCACTTCTCCATCTTCTACC 
GGCAGGAAGCGTGATGCC 
GGCAGGAAGCGTGATGCT 
239 
ITGA1_DR_F 
ITGA1_DR_R 
CTCAGGAGAAAGCAGTTGTG 
CACCCATCCAACATGAAGAC 
537 66 
Chr 3: 
52548167 
STAB1_NF6_F 
STAB1_NF6_R_G 
STAB1_NF6_R_A 
CATCCTCAGCCAGGTACAG 
GGCACAAAGATGGTGTAGGC 
GGCACAAAGATGGTGTAGGT 
389 
IOP1_DR_F 
IOP1_DR_R 
GTGAAGGGTGAAGGTCAGTG 
CAGGTGAATTCGACCAGTGG 
532 69 
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Gene 
 
rs ID or 
Chr: end 
position 
Primer name 
Primer sequence  
(5’>>3’) 
Frag. 
size 
(bp) 
Control primer 
name 
Control primer sequence  
(5’>>3’) 
Control 
frag. 
size 
(bp) 
Optimized 
Ta (ºC) 
M
M
P
2
5
 
Chr 16: 
3108251 
MMP25_NF_F_T 
MMP25_NF_F_C 
MMP25_NF_R 
CGCACGGCTGCACCGCTT 
CGCACGGCTGCACCGCTC 
GTCACCTGGAGGAGCAGAG 
599 
PRKCQ_DR_F 
PRKCQ_DR_R 
GTGCTCTGTCCTCCTTATAC 
GGTATTCGTCTTGGCATCTC 
355 
- 
MMP25_NF_F_T 
MMP25_NF_F_C 
MMP25_NF_R2_N 
CGCACGGCTGCACCGCTT 
CGCACGGCTGCACCGCTC 
CTCGCACTGACAATCGCAGG 
782 
IOP1_DR_F 
IOP1_DR_R 
GTGAAGGGTGAAGGTCAGTG 
CAGGTGAATTCGACCAGTGG 
532 
MMP25_NF_F_N 
MMP25_NF_R_T_N 
MMP25_NF_R_C_N 
GTGTCAGCCTCCCAATGTGC 
CGGGCAGCCCCTCCCAGA 
CGGGCAGCCCCTCCCAGG 
318 
IOP1_DR_F 
IOP1_DR_R 
GTGAAGGGTGAAGGTCAGTG 
CAGGTGAATTCGACCAGTGG 
532 
Chr 16: 
3108573 
MMP25_NF1_F_C 
MMP25_NF1_F_A 
MMP25_NF_R 
GCAGTACTGGCGCTACGAC 
GCAGTACTGGCGCTACGAA 
GTCACCTGGAGGAGCAGAG 
278 
IOP1_DR_F 
IOP1_DR_R 
GTGAAGGGTGAAGGTCAGTG 
CAGGTGAATTCGACCAGTGG 
532 66 
C
U
X
1
 
Chr 7: 
101758496 
CUX1_NF_F_A 
CUX1_NF_F_T 
CUX1_NF_R 
GCCTTTCAGCCCTGGAAAA 
GCCTTTCAGCCCTGGAAAT 
CTAGCGTTGTTAGGTGTGAC 
507 
PRKCQ_DR_F 
PRKCQ_DR_R 
GTGCTCTGTCCTCCTTATAC 
GGTATTCGTCTTGGCATCTC 
355 62 
bp: base-pairs; ºC: degrees Celsius; Chr: chromosome; Frag.: fragment; Ta: annealing temperature. 
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Table 6. Final concentration of the reagents used in ASO-PCR. 
Alt.: altered; Chr: chromosome; dATP: deoxyadenosine triphosphate; dCTP: deoxycitidine triphosphate; dGTP: deoxyguanosine triphosphate; DNA: deoxyribonucleic acid; dTTP: 
deoxythymidine triphosphate; M: molar; MgCl2: magnesium chloride; μM: micromolar; mM: millimolar; ng/μL: nanograms per microliter; NH4: ammonium; Ref.: reference; U/μL: 
units per microliter. 
          Rare Variants 
Reagents 
rs371042844 rs41292856 rs149944392 rs199636230 rs143836348 
Chr 3: 
52546850 
Chr 3: 
52548167 
Chr 16: 
3108251 
Chr 16: 
3108573 
Chr 7: 
101758496 
10x NH4 Reaction 
Buffer 
3.33x 3.33x 3.33x 3.33x 3.33x 3.33x 3.33x 3.33x 3.33x 3.33x 
MgCl2 Solution  
(50 mM) 
7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 7.08 mM 
dATP (100 mM) 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 
dCTP (100 mM) 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 
dGTP (100 mM) 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 
dTTP (100 mM) 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 0.67 mM 
Betaine Solution  
(5 M) 
- - - - - - - 1.50 M 1.50 M - 
Ref. allele primer (10 
μM) 
2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 1.00 μM 2.00 μM 2.00 μM 2.00 μM 
Alt. allele primer  
(10 μM) 
2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 1.00 μM 2.00 μM 2.00 μM 2.00 μM 
Common primer  
(10 μM) 
2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 2.00 μM 1.00 μM 2.00 μM 2.00 μM 2.00 μM 
Control forward 
primer (10 μM) 
0.50 μM 1.00 μM 0.50 μM 1.50  μM 2.00 μM 1.00 μM 0.75 μM 2.00 μM 0.50 μM 1.50  μM 
Control reverse 
primer (10 μM) 
0.50 μM 1.00 μM 0.50 μM 1.50  μM 2.00 μM 1.00 μM 0.75 μM 2.00 μM 0.50 μM 1.50  μM 
BIOTAQ DNA               
Polymerase (5 U/μL) 
0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 0.05 U/μL 
DNA (20 ng/μL) 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 3.96 ng/μL 
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Table 7. Amplification conditions used in ASO-PCR. 
Temperature (ºC) Time Cycles 
94 3 minutes 1 
94 30 seconds 
30 Optimized Ta for each variant 45 seconds 
72 1 minute 
72 2 minutes 1 
ºC: degrees Celsius; Ta: annealing temperature. 
                 
Sanger sequencing was also used in the validation process for the rare variants 
approach. However, this method was only used as a confirmation method, since it was 
performed to confirm the genotype of a single exome in which doubts had arisen in its 
validation by the previously mentioned methods. This sequencing method is based on the 
ability of DNA polymerases to incorporate dNTPs and dideoxynucleotides (ddNTPs). The 
DNA polymerases copy single-stranded DNA templates by adding dNTPs to a growing 
chain, however, when they incorporate ddNTPs at the 3’ end of the growing chain, chain 
elongation is prematurely terminated on a specific nucleotide (A, T, C or G), resulting in 
different size fragments. Each of the chain-terminating ddNTPs are differently 
fluorescently labeled, which, along with the size difference of each fragment, makes it 
possible to separate the fragments by capillary electrophoresis and “construct” the DNA 
sequence. Therefore, for the genotype confirmation by Sanger sequencing, the gene region 
of interest was amplified using a forward and reverse primer, designed in the Oligo 
Explorer software, version 1.2 (Gene Link
TM
, Hawthorne, New York, United States of 
America) (Table 8). 
 
Table 8. Information regarding the primers used for the amplification of the region of interest for 
Sanger sequencing. 
 
Gene 
 
Chr: 
end 
position 
Primer name 
Primer sequence 
(5’>>3’) 
Frag. 
size 
(bp) 
Optimized 
Ta (ºC) 
MMP25 
Chr 16: 
3108251 
MMP25_NF_F_N 
MMP25_NF_R 
GTGTCAGCCTCCCAATGTGC 
GTCACCTGGAGGAGCAGAG 
882 62 
bp: base-pairs; ºC: degrees Celsius; Chr: chromosome; Frag.: fragment; Ta: annealing temperature. 
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For this PCR reaction, the conditions were optimized using Phusion High-Fidelity DNA 
Polymerase (Thermo Scientific, Lithuania), dNTPs (BIORON, Ludwigshafen, Germany) 
and betaine solution (VWR, Denmark), with a final reaction volume of 50 μL. The reagents 
final concentrations are presented in Table 9.  
 
Table 9. Final concentration of the reagents used in the PCR reaction. 
                                                    Rare Variant 
Reagents 
Chr 16: 3108251 
5x Phusion GC Buffer 1.00x 
dNTPs mix (5 mM) 0.20 mM 
Betaine (5 M) 1.50 M 
Forward primer (10 μM) 0.30 μM 
Reverse primer (10 μM) 0.30 μM 
Phusion DNA Polymerase (2 U/μL) 0.02 U/μL 
DNA (20 ng/μL) 2.00 ng/μL 
Chr: chromosome; DNA: deoxyribonucleic acid; dNTPs: deoxynucleotides; M: molar; μM: 
micromolar; mM: millimolar; ng/μL: nanograms per microliter; U/μL: units per microliter. 
  
The amplification process was performed by MyCycler
TM
 Thermal Cycler (Bio-Rad 
Laboratories, Hercules, California, United States of America) under the conditions 
presented in Table 10. The region of interest in this gene had a high percentage of GC 
content, and a touchdown polymerase chain reaction (TD-PCR) was selected for its 
amplification. This type of PCR represents an empirical approach to favoring the most 
specific primer–template interactions, and can be incorporated as a standard part of any 
PCR to enhance specificity and product formation. The key principle in TD-PCR is to 
employ successively lower annealing temperatures, beginning with an annealing 
temperature above the projected melting temperature, then transitioning to a lower, more 
permissive temperature over the course of 10–15 cycles. This approach exploits the 
exponential nature of PCR, where the first stages of annealing and amplification are the 
most critical in producing the desired product (155). 
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Table 10. Amplification conditions used in TD-PCR. 
Temperature (ºC) Time Cycles 
98 3 minutes 1 
99 1 minute 1 
98 10 seconds 
14 76-1/cycle 30 seconds 
72 30 seconds 
98 10 seconds 
21 62 30 seconds 
72 30 seconds 
72 5 minutes 1 
ºC: degrees Celsius. 
 
Lastly, the results were visualized by performing an electrophoresis on a 1% (w/v) 
agarose gel with TAE buffer, in which, besides the sample, a molecular marker, the 
NZYDNA Ladder I (NZYTech, Lisbon, Portugal). A current of 90 V was applied for 30 
minutes to the agarose gel and the gel, stained with ethidium bromide, was visualized 
under ultraviolet light with the Molecular Imager Gel Doc XR System (Bio-Rad 
Laboratories, Hercules, California, United States of America). A negative control, as well 
as a wild-type and a heterozygous sample, was performed for this PCR reaction, using the 
same conditions. 
After this process, the amplified fragment was purified using magnetic beads, the 
Agencourt
® 
AMPure
®
 XP (Beckman Coulter Inc., Brea, California, United States of 
America), that connect to the amplified DNA fragment, allowing the unamplified material 
to be discarded. This procedure was performed accordingly to the manufacturer 
instructions. Finally, the purified fragment was sent to GATC Biotech in Cologne, 
Germany, for Sanger sequencing.     
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 3| Results and Discussion 
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1. Characterization of the population under study 
 
Case-control studies are used to compare the frequency of SNP alleles in two different 
but well-defined groups of individuals, the cases, who have been diagnosed with the 
disease under study, and the controls, who are either known to be unaffected or who have 
been randomly selected from the population. One of the major problems in this type of 
studies is ensuring a good match between the genetic background of cases and controls so 
that any genetic difference between them is related to the disease under study and not to 
biased sampling. Therefore, cases and controls should be from similar ethnic groups and 
have similar characteristics (156).   
A total of 36 individuals were included in this study, 20 (55.6%) men and 16 (44.4%) 
women. From those individuals, 19 subjects composed the control group and 17 subjects 
were included in the case group, according to the nephropathy clinical diagnosis. The 
characteristics of each exome used in this study are presented in Appendix B – Table B1 
and Table B2, while the overall characteristics of both groups are presented in Table 11.  
 
Table 11. Statistics of the individuals in the control and case groups for the covariates used in the 
statistical analysis.  
χ2: chi-square test; HbA1c: glycated hemoglobin; n: number of individuals.    
                                                         Statistics 
     Covariates 
Mean ± 
Standard 
Deviation   
t-test  
(p-value) 
% 
χ2 
(p-value) 
Age 
(years) 
Controls (n=19) 62.2 ± 8.1 
0.022 - - 
Cases (n=17) 67.8 ± 5.7 
Disease 
duration 
(years) 
Controls (n=19) 14.7 ± 9.5 
0.556 - - 
Cases (n=17) 16.5 ± 9.1 
HbA1c 
(%) 
Controls (n=19) 9.6 ± 2.2 
0.279 - - 
Cases (n=17) 8.7 ± 2.6 
Sex 
Controls 
(n=19) 
Male (n=9) 
- - 
47.4 
0.296 
Female (n=10) 52.6 
Cases  
(n=17) 
Male (n=11) 
- - 
64.7 
Female (n=6) 35.3 
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The covariate age was the only one that presented a statistically significant difference 
between the control and case groups (p-value ≤ 0.05), while the remaining covariates 
disease duration, HbA1c and sex, showed no statistically significant difference between the 
two groups (p-value ≥ 0.05). However, despite the difference between the groups for age, 
the performed statistical tests were adjusted for this parameter, as well as for the remaining 
covariates.     
One of the major determinants of the development of microalbuminuria or the 
progression of microalbuminuria (incipient diabetic nephropathy) to macroalbuminuria 
(overt diabetic nephropathy) is age, where individuals diagnosed with diabetic nephropathy 
are older (54). This is in accordance with the mean of age of both groups in this study, 
where the case group presented a higher mean of age (67.8 years) compared with the 
control group (62.2 years). It is also well known that blood pressure increases with age, 
and systemic hypertension is a risk factor for the initiation and progression of diabetic 
nephropathy (54,55). Regarding the covariate diasease duration, its mean in this study was 
also higher in individuals from the case group (16.5 years) in comparison to controls (14.7 
years). Therefore, a correlation between age and disease duration with the development of 
diabetic nephropathy can be found, since the case group is the one that presents individuals 
diagnosed with diabetic nephropathy, as well as older individuals and individuals with 
longer disease duration. The measurement of HbA1c levels is used to monitor the degree 
of control regarding glucose metabolism in diabetic individuals. In the normal 120-day 
lifespan of the red blood cells, glucose molecules react with hemoglobin through a 
posttranslational, non-enzymatic, substrate-concentration dependent irreversible process, in 
which the aldehyde group of glucose binds with the N-terminal of valine in the β-chain of 
hemoglobin, forming glycated hemoglobin. The International Diabetes Federation and 
American College of Endocrinology recommends a HbA1c value below 6.5%, while the 
American Diabetes Association recommends that the HbA1c be below 7.0% for most 
patients (157). In this study, the means for HbA1c in the control group (9.6%) as well as in 
the case group (8.7%) are above the recommended values by the International Diabetes 
Federation and American College of Endocrinology and the American Diabetes 
Association. This indicates that most of the individuals present in each of the groups have 
poor glycemic control. Clinical trials have demonstrated that a normalization of glycemia 
can greatly reduce the incidence of the diabetic complications associated with T2D. 
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However, in clinical practice, normalizing the blood glucose levels is not a trivial task, and 
almost 50% of diabetic subjects fail to reach the recommended HbA1c values (158). In 
respect to the covariate sex, it can be observed that the controls present more female sex 
individuals than males (52.6% against 47.4%) and the majority of individuals in the case 
group are male rather than female (64.7% against 35.3%).  
Lastly and curiously, the study participant corresponding to exome 136, a 70 years old 
man, with a disease duration of 22 years and a HbA1c of 8.5% (Chapter 6| Appendices – 
Appendix B – Table B1), even though it possess all the determinants for having an 
increased risk of developing diabetic nephropathy, this individual does not present the 
diabetic complication, being part of the control group. However, the participant 
corresponding to exome 132, a 56 years old woman, with a disease duration of only 2 years 
and a HbA1c of 5.4% (Chapter 6| Appendices – Appendix B – Table B2) that do not 
present any of the factors responsible for an increased risk of developing diabetic 
nephropathy, presents the complication, being part of the case group. These observations 
support the idea of a genetic contribution for the development of diabetic nephropathy. 
 
2. Whole-Exome Sequencing 
 
2.1. DNA extraction and Quality Control 
 
After the DNA extraction and before the initiation of the sequencing process, it is 
crucial to verify DNA integrity of all the samples that will be sequenced. That integrity 
was evaluated on an agarose gel. An example of the evaluation of sample DNA integrity is 
presented in Figure 22. The samples run in the gel were from exome 1 to exome 10, being 
exomes 2,3,4 and 7 the only ones that were included in this study. 
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Figure 22. Electrophoresis of DNA samples in a 1% (w/v) agarose gel, using the molecular marker 
NZYDNA Ladder III. The DNA samples (exomes) to which each band in the gel corresponds are 
presented above the gel, and the band size, in base-pairs, of the ladder is represented on the left side 
of the agarose gel.  
 
In the step following DNA extraction, namely the exome library preparation, high 
molecular weight genomic DNA is required. Therefore, if the DNA had good integrity, 
only a high molecular weight band was visible in the gel. Regarding all the DNA samples 
of individuals participating in this study, the gels performed to evaluate DNA integrity 
showed the presence of only a high molecular weight band and no other bands for smaller 
molecular weights, meaning that all the DNA samples revealed high integrity, allowing 
their exome library preparation and sequencing.    
 
2.2. Sequencing process 
 
After the exome library preparation, quality control was performed by evaluating the 
library profile, which allows to assess DNA fragments size and to verify if primer-dimers 
were present. An example of the expected library profile from Bioanalyzer of two different 
exomes from individuals participating in this study is presented in Figure 23. 
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Figure 23. Expected exome library profile from Bioanalyzer. (A) library profile of exome 142, (B) 
profile of the library from exome 161. The black numbers on the peaks represent the size of the 
DNA fragments and the purple and green numbers represent the size of the markers (upper and 
lower markers, respectively).    
 
The exome library quality is a critical determinant of the success of a sequencing run. 
The library profile obtained from Bioanalyzer for all the exome samples showed the peak 
corresponding to the expected size for the exon amplicons (around 200-300 bp), but also a 
larger peak with higher molecular weight that resulted from the overamplification during 
the PCR step (159). The larger amplicons are not included in the PCR emulsions and do 
not interfere with the sequencing. Primer-dimers (around 80-85 bp) can also be formed 
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during PCR, however, these PCR artifacts were not present in any of the 36 exome 
libraries. The library profile from all the individuals participating in this study was 
therefore the expected one, allowing the continuation of the sequencing process. 
 
After each sequencing run in Ion Proton
TM
 Sequencer several metrics are obtained for 
the sequenced exomes. In Figure 24, as an example, a sequencing run report of two exomes 
sequenced at the same time is displayed. 
 
 
Figure 24. Sequencing run report from Ion ProtonTM Sequencer. This report refers to the run 
where exome 142 and exome 161 were sequenced. 
 
A full report with the exome sequencing metrics is provided. The report example from 
exome 142 and exome 161 indicated a 90% chip load and a total of 92,624,052 reads with 
a mean read length of 191 bp, from both exomes combined. For the remaining 36 exomes, 
full reports for every 2 sequenced exomes were also obtained, with similar results to the 
ones presented here. The sequencing metrics obtained for the 36 exomes integrating this 
study were within the value range predefined by Life Technologies
TM
 for exome 
sequencing. For a minimum coverage of 20x per base, the predefined values include a 
minimum of 30,000,000 reads per exome library and a minimum mean read length of 140 
bp. 
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2.3. Bioinformatics Analysis 
 
In WES, there is still a high variation in coverage, regardless of the sequencing platform 
used. Therefore, an average depth of coverage of 80x is required to cover 89.6% to 96.8% 
of the target region (160). The coverage analysis for each exome is presented in Appendix 
C – Table C1 and, in Table 12, only the mean and standard deviation of the coverage 
analysis from the reads obtained in the sequencing process is showed.  
 
Table 12. Mean and standard deviation of the coverage analysis metrics. 
Coverage Analysis metrics Mean ± Standard Deviation 
Mapped Reads (number) 40,674,699 ± 7,782,233 
Reads on Target (%) 94.41 ± 0.01 
Mean Depth (x) 116.24 ± 24.38 
Uniformity (%) 92.42 ± 0.01 
   
Many factors influence the minimum read depth of coverage that is required to address 
adequately a biological question using exome sequencing. A higher depth of coverage is 
usually associated with a more reliable calling of the genetic variants present in a given 
population, allowing a reduction of the false-discovery rate in the variant calling step 
(160). Therefore, the coverage analysis metrics obtained for the 36 exomes was, for the 
mapped reads, namely the number of reads aligned with the reference genome, a mean of 
40,674,699 reads; the mean of the reads on target, reads that were aligned to the target 
region, was 94.41%; the mean of the mean depth of coverage, in other words, the average 
number of times that a particular nucleotide is represented in a collection of random 
sequences, was 116.24x and lastly, the coverage uniformity, meaning the “horizontal” 
coverage of the targeted genomic intervals, was 92.42%. Since a depth of coverage around 
80x is the required for the coverage of 89.6% to 96.8% of the target region, it can be 
considered that all exomes in this study, with the exception of exome 3, 4 and 116, 
presented a good coverage of the intended target region (Chapter 6| Appendices – 
Appendix C – Table C1). The obtained coverage analysis metrics for the total of exomes 
studied were within the value range predefined by Life Technologies
TM
 for exome 
sequencing. For a minimum coverage of 20x per base, the predefined values are a 
 78 
 
minimum of 30,000,000 mapped reads per exome library and a minimum of 85% of reads 
on target and uniformity. 
       
The mapping step in the bioinformatics analysis consisted in the alignment of the reads 
to the human genome reference sequence hg19. This ultimately allowed the execution of the 
variant calling step. In this step, all the positions in which the aligned sequence deviates 
from the reference sequence, creating genetic variants, are identified. All types of genetic 
variants present in the 36 exomes under study, as well as the number of homozygous and 
heterozygous for each variant type, are represented in Figure 25. The table from which the 
graphic representation originated, with the total number of genetic variants present in the 
study population, as well as the number of homozygous and heterozygous for each variant 
type by exome, is presented in Appendix C – Table C2.   
 
 
Figure 25. Graphic representation of the number of homozygous and heterozygous for each variant 
type in the 36 exomes. DEL HM: homozygous deletion; DEL HT: heterozygous deletion; INS HM: 
homozygous insertion; INS HT: heterozygous insertion; MNP HM: homozygous multiple 
nucleotide polymorphism; MNP HT: heterozygous multiple nucleotide polymorphism; SNP HM: 
homozygous single nucleotide polymorphism; SNP HT: heterozygous single nucleotide 
polymorphism.  
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Number of variants by type in the 36 exomes
SNP HM SNP HT INS HM INS HT
DEL HM DEL HT MNP HM MNP HT
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In the 36 exomes there was a total of 634,536 homozygous and 1,085,642 heterozygous 
SNPs, 19,086 homozygous and 40,980 heterozygous insertions, 20,708 homozygous and 
53,971 heterozygous deletions and lastly a total of 2,635 homozygous and 7,611 
heterozygous multiple nucleotide polymorphisms (MNPs). In general, there were more 
heterozygous genotypes for each variant type than homozygous. This latter genotype 
represented a combination of wild-types and altered homozygous. Furthermore, MNPs 
were, by far, the less common variant type found in the study population, while SNPs were 
the main type of variant found, being also the type of variant in which this work focused. 
 
3. Common Variants Approach 
 
3.1. Statistical Analysis 
 
As previously stated, it has been proposed that complex diseases be, in part, determined 
by genetic factors. This suggestion made it essential to identify the genetic basis for all 
complex diseases, and several methods emerged to study those bases (9,19). With an ever 
increasing number of methods developing, it became possible to identify and associate 
common variants with complex diseases, being a large number of those variants, primarily 
SNPs, already identified and associated with most of the complex human diseases and 
related traits (104).  
In this study, a list of common variants was obtained from the statistical analysis. Since 
the number of statistically significant common variants obtained, those with a p-value ≤ 
0.05, was high (654 common variants), several filters were applied to prioritize the 
variants. Therefore, the variants present in the 3’ or 5’-UTR, those intronic, the ones 
upstream or downstream of the gene, as well as the synonymous variants, had to have a 
CADD (135) ˃ 15 and be in conserved regions. Missense variants had to have at least one 
of the prediction programs (PolyPhen-2 (132), SIFT (134), and CADD) indicating that the 
variant was pathogenic or the variant had to be in a conserved region. In Appendix D – 
Table D1, a list of all the filtered genetic variants (135 common variants) is presented. 
Those filtered common variants were then studied based on the literature, to detect the 
most biologically relevant to the pathogenesis of diabetic nephropathy. Therefore, with this 
approach, 6 common variants present in 5 different genes were found as the most relevant 
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to the pathogenesis of diabetic nephropathy. Of those, 4 variants (rs1051303 and 
rs1131620 in LTBP4, rs660339 in UCP2 and rs2589156 in RPTOR) were considered 
protective variants, presenting an odds ratio (OR) < 1 and being primarily present in the 
control group. The remaining 2 variants (rs2304483 in SLC12A3 and rs10169718 in 
ARPC2) were considered risk variants, presenting an OR > 1 and being mainly present in 
the case group. An increased frequency of an altered allele or genotype in the case group 
compared to the control group indicates that the altered allele or genotype may be involved 
in an increased risk for developing the disease being studied (156).  
The annotation of the relevant common variants is presented in Table 13. The software 
applications PolyPhen-2, SIFT, and CADD indicated the impact of the SNP variants in the 
coding regions, while the programs SplicePort: An Interactive Splice Site Analysis Tool 
(161), Human Splicing Finder (HSF) (162), Analyzer Splice Tool, Splice Site Prediction 
by Neural Network (NNSplice) (163), HBond Score Web-Interface (164) and USD 
SplicePredictor Online Service (165) classified genetic variants in the splice regions. The 
results from those programs are available in Appendix D – Table D2.  
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Table 13. Annotation of the common variants biologically relevant to diabetic nephropathy.  
 Gene rs ID 
Ref. 
allele 
Alt. 
allele 
MAF 
(cases) 
MAF 
(controls) 
MAF 
(EUR) 
ESP/ 
1000G 
Type of 
variant 
PolyPhen-2 
* 
SIFT 
** 
CADD 
*** 
p-value 
Odds ratio 
(95% CI) 
Associated 
mechanism 
P
ro
te
ct
iv
e
 LTBP4 
rs1051303 A G 0.29 0.68 0.42/0.45 Missense Benign Tolerated 0.07 0.03 
0.21 
(0.051-0.853) Regulation of 
TGF-β release 
rs1131620 A G 0.31 0.68 0.42/0.45 Missense Benign Tolerated 0.00 0.05 
0.30  
(0.091-0.997) 
UCP2 rs660339 G A 0.26 0.58 0.41/0.42 Missense Benign Tolerated 9.07 0.02 
0.07  
(0.006-0.656) 
Oxidative stress 
RPTOR rs2589156 G A 0.03 0.26 0.13/0.10 Splice - - 10.18 0.01 
0.04  
(0.003-0.460) 
mTOR signaling 
pathway 
R
is
k
 SLC12A3 rs2304483 T C 0.68 0.42 0.38/0.42 Splice - - 2.18 0.01 
18.40  
(1.973-171.566) 
Systemic 
hypertension 
and RAAS 
pathway 
ARPC2 rs10169718 A G 0.62 0.32 0.49/0.53 Splice - - 6.68 0.03 
7.83  
(1.284-47.735) 
Actin 
polymerization 
1000G: 1000 genomes project; Alt.: altered; CADD: combined annotation dependent depletion; CI: confidence interval; ESP: exome sequencing project; EUR: Europe; MAF: minor 
allele frequency; mTOR: mammalian target of rapamycin; PolyPhen-2: polymorphism phenotyping v2; RAAS: renin-angiotensin-aldosterone system; Ref.: reference; SIFT: sorting 
intolerant from tolerant; TGF-β: transforming growth factor β.  
*PolyPhen-2 (132): “benign” (≥ 0 and ≤  0.452); “possibly damaging” (≥ 0.453 and ≤ 0.956) and “probably damaging” (≥ 0.957 and ≤ 1) 
**SIFT (134): “deleterious” (≤ 0.05) and “tolerated” (˃ 0.05) 
***CADD (135): higher scores corresponds to a higher pathogenicity (in this study a genetic variant was considered pathogenic with a score ≥ 12)     
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The variants rs2589156 in the RPTOR gene, rs2304483 in SLC12A3 and rs10169718 in 
the ARPC2, are splice region variants. For the variant present in RPTOR, there is a possible 
loss of the splice region, since the scores obtained from the prediction programs for the 
sequence with the variant were well below the ones obtained for the reference sequence. 
This variant is present in a donor splice site, which implies a possibility for the intron to 
start being considered an exon. For the remaining variants, rs2304483 in SLC12A3 and 
rs10169718 in the ARPC2, not all the prediction programs are in accordance. However, the 
majority considered these variants benign ones, since the scores obtained for the sequence 
with the variant are similar to the ones obtained for the reference sequence. This suggests 
that the variants do not affect the splice region. Furthermore, all of these common variants 
presented the minor alleles as altered alleles, with the exception of the variant rs2304483 in 
the SLC12A3 gene. In this variant, the minor allele corresponds to the reference allele. 
The genetic variants found in this approach are associated with several different 
mechanisms. The variants rs1051303 and rs1131620 present in LTBP4 gene play a role in 
releasing and activating TGF-β, the variant rs660339 UCP2 contributes for oxidative 
stress, the rs2589156 in RPTOR is involved in the mammalian target of rapamycin 
(mTOR) signaling pathway, the genetic variant rs2304483 in the gene SLC12A3 can be 
related to systemic hypertension and appears to be involved in RAAS pathway, and lastly, 
the variant rs10169718 present in the gene ARPC2 is implicated in actin polymerization.   
There is accumulating evidence that suggest that the TGF-β system plays an important 
role in the pathogenesis of diabetic nephropathy by regulating ECM proteins metabolism 
(mainly regulated by the TGF-β1 isoform). This factor is secreted in a large complex with 
no biological activity that consists of TGF-β, LAP and LTBP, being cleavage of both LAP 
and LTBP necessary for TGF-β activation (166). Like the others LTBPs, the LTBP4, 
encoded by the LTBP4 gene, is the constituent of the large latent complex responsible for 
TGF-β1 transportation into the ECM, limiting its availability to interact with TGF-β 
receptors (type II and type I serine/threonine kinase receptors). Thereby, proteolytic 
cleavage of LTBP4 allows the release of TGF-β1 from the ECM, rendering it accessible to 
connect with TGF-β receptors and consequently exert its effects on the ECM proteins 
metabolism through the Smad proteins (Figure 26) (167).  
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Figure 26. Model for LTBP4 action (taken from (167)). LTBP: latent TGF-β binding protein; 
SMAD-P: Smad proteins phosphorylation; TGF-β: transforming growth factor β.     
 
The LTBPs are produced in excess to TGF-β, and since TGF-β secretion is very 
inefficient in the absence of LTBPs, it is probable that most secreted cellular TGF-β is in 
large latent complexes (78). Therefore, an enhanced proteolytic susceptibility of LTBP4 is 
associated with increased TGF-β1 release and consequent Smad activation, being LTBP4 
responsible for the regulation of TGF-β secretion and activation (166,167). Furthermore, 
both of these variants, as well as others present in the LTBP4 gene, were also associated to 
Duchenne muscular dystrophy (DMD), the most common muscular dystrophy 
characterized by progressive muscle degeneration. This disease course varies among 
patients, but most of those patients lose ambulation between 6 and 12 years of age. The 
reason behind the differences in disease progression is still not clear. However, genetic 
modifiers in the LTBP4 gene have been proposed to contribute to those differences. This 
study shows a significant association between four SNPs in the LTBP4 gene, including the 
two variants associated to diabetic nephropathy in this study, and DMD progression. The 
four SNPs were associated with prolonged ambulation due to reduced TGF-β signalling. 
TGF-β is known to increase fibrosis in muscle tissue and several studies have shown that 
inhibition of its function decreases the presence of fibrosis and increases muscle strength in 
mdx mice, a surrogate for DMD (168). 
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The gene UCP2, where the common variant rs660339 is present, is associated with ROS 
production. Nowadays, there is increasing evidence that the overproduction of ROS is one 
of the major factors responsible for the development of diabetes itself as well as diabetic 
complications (169). Excessive amounts of ROS, mainly from the mitochondrial electron 
transport chain and nicotinamide adenine dinucleotide (NADH)/NADPH oxidases, after 
surpassing various endogenous anti-oxidative defensive mechanisms, oxidize various 
tissue biomolecules, such as, DNA, proteins, carbohydrates and lipids, being this state 
commonly referred to as oxidative stress (42). In diabetic nephropathy, ROS, in addition to 
mediate high glucose-induced angiotensinogen activation consequently increasing 
angiotensin II and contributing for RAAS over-activity, also induce TGF-β1 
overexpression in mesangial cells. It is known that a combination of strategies to prevent 
the overproduction of ROS (good glycemic control and/or inhibition of cytokines and 
growth factors) and to increase the removal of pre-formed ROS (conventional or catalytic 
antioxidants) may prove to be effective in preventing the development and progression of 
diabetic nephropathy (169).  
The uncoupling proteins (UCPs) belong to the mitochondrial anion transporter 
superfamily located in the inner mitochondrial membrane, having been described UCP 
homologs from 1-5 in mammals. It is well known that the protein UCP2, encoded by the 
UCP2 gene, is a mitochondrial antioxidant protein, whose inhibition induces oxidative 
stress favoring the formation of mitochondrial superoxide (170). Superoxide is the initial 
oxygen free radical formed by the mitochondria, which is then converted to other more 
reactive species that can damage cells in numerous ways. Normally, electron transfer 
through complexes I, III, and IV extrudes protons outward into the intermembrane space, 
generating a proton gradient that drives ATP synthase (complex V) as protons pass back 
through the inner membrane into the matrix. In diabetic cells, due to the high intracellular 
glucose concentration, there is more glucose-derived pyruvate, which generates more 
electrons donors (NADH and flavin adenine dinucleotide (FADH2)), resulting in an 
increased flux of electrons in the electron transport chain and consequently increased 
proton gradient across the inner mitochondrial membrane. As a result of this increase, 
electron transfer inside complex III is blocked, causing the electrons to back up to 
coenzyme Q, which donates the electrons one at a time to molecular oxygen, thereby 
generating superoxide. The mitochondrial isoform of the enzyme superoxide dismutase 
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(SOD) degrades this oxygen free radical to hydrogen peroxide, which is then converted to 
water (H2O) and oxygen (O2) by other enzymes (Figure 27) (171). 
 
 
Figure 27. Production of ROS by the mitochondrial electron transport chain (adapted from (171)). 
ADP: adenosine diphosphate; ATP: adenosine triphosphate; Cyt c: cytochrome c; FAD/FADH2: 
flavin adenine dinucleotide; H
+
: hydrogen ion; H2O: water; Mn-SOD: manganese-dependent 
superoxide dismutase; NAD
+
/NADH: nicotinamide adenine dinucleotide; O2: oxygen; O2
∙ -
: 
superoxide; Pi: inorganic phosphate; Q: coenzyme Q; UCP: uncoupling protein.  
 
As mentioned above, the passage of electrons through the chain generates a proton 
gradient across the membrane, being these protons allowed passage either via ATP 
synthase, which drives oxidative phosphorylation and consequent ATP production, or via 
UCPs, which dissipate the energy of the proton gradient as heat (44,171). It is then clear 
that UCPs increase proton conductance of the mitochondrial inner membrane, but only 
when they are activated by products of ROS metabolism, such as hydroxynonenal. In their 
absence, they do not affect the basal proton conductance of the membrane. Therefore, it is 
thought that superoxide production from the electron transport chain contributes to UCPs 
activation, being in this particular case, the activation of protein UCP2 (Figure 28) (172). 
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Figure 28. Model for the activation of the protein UCP2 (taken from (172)). H: hydrogen atom; 
H
+
: hydrogen ion; HO2
∙
: hydroperoxyl radical; O2: oxygen; O2
∙ -
: superoxide; OH: hydroxide; UCP: 
uncoupling protein. 
 
Superoxide, or its more lipid-soluble protonated form, hydroperoxyl radical, diffuses 
into the inner membrane, where it attacks n-6 polyunsaturated fatty acyl chains of 
membrane phospholipids, such as arachidonate, extracting a hydrogen atom and leaving 
behind a carbon-centered fatty acyl radical. This carbon-centered fatty acyl radical can 
react with molecular oxygen to form a lipid peroxyl radical, which initiates another round 
of carbon-centered radical production and breaks down to fragments like 4-
hydroxynonenal. In this way, a single hydroperoxyl radical can initiate a cascade that 
generates a large number of hydroxynonenal molecules that will activate, in this particular 
case, UCP2 (172). Activated UCP2 mildly uncouples substrate oxidation from ATP 
synthesis, thereby dissipating a portion of the mitochondrial proton gradient and, 
consequently, decreasing ATP production by the electron transport chain (173). Therefore, 
this uncoupling renders the electron flow through the electron transport chain complexes 
more efficient and decreases mitochondrial superoxide production, ultimately leading to a 
decreased ROS formation by mitochondria (170,173). The attenuation of mitochondrial 
ROS production eventually protects against ROS-related cellular damage (172). 
Podocytes play a critical role in preventing plasma proteins from leaking into the urine, 
being essential in the glomerular filtration barrier. Therefore, any kind of podocyte injury 
is believed to contribute to the development of diabetic nephropathy (174). The mTOR is 
an evolutionarily conserved protein kinase that plays a major role in cell growth and cell 
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size control. This serine/threonine kinase is the catalytical subunit of two multi-protein 
complexes, the mTOR complex 1 (mTORC1) and the mTOR complex 2 (mTORC2) 
(174,175,176). These complexes can be distinguished by their unique composition and 
different substrates. The mTORC1 is composed of five elements, the mTOR, its catalytic 
subunit, the regulatory-associated protein of mTOR, complex 1 (RPTOR, also known as 
Raptor), the mammalian lethal with Sec13 protein 8 (mLST8, also known as GβL), the 
proline-rich AKT substrate 40 kDa (PRAS40) and the DEP-domain-containing mTOR-
interacting protein (Deptor), being their exact function still elusive. The mTORC2 
comprises six different proteins, several of which are common to mTORC1 and mTORC2 
(176,177). The mTORC1 is rapamycin-sensitive and regulates a wide array of cellular 
processes including cell growth, proliferation, and autophagy, in response to nutrients such 
as insulin, glucose and amino acids. In response to these stimuli, mTORC1 is activated by 
two families of Ras-related small guanosine triphosphate (GTP)ases, the Ras homolog 
enriched in brain (Rheb) and Rags, even though the precise molecular mechanisms by 
which they activate mTORC1 remain unclear (175,178). Growing evidence suggests that 
increased activation of mTORC1 is likely to be associated with the pathogenesis of 
diabetic complications, being mTORC1 pathologically activated in podocytes in diabetic 
nephropathy early stages and its inactivation responsible for ameliorating podocyte injury. 
Furthermore, it was also found that high mTORC1 activation led to mislocalization of 
nephrin, a podocyte cell surface protein, causing it to be retained in the cytoplasm and, 
therefore, preventing the correct formation of the filtration barrier (Figure 29) (174,175). 
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Figure 29. mTOR signaling and nephrin localization in podocytes (adapted from (174)). In (A) is 
shown the mTOR signaling and nephrin localization in normal podocytes, and in (B) is shown the 
pathological mTORC1 activation that contributes to podocyte injury. AKT: alpha serine/threonine 
protein kinase; AMPK:  adenosine 3′,5′-monophosphate-activated protein kinase; GBM: 
glomerular basement membrane; GTP: guanosine-5’-triphosphate; mLST8: mammalian lethal with 
Sec13 protein 8; mTOR: mammalian target of rapamycin; mTORC1: mammalian target of 
rapamycin complex 1; mTORC2: mammalian target of rapamycin complex 2; Raptor: also known 
as RPTOR (regulatory-associated protein of mTOR, complex 1); Rheb: Ras homolog enriched in 
brain; Rictor: RPTOR independent companion of mTOR, complex 2; TSC1: tuberous sclerosis 
complex 1; TSC2: tuberous sclerosis complex 2.  
 
Increased activation of mTORC1 in podocytes resulted in proteinuria, loss of podocytes 
and foot processes, foot processes effacement and changes in the components of the 
glomerular basement membrane. Therefore, this complex inhibition has recently been 
suggested as a new therapeutic target to prevent diabetic nephropathy. However, the 
inhibition of mTORC1 also causes podocyte dysfunction leading to proteinuria, which 
suggests that a basal level of mTORC1 activity is required for maintaining the basic 
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physiology of podocytes. So, it is speculated that, under normal conditions, mTOR activity 
is essential for normal podocyte development and function (45,174,175). Although the 
precise molecular mechanisms of how mTORC1 deregulation might affect podocyte needs 
to be delineated, it is thought that the increase in its activity associated with diabetic 
nephropathy is likely an attempt to maintain podocyte homeostasis. However, this 
activation, which may provide some short-term benefits, ultimately causes this complex to 
mediate adverse effects (45,176). The protein encoded by the RPTOR gene, the gene in 
which the common variant found in this study population as associated with diabetic 
nephropathy, is an essential component of mTORC1, affecting this complex activity by 
regulating its assembly and recruiting the necessary substrates. Furthermore, this protein 
also plays a crucial role in determining the subcellular localization of mTORC1 and is the 
target of rapamycin, the mTORC1 inhibitor that performs its function by enhancing the 
dissociation of this protein from the complex, ultimately resulting in mTORC1 inhibition, 
which, as mentioned above causes podocyte dysfunction leading to proteinuria 
(174,179,180).  
The variant rs2304483 in the SLC12A3 gene has not yet been reported as associated 
with diabetic nephropathy. However, another common variant, rs11643718, also present in 
this gene, was associated in a Malaysian (181) as well as in a Japanese population (182) of 
type 2 diabetic individuals, as having a protective effect in diabetic nephropathy, therefore 
reducing the risk to develop this complication. Furthermore, another study in a type 2 
diabetic Korean population implicated an association between this same genetic variant 
and an increased risk for developing ESRD caused by diabetic nephropathy (183). On the 
other hand, there was also a study in which no association was found between this variant 
and diabetic nephropathy among a type 2 diabetic American Caucasians population (184). 
These studies performed so far present conflicting data, being one hypothesis for 
explaining that data divergence the fact that the effect of SLC12A3 genetic variants could 
be population specific (181,184). Therefore, it is necessary to carry further studies to 
clarify the effects of genetic variants present in the SLC12A3 gene in diabetic nephropathy 
(181).  
So far, little is known about the biological function of this gene, being only recognized 
that SLC12A3 encodes a thiazide-sensitive sodium/chloride (Na
+
/Cl
-
) co-transporter in the 
kidney. This co-transporter is responsible for the reabsorption of sodium (Na
+
) and 
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chloride (Cl
-
) from the lumen into the kidney endothelial cell in the distal convoluted 
tubule, being Na
+
 then returned to the blood system via the ATP-dependent sodium-
potassium pump (181,182). This transporter is thiazine-sensitive, being a hypothesis for the 
connection between this gene biological function and diabetic nephropathy that, as thiazide 
is widely used for systemic hypertension treatment, a known risk factor for the 
development and progression of diabetic nephropathy, a loss of function of this co-
transporter could be associated with a reduced blood pressure. Alternatively, this 
transporter could also regulate the reabsorption of unknown molecules, being a sustained 
decrease in its activity responsible for the accumulation of nephrotoxic substances (182). 
Furthermore, loss of function mutations in SLC12A3 are responsible for Gitelman 
syndrome, an inherited autosomal recessive trait characterized by low blood pressure due 
to renal Na
+
 wasting and electrolyte abnormalities, such as hypokalemia, metabolic 
alkalosis and hypocalciuria (182,183). This gene is also involved in the RAAS pathway in 
the lumen of a kidney cell. However, its precise role in this pathway still needs to be 
explored (181). 
The biological function of the ARPC2 gene is associated with a component of the 
glomerular filtration barrier, the podocytes. Over the years, it has become clear that 
podocytes are structurally and functionally complex cells that play a key role in preventing 
proteinuria, being a correct organization and regulation of the actin cytoskeleton in the 
podocyte essential for the maintenance of its morphology and consequently their function 
(185). In diabetic nephropathy, there can be a disruption of the actin cytoskeleton due to 
the impairment or collapse of actin filaments, which may cause podocyte foot process 
effacement and the emergence of proteinuria (185,186).  
It is now recognized that the nephrin-neph1-podocin receptor complex interact with 
actin cytoskeleton associated proteins, thereby signaling to regulate foot process 
cytoskeletal dynamics and morphology (92). This receptor complex is capable of 
assembling the protein complex responsible for inducing polymerization and elongation of 
the actin filaments, the actin-related protein-2/3 (ARP2/3) complex. Once the receptor 
complex is activated by tyrosine phosphorylation, it recruits the non-catalytic region of 
tyrosine kinase adaptor protein (Nck) and the growth factor receptor-bound protein 2 
(Grb2) to initiate actin polymerization. The first protein serves as an adaptor protein that 
recruits actin associated proteins such as neural Wiskott-Aldrich syndrome protein (N-
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WASP), components of the ARP2/3 complex and other components of the actin 
polymerization machinery that are necessary for its induction and regulation (187). The 
actin filaments are constituted by a fast growing end (barbed end) and a slower growing 
end (pointed end) and the dynamic assembly and disassembly of those filaments are crucial 
aspects of the actin function, being controlled by over a hundred actin-binding proteins. 
These proteins bind directly to filaments or monomers and control actin structure and 
dynamics by nucleating, capping, stabilizing, severing, depolymerizing, crosslinking, 
bundling, sequestering or delivering monomers, or by promoting monomer nucleotide 
exchange. An important set of actin regulators initiates formation of new actin filaments by 
a process called nucleation.  
The spontaneous nucleation is a kinetic hurdle in the process of actin polymerization, 
and, therefore, factors that can accelerate or bypass this step are important for efficient 
actin assembly in the cell. So far, three classes of protein have been identified that initiate 
new filament polymerization: the ARP2/3 complex, the formins, and spire (188). The 
ARP2/3 complex was the first of these molecules to be identified and has since been 
shown to have a crucial role in the formation of branched-actin-filament networks 
(186,188). This complex consists of a stable assembly of seven polypeptides, the actin-
related protein 2 and 3 (ARP2 and ARP3) and the remaining subunits are actin-related 
protein complex 1 to 5 (ARPC1, ARPC2, ARPC3, ARPC4 and ARPC5). The ARP2/3 
complex possesses little biochemical activity on its own. However, when engaged by 
nucleation-promoting factor (NPF) proteins, it is activated to initiate the formation of a 
new (daughter) filament that emerges from an existing (mother) filament in a y-branch 
configuration with a regular 70
º
 branch angle (Figure 30). The actin polymerization by this 
complex is autocatalytic, being the manner by which the nucleation and branching 
activities are linked together still a matter of debate (188). 
 
 
 
 
 
 
Figure 30. Diagram of ARP2/3 complex (adapted from (188)). ARP2/3 complex: actin-related 
protein-2/3 complex. 
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The protein ARPC2, encoded by the gene ARPC2, along with ARPC4 form the 
structural core of the complex, being the remaining subunits organized around them. The 
proposed models for this complex structure share the common principles that ARP2 and 
ARP3 interact with the pointed end of the daughter filament while the proteins ARPC2 and 
ARPC4 make substantial contacts with the mother filament (188). 
 
Furthermore, the biologically relevant common variants were localized in their 
respective genes to determine if some gene presented a variant “hotspot” (Figure 31).  
Figure 31. Localization of the common variants in their respective genes. (A) two variants present 
in LTBP4, (B) variant present in UCP2, (C) variant in RPTOR, (D) variant present in SLC12A3 and 
(E) variant localized in ARPC2. The gene sequences used were from version GRCh37 of Ensembl 
(139).   
 
The presence of a variant “hotspot” could not be determined in any of the genes, since 
the number of genetic variants present in each gene was reduced. However, in the LTBP4 
gene, two statistically significant common variants were found. Their localization, even 
though not enough to determine if there is or not a “hotspot” in this gene, can provide a 
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general idea of the subject. Therefore, those variants are located in neighboring exons of 
the gene, allowing the speculation of whether not an exon but the region surrounding them 
can be considered a variant “hotspot”. Nonetheless, in order to determine a “hotspot” in 
any gene with a certain degree of certainty, the presence of a significant number of genetic 
variants in that same gene is required.  
 
The missense genetic variants also have an impact regarding proteins, since they are 
localized in the genes coding regions (exons). The changes in amino acids that occur as a 
consequence of those genetic variants are presented in Table 14.   
 
 Table 14. Functional impact of the missense common genetic variants. 
 Alt.: altered; Ref.: reference. 
 
The structure for the LTBPs proteins is highly repetitive. They are mainly composed of 
epidermal growth factor (EGF)–like repeats, eight cysteine (8-Cys) repeats, as well as 
flanking regions containing proline-rich areas, or in some cases, glycine-rich areas. The N-
terminal of all LTBPs contains two or three copies of EGF-like repeats, one 8-Cys repeat, 
and another 8-Cys repeat often called the hybrid domain. That hybrid domain contains 
seven cysteines and shares similarity with both EGF and 8-Cys repeats (78). The N-
terminal of these proteins is responsible for the interactions between the LTBPs and the 
ECM. In the case of the LTBP4 protein, following the N-terminal domain, there is a 
protein sensitive region, called the hinge region, which is rich in proline and basic amino 
acid residues. Proteolytic cleavage at this region is thought to be responsible for the latent 
TGF-β release from the ECM and activation (78,167). The central part of all the LTBPs is 
a region resistant to proteolysis that consists of 9-14 EGF-like repeats and is supposed to 
form a helical rod-like structure. Moreover, these EGF-like repeats participate in protein-
protein interactions in addition to providing stability to protein structures via calcium 
binding (78). At the C-terminal of all LTBPs and consequently also in LTBP4, the 8-Cys 
Gene rs ID 
Ref. amino 
acid 
Alt. amino 
acid 
Change 
position/Protein 
length 
Codon change 
LTBP4 
rs1051303 Threonine Alanine 273/899 Acc/Gcc 
rs1131620 Threonine Alanine 240/899 Act/Gct 
UCP2 rs660339 Alanine Valine 55/225 gCc/gTc 
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repeats bind the small latent TGF-β complex, forming the large latent complex (78,167). 
The LTBP4 protein structure is shown in Figure 32. 
 
 
Figure 32. Protein structure for LTBP4 (adapted from (167)). 8-Cys: eight cysteine; ECM: 
extracellular matrix; EGF: epidermal growth factor; TGF-β: transforming growth factor β.  
 
Both variants present in the LTBP4 gene, rs1051303 and rs1131620, cause a change 
from the amino acid threonine to alanine at the protein positions 273 and 240, respectively. 
This change switches an essential amino acid characterized by a polar side chain 
(threonine) for a non-essential amino acid with a nonpolar side chain (alanine) in an 
interspecies conserved region for both variants. This change, theoretically, leads to a 
higher functional impact. Based on the information provided by UniProtKB, it can be 
verified that both of the amino acid changes occur between domains, not directly affecting 
neither of them. Therefore, it is probable that neither of the genetic variants results in a 
high impact regarding protein function, which complies with the information obtained 
from the impact prediction programs (PolyPhen-2, SIFT, and CADD). These programs are 
all in agreement with each other and classify both variants as benign. 
Regarding the UCP2 protein, the information available was limited compared with the 
one for the LTBP4 protein. Therefore, it was not possible to have a full knowledge of this 
protein structure, being only known that it contains 3 solute carrier (solcar) repeats. The 
genetic variant rs660339 in the UCP2 gene, causes a change from the amino acid alanine 
to valine at the protein position 55. This variant, present in a conserved interspecies region, 
results in a change from a non-essential amino acid with a nonpolar side chain (alanine) to 
an essential amino acid that also possesses a nonpolar side chain (valine). This change, 
theoretically, only causes a low functional impact since both of the amino acids belong to 
the same group and share similarities. Based on the information provided by UniProtKB, 
the amino acid change occurs in the solcar 1 repeat. The information obtained from the 
different impact prediction programs (PolyPhen-2, SIFT, and CADD) is in concordance 
with each other, since all of them classify this genetic variant as benign. 
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The splice variants do not possess a protein functional impact. Nonetheless, the variant 
rs2589156 in the RPTOR gene can have as a consequence a possible loss of the splice 
region. Therefore, the transcript that could be originated from this variant was searched for. 
However, no transcript where this loss is described was found, being all transcripts similar 
for the exons and introns positions. As the documented transcripts belong to supposedly 
healthy individuals, the absent of this possible transcript gives emphasis to the likely 
pathogenicity of this variant. The remaining variants, rs2304483 in the SLC12A3 gene and 
rs10169718 in the ARPC2 gene, were considered benign variants, which suggest that they 
do not affect the splice region. In compliance with this is the fact that no protein-coding 
transcripts were found as a consequence of these variants. 
 
3.2. Candidate Genes 
 
The candidate gene approach is one of the approaches being used to expand the 
knowledge regarding mechanisms linking the diabetic milieu to tissue damage, hoping that 
location and function of the identified variants will point to genes and molecular pathways 
that can be involved in the etiology of these conditions (158). This approach assumes a 
high probability of association between the development of the disease being studied and 
common genetic variants, based on the gene known function (40). Nonetheless, and even 
though valuable, it is difficult to draw firm conclusions from these studies. Some of the 
performed studies have often been small and have yielded p-values that are only nominally 
significant and cannot withstand an adjustment for multiple comparisons. In other cases, 
limited or no attempts were made to replicate the findings and, when those attempts were 
made, multiple reports were published with conflicting findings resulting either from false 
positives due to the marginal p-values or from false negatives due to the lack of statistical 
power. However, and despite these problems, interesting associations have emerged (158). 
 So far, only a small number of genetic variants in an also small number of candidate 
genes were identified (40). The complete list of the candidate genes, as well as their 
respective genetic variants, for European type 2 diabetic individuals, is available in 
Appendix D – Table D3. From those 19 candidate genes and their genetic variants, none of 
them was found in the common variants list that resulted from the statistical analysis of the 
population in this study.   
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The candidate genes found so far were selected on the basis of their postulated role in 
cellular pathways linking glucose to tissue damage, being mainly genes implicated in the 
pathways regulating the production of cellular toxins in response to hyperglycemia, 
namely, ROS, sorbitol and AGEs, and genes from pathways involved in the tissue-specific 
organ damage induced by these toxins (40,158). The ADIPOQ gene encodes for 
adiponectin, a cytokine exclusively produced by adipocytes that has insulin-sensitizing 
effects (158). Adiponectin levels are high in cases of diabetic nephropathy, but it remains 
unclear whether these high levels are a cause or a consequence of the disease. In the study 
performed it was verified that the two associated variants in this gene (rs17300539 and 
rs2241766) are determinants of renal risk by leading to high circulating adiponectin 
concentrations (189). In the gene that encodes the receptor for AGEs, the AGER gene, a 
SNP was identified as a significant predictor for diabetic nephropathy (2184A>G). 
Nowadays, there is an increasing amount of evidence supporting the role of AGEs, for 
which AGER is a receptor, in diabetic nephropathy pathogenesis (190).  
Of 31 SNPs associated with diabetic nephropathy in African Americans, the SNPs 
rs7285167 in the APOL2 gene, as well as rs61098917 and rs3747154 in LIMK2 and 
rs4478844 in OR2AK2, were also found to be associated with this complication in a 
European American population. The APOL2 gene encodes an apolipoprotein, while 
LIMK2, a LIM kinase, is involved in the regulation of the actin cytoskeleton, and OR2AK2 
is an odorant receptor (191). The carnosine dipeptidase genes, CNDP1 and CNDP2, 
present two and one variants associated with diabetic nephropathy, respectively. The 5-5 
leucine repeat polymorphism in CNDP1 was associated with a significantly reduced risk of 
developing diabetic nephropathy, while rs2346061 also in this gene and rs7577 in the 
CNDP2 gene were associated with an increased risk of developing the complication. These 
variants are located in the regulatory region of their respective genes, and could thereby 
modulate carnosinase activity. The CNDP1 encodes a dipeptidase that hydrolyses the 
substrate L-carnosine (β-alanyl-L-histidine) specifically while CNDP2 encodes a non-
specific dipeptidase. Carnosine has been linked to diabetic nephropathy, since it has been 
described as having anti-oxidant effects since it serves as a scavenger of oxygen radicals 
and thus can inhibit the formation of AGEs (192,193).  
The EPO gene encodes the angiogenic factor erythropoietin (EPO). In this gene, a SNP 
in the promoter region was identified and associated with elevated EPO, resulting in an 
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increased risk for the development of diabetic nephropathy (158,194). Furthermore, some 
reports suggest that iron overload might cause diabetic nephropathy. An increased 
accumulation of iron could affect insulin synthesis and secretion in the pancreas, as well as 
it could enhance oxidation of free fatty acids through accelerated production of free 
radicals. Moreover, it was suggested that accumulation of iron might causes kidney 
damage during the course of diabetes. Therefore, a study was conducted to evaluate the 
role of genetic variants in the hemochromatosis gene, the HFE gene, as a risk factor for 
type 2 diabetes associated diabetic nephropathy. This study concluded that rs1799945 in 
this gene was associated with the development of diabetic nephropathy (195). The HMGA2 
gene is ascribed as having an important role in the control of stem-cell development and 
proliferation, being an increase in its expression found in many benign, as well as 
malignant, tumors. Although the role of this gene in diabetic nephropathy or even in 
diabetes is still not fully understood, it was demonstrated that overexpression of HMGA2 
was associated with the formation of micropolycystic kidney, which suggested the 
involvement of this gene in kidney development. Furthermore, changes in HMGA2 
expression may ultimately increase the risk of developing irreversible glomerulosclerosis 
and tubulointerstitial fibrosis, both of which are involved in the pathogenesis of diabetic 
nephropathy. The performed study demonstrated that the HMGA2 variant (rs1531343) 
seems to be associated with increased risk of developing nephropathy in patients with type 
2 diabetes (196).  
The heat-shock proteins (HSPs) are molecular chaperones, synthesized under stress 
conditions, involved in renal cell survival and matrix remodeling in acute and chronic renal 
diseases. A study performed to investigate whether gene polymorphisms in HSPA1A 
affected diabetic nephropathy susceptibility in type 2 diabetic individuals indicated that 
rs1008438 and rs1043618 in this gene were associated with a predisposition to diabetic 
nephropathy (197). An association between the IL1RN gene, an interleukin-1 receptor 
antagonist, and several inflammatory diseases has already been found, being this gene 
implicated in that disease inflammatory mechanism. Therefore, an association was tested 
between this specific gene and complications of diabetes which have an inflammatory 
tissue component. From this experiment, an 86 bp variable number tandem repeat 
polymorphism in the intron 2 of this gene was found to be linked with T2D associated 
renal complications, being the functional significance of that polymorphism still being 
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investigated (198). The MYH9 gene encodes non-muscle myosin IIA and is expressed in 
glomerular podocytes and mesangial cells. Polymorphisms in this gene are strongly 
associated with idiopathic and HIV-associated forms of focal segmental glomerulosclerosis 
(FSGS) and nondiabetes-associated ESRD in African Americans, idiopathic FSGS and 
non-diabetic kidney disease in European Americans and non-diabetic ESRD in Hispanic 
Americans. However, gene polymorphisms in MYH9 have not been evaluated for 
association with diabetic nephropathy and consequent ESRD in type 2 diabetic individuals 
in a European American population. The conducted study presented the variants 
rs4821480, rs4281481, rs2032487 and rs3752462 as associated with the development and 
progression of diabetic nephropathy to ESRD in European Americans (199).  
The endothelial isoform of the nitric oxide synthase, encoded by the NOS3 gene, is a 
well-documented functional candidate gene for diabetic nephropathy susceptibility due to 
its involvement in catalyzing the production of nitric oxide, which is involved in the 
regulation of the vascular tone (190,200). So, in the performed study with the objective of 
investigating this gene possible role in the progression of nephropathy, the genetic variant 
894G>T was identified. This variant was considered a risk factor for the progression of 
diabetic nephropathy in type 2 diabetic individuals (200). In a study performed to evaluate 
an association between variants and diabetic nephropathy in individuals with type 2 
diabetes, 11.152 SNPs were investigated. From those, the top ranked SNPs were 
rs2285372 and rs2301572 in the PLXND1 gene, and rs1543547 in RAET1L. The PLXND1 
gene is expressed in human vascular endothelial cells and is required for the normal 
development of vasculature, while genes from the same family as RAET1L encode 
glycoproteins that are anchored to the membrane via GPI linkage (201). The SOD1 gene 
encodes for a superoxide dismutase enzyme. These enzymes play a major role in 
detoxification of ROS and protection against oxidative stress, since they catalyze the 
dismutation of superoxide into oxygen and hydrogen peroxide. Associations of SOD1 gene 
variants with diabetic nephropathy were reported in patients with type 1 diabetes. 
Therefore, in a conducted study in 2012, the association of variations in the SOD1 gene 
with nephropathy in patients with type 2 diabetes was investigated. From this study 
resulted the variant rs1041740, which showed an association with the prevalence of 
incipient nephropathy (microalbuminuria) (202).  
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As already known, TGF-β is one of the triggers of ECM protein overproduction, being 
an increased TGF-β1 production been reported as associated with the development of 
diabetic nephropathy. Thereby, the study conducted aimed to investigate the potential role 
of variants in the TGFB1 gene in microvascular diabetic complications such as diabetic 
nephropathy. The results of this study showed that the 869T>C variant in this gene was 
associated with an increased susceptibility to the development of diabetic nephropathy 
(203). Lastly, regarding the UMOD gene, several studies have identified this gene, which 
encodes the most common protein in human urine, to be associated with hypertension, a 
risk factor for diabetic nephropathy, and also with chronic kidney disease (CKD). Thus, the 
objective of the performed study was to examine the association of a single common 
variant in this gene (rs13333226) with type 2 diabetic nephropathy and kidney function. 
From the results obtained, this variant was associated with a decreased risk of nephropathy, 
being also associated with better kidney function and lower blood pressure. Nonetheless, 
the association with diabetic nephropathy was independent of blood pressure and kidney 
function (204).   
 
3.3. Validation 
 
The common variants described in Table 13 were validated by two different methods. 
First, each exome BAM file was manually verified for the positions of the genetic variants 
present in that same exome. This verification allows to distinguish between the real 
variants that were correctly identified in the variant calling step and the variants that were 
only identified in that step due to sequencing errors, being, therefore, an important 
validation step for all the genetic variants. An example of a BAM file for a wild-type, an 
altered homozygous and a heterozygous exome for each common variant is presented in 
Figure 33.  
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Figure 33. BAM file example for a wild-type, an altered homozygous and a heterozygous exome 
for each common variant. In (A) are represented the variants present in LTBP4, (B) refers to the 
variant present in UCP2, (C) considers the variant in RPTOR, (D) shows the genetic variant present 
in SLC12A3 and in (E) the common variant localized in ARPC2. The blue reads are the reverse 
strands and the pink reads represent the forward strands. HM Alt: altered homozygous; HT: 
heterozygous; WT: wild-type.  
 
In addition to the BAM files verification, all of the biologically relevant common 
variants obtained were also validated by the technique used to validate the sequencing 
technology. For that, 4 of the 36 exomes were genotyped by the Illumina microarray with 
the HumanOmniExpressExome. In this procedure, the various genotypes obtained by the 
Illumina microarray regarding specific variants in those 4 exomes were compared to the 
genotypes obtained by the Ion Proton
TM
 Sequencer for the same specific variants in the 
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same exomes, being those genotypes a match. The validation by this microarray is only 
possible for variants with rs ID.  
All the common variants were, thereby, checked and validated as real, both by the 
visualization of the BAM files, as well as by the comparison between the results obtained 
from the microarray with the ones obtained by the Ion Proton
TM
 Sequencer. Therefore, in 
the common variants approach, the performed validation procedures confirmed all of the 
results obtained by exome sequencing. 
 
4. Rare Variants Approach 
 
4.1. Statistical Analysis 
 
 
Until now, the common variants studies conducted have had little success in implicating 
specific genes in specific diseases, being thought that rare genetic variants can play a key 
role in influencing the development of complex diseases and its related traits (104,205).  
However, standard statistical methods used to test for association with single common 
genetic variants are underpowered for rare variants, unless sample sizes or effect sizes are 
very large. An alternative approach are burden tests that can assess the cumulative effects 
of multiple rare variants in a determined genomic region (205). Therefore, in this study, the 
rare genetic variants were grouped by gene using EPACTS (154), followed by a binary 
(cases vs. controls) gene-wise burden test. Statistically significant results, p-value ≤ 0.05, 
were obtained for 128 rare variant accumulating genes. Those genes are presented in 
Appendix E – Table E1. From the results obtained, each one of the statistically significant 
genes with accumulated rare variants was studied, based on the literature, to identify the 
most biologically relevant genes to the pathogenesis of diabetic nephropathy. From that 
search, 3 genes accumulating rare variants were selected as the most relevant genes. Of 
those, 2 genes (STAB1 and CUX1) were considered protective genes, presenting genetic 
variants mainly present in the control group. The remaining gene (MMP25) was considered 
a risk gene, with its accumulated variants primarily present in the case group.  
The annotation of the relevant genes and their respective accumulated rare variants is 
presented in Table 15. The software applications PolyPhen-2 (132), SIFT (134), and 
CADD (135) indicated the impact of the SNP variants in the coding regions, while the 
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programs SplicePort: An Interactive Splice Site Analysis Tool (161), HSF (162), Analyzer 
Splice Tool, NNSplice (163), HBond Score Web-Interface (164) and USD SplicePredictor 
Online Service (165) classified genetic variants in the splice regions. The results from 
those programs are available in Appendix E – Table E2.  
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Table 15. Annotation of the rare variants accumulated in genes biologically relevant to diabetic nephropathy. 
 Gene 
rs ID or Chr: 
end position 
Ref. 
allele 
Alt. 
allele 
Type of 
variant 
PolyPhen-2 
* 
SIFT 
** 
CADD 
*** 
MAF 
(cases) 
MAF 
(controls) 
p-value 
Associated 
mechanism 
P
ro
te
ct
iv
e
 
STAB1 
rs371042844 C T Splice - - 2.39 0.00 0.03 
0.01 
“Clearance” of 
AGEs 
 
rs41292856 A G Missense Benign Tolerated 11.49 0.00 0.03 
rs149944392 G A Missense Probably damaging Deleterious 21.40 0.03 0.00 
rs199636230 C T Splice - - 12.83 0.00 0.03 
rs143836348 T C Splice - - 2.50 0.00 0.03 
Chr 3: 52546850 G A Missense Benign Tolerated 8.11 0.00 0.03 
Chr 3: 52548167 G A Missense Possibly damaging Tolerated 16.07 0.00 0.03 
rs148915659 A G Missense Benign Deleterious 9.94 0.00 0.05 
rs143242234 C G Missense Possibly damaging Tolerated 17.20 0.00 0.03 
R
is
k
 
MMP25 
Chr 16: 3108251 T C Missense Probably damaging Deleterious 17.64 0.03 0.00 
0.01 
ECM 
degradation Chr 16: 3108573 C A Missense Probably damaging Deleterious 14.70 0.03 0.00 
P
ro
te
ct
iv
e
 
CUX1 
Chr 7: 101758496 A T Missense Benign Tolerated 15.94 0.00 0.03 
0.04 
Regulation of 
collagen I 
transcription rs148760130 G A Missense Benign Tolerated 16.10 0.00 0.03 
AGEs: advanced glycation end-products; Alt.: altered; CADD: combined annotation dependent depletion; Chr: chromosome; ECM: extracellular matrix; MAF: minor allele 
frequency; PolyPhen-2: polymorphism phenotyping v2; Ref.: reference; SIFT: sorting intolerant from tolerant.  
*PolyPhen-2 (132): “benign” (≥ 0 and ≤  0.452); “possibly damaging” (≥ 0.453 and ≤ 0.956) and “probably damaging” (≥ 0.957 and ≤ 1) 
**SIFT (134): “deleterious” (≤ 0.05) and “tolerated” (˃ 0.05) 
***CADD (135): higher scores corresponds to a higher pathogenicity (in this study a genetic variant was considered pathogenic with a score ≥ 12)     
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The variants rs371042844, rs199636230 and rs143836348 in the STAB1 gene are splice 
region variants. For rs371042844, all of the prediction programs displayed concordant 
results, with the scores from each software showing little or no variation for the sequence 
with the variant in comparison to the reference sequence. For the rs199636230 and 
rs143836348, the prediction programs were not all in accordance. However, the majority 
of those programs exhibited scores for the sequence with the variant that were similar or 
close to the scores obtained for the reference sequence. Therefore, all of these variants in 
the STAB1 gene can be considered benign variants, which suggests that they do not affect 
the splice region.  
The genes accumulating rare variants found with this approach are associated with 
different mechanisms. The STAB1 gene is responsible for the “clearance” of AGEs, the 
MMP25 gene is involved in ECM degradation, and lastly, the CUX1 gene presents a 
biological function associated with the regulation of collagen I transcription. 
Glycation describes the spontaneous reaction of nucleophilic groups of biomolecules 
with a broad spectrum of reactive carbonyl compounds, such as glucose, ribose, glyoxal, 
and MG. This reaction affects nucleic acids, lipids and, most importantly, proteins. Within 
proteins, glycation occurs mostly at the N-terminal and in the side chains of arginine and 
lysine residues due to their abundance and chemical reactivity. This reaction end-products 
are collectively referred to as AGEs, and its formation is slow, taking place over days and 
weeks (206). These products, generated by nonenzymatic glycation mainly of proteins, 
elicit a wide variety of cellular responses, including, induction of growth factors and 
cytokines, adhesion molecules, chemokines and oxidant stress production (207,208). These 
responses are thought to contribute to the development of pathologies associated with 
aging, DM and Alzheimer’s disease (207). In T2D, the increased formation of AGEs due 
to the chronic exposure to hyperglycemia can contribute to the development of 
complications associated with diabetes, namely diabetic nephropathy (Figure 34) 
(206,209,210). 
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Figure 34. Formation of AGEs (adapted from (210)). AGEs: advanced glycation end-products; 
CML: N(6)-Carboxymethyllysine; CTGF: connective tissue growth factor; GOLD: glyoxal-lysine 
dimer; HbA1c: glycated hemoglobin; IL-1: interleukin-1; TGF-β: transforming growth factor β; 
TNF: tumor necrosis factor.  
 
The AGEs can cause tissue damage by two main pathways, they either form cross-links 
that disrupts the structure and function of short and long-lived proteins and lipids, or they 
either interact with specific and nonspecific cell surface receptors, leading to altered 
intracellular events that induce oxidative stress and inflammation (208). The receptors and 
binding proteins through which they may exert their effects are classified as either 
inflammatory or “clearance” receptors. The inflammatory receptors include the advanced 
glycation end-product receptor (AGER, also known as RAGE), while the “clearance” 
receptors account for the cell surface glycoprotein cluster of differentiation 36 (CD36); the 
oligosaccharyl transferase complex protein 48, also known as advanced glycation end-
product receptor 1 (AGE-R1); the 80K-H protein, also known as advanced glycation end-
product  receptor 2 (AGE-R2); galectin-3, also known as advanced glycation end-product 
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receptor 3 (AGE-R3); the scavenger receptor class B type I (SR-BI) and type II (SR-BII); 
the macrophage scavenger receptor class A type I (SR-AI) and type II (SR-AII) and also 
the stabilin-1 (STAB1, also known as FEEL-1) and stabilin-2 (STAB2, also known as 
FEEL-2) (42,206,207,209). Circulating AGE levels reflect the equilibrium between 
endogenous formation and catabolism, including tissue degradation and renal elimination 
(208). Modulation of these products receptors expression has been shown to be important 
in the development of diabetic nephropathy, being changes in that expression closely 
associated with renal impairment (209).  
In diabetic nephropathy, AGEs can become accumulated in tissues, being its levels 
correlated with the complication severity. The mechanisms by which these products are 
involved in the development of diabetic nephropathy include modifications of various 
ECM proteins, such as collagens (non-receptor dependent mechanisms), as well as ROS 
generation through the interaction of tissue accumulated AGEs with AGER (receptor 
mediated mechanisms) (42). Because of their slow turnover, ECM proteins are highly 
susceptible to AGE modification, resulting in both altered structures and functions (210). 
The glycation of collagens yields cross-linking of these molecules, which leads to 
structural alterations, such as changes in packing density and surface charge, manifested by 
increased stiffness, reduced thermal stability and resistance to collagenase digestion 
(42,210). Also, interactions between matrix proteins can also be disturbed by AGE 
modifications. The affinity of laminin and fibronectin for type IV collagen and heparan 
sulfate proteoglycan is decreased after AGE modification. Furthermore, not only are AGE-
modified proteins more resistant to enzymatic digestion but also AGEs accumulation in 
vascular tissues is associated with a reduction in the matrix degradative capacity of the 
kidney (210). The interaction of AGEs with their receptor, AGER, may generate ROS 
through stimulation of NADPH oxidase. This ultimately contributes to the induction of 
growth factors such as TGF-β and CTGF (42,210,211). These factors, induced via the 
MAPK signaling pathway, are known to mediate the overproduction and decreased 
degradation of several ECM proteins (211). Moreover, AGEs directly potentiates the 
formation of ROS through catalytic sites in their molecular structure (210). All of these 
factors combined, in particular, the induction of TGF-β, eventually disrupt the metabolic 
turnover of the ECM, causing ECM accumulation, a diabetic nephropathy hallmark 
(42,210). That accumulation ultimately leads to mesangial expansion and glomerular 
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basement membrane thickening (211). Therefore, both the enhanced formation as well as 
the decreased clearance of AGEs is responsible for their tissue accumulation, resulting in a 
higher AGE load that requires clearance and detoxification as a protective mechanism 
(209,211). The STAB1 gene encodes for an endocytic “clearance” receptor for AGEs, the 
STAB1. The structure of this receptor is unique and unrelated to other “clearance” 
receptors, but its precise functions remain unclear. The STAB1 scavenges AGEs 
accumulated in vascular tissues in pathologies associated with aging or diabetes, playing a 
significant role in their elimination. Thereby, this receptor can be implicated in pathologies 
associated with aging or diabetes and can directly contribute to the development of diabetic 
vascular complications (207).  
The gene MMP25 is involved in ECM remodeling. During this remodeling, cleavage of 
the different ECM components is important for regulating matrix abundance, composition 
and structure (73). The MMPs have long been identified as critical mediators of ECM 
degradation and collectively they can degrade all of the ECM proteins (73,75). In diabetic 
nephropathy, the balance between ECM synthesis and degradation is one of the most 
important processes for maintaining the glomerular structural and functional integrity. 
Therefore, there is an increasing amount of evidence supporting an important role for 
MMPs in this complication development and progression, since the imbalance between 
ECM synthesis and degradation could lead to abnormal ECM deposition (75). The MMP25 
gene encodes for the MMP25 protein, also known as MT6-MMP, a GPI-anchored protein. 
This MMP is a relatively recent member of the MT-MMPs and has the capability of 
degrading specific substrates, such as collagen IV, gelatin and fibronectin (73,75,212). The 
type IV collagen and fibronectin are known ECM proteins that are accumulated in the 
kidney of individuals with diabetic nephropathy (44). Furthermore, in addition to those 
substrates, MMP25 also cleaves others MMPs, such as pro-MMP2 and pro-MMP9, 
activating them (73,74,75). In MMP9, a dinucleotide repeat polymorphism was shown to 
be protective against the development and progression of diabetic nephropathy (213).   
The CUX1 gene acts as a transcriptional modifier, being reported that this gene 
transcriptionally suppresses several other genes. In diabetic nephropathy, TGF-β, more 
specifically the isoform TGF-β1, has been characterized as a cytokine that plays a vital role 
in inducing the synthesis of matrix proteins, including collagen I. This growth factor shifts 
the balance towards the overproduction of ECM proteins, leading to scarring (214). The 
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gene CUX1 encodes the CUX1 protein, a member of the homeodomain family of DNA 
binding proteins that acts as a transcription factor. The majority of published studies 
describe it as a transcriptional repressor (22,214). This gene is important for kidney 
development, with its abnormal expression being implicated in kidney associated diseases 
(22). The transcription of the COL1A2 gene, the gene responsible for collagen I, is tightly 
regulated by transcription factors. The proximal promoter of COL1A2 is under the control 
of a CCAAT motif that is located at −80 bp relative to the transcriptional start site (TSS) 
and is recognized by a protein called CCAAT binding factor (CBF)/nuclear factor (NF)-Y. 
Studies have showed that single nucleotide base changes on the CCAAT motif of COL1A2 
lead to a defective transcription of the type I collagen gene. The CUX1 protein has been 
reported to carry a CCAAT displacement activity that enables it to compete for binding 
with CBF/NF-Y in relevant promoter/enhancers of genes. Therefore, CUX1 suppresses 
type I collagen by inhibiting the normal transcription of its gene, in a dose-dependent 
manner. This protein physically interacts with the COL1A2 proximal promoter, which 
leads to a partial competition for binding occupancy with CBF/NF-Y. As CBF/NF-Y is an 
activator of type I collagen gene expression, its displacement and therefore inability to 
associate with the promoter, results in a significant decrease in promoter activity. With the 
reduced promoter activity, a reduction of COL1A2 transcriptional activity also occurs, 
leading to a direct down-regulation of COL1A2 transcription. Furthermore, CUX1 has been 
shown to be a TGF-β responsive gene, since the growth factor induces CUX1 expression in 
a dose-dependent manner. In addition to this, TGF-β also promotes the movement of 
CUX1 to the nucleus, where it then becomes bioavailable to exert its inhibitory effects. In 
conclusion, a deregulation of the CUX1 gene may be a key factor leading to renal 
abnormalities due to ECM proteins accumulation. However, the repression of collagen I by 
transcriptionally switching off the collagen gene cannot be permanent, because collagen I 
is required during normal development and is necessary for tissue remodeling (214). 
 
Furthermore, the rare variants accumulated in the biologically relevant genes, were 
localized, to determine if some gene presented a rare variant “hotspot” (Figure 35). 
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Figure 35. Localization of the rare variants accumulated in their respective genes. In (A) are the 9 
variants present in STAB1, (B) refers to the 2 genetic variants present in MMP25 and (C) considers 
the 2 genetic variants accumulated in CUX1. The gene sequences used were from version GRCh37 
of Ensembl (139).  
 
The STAB1 gene is the gene with the highest number of rare variants accumulated. 
However, most of those variant are spread across the gene exons, not being evident the 
presence of a variant “hotspot”. Nonetheless, the variants rs148915659 and rs143242234 
share the same exon, creating a possible “hotspot”. Furthermore, also the variants Chr3: 
52546850 and rs41292856, even though not present in the same exon, are in neighboring 
exons. Nevertheless, even though the STAB1 gene presents a high number of rare variants, 
for the confirmation of the possible “hotspots” a greater number of variants are necessary. 
Regarding the MMP25 and CUX1 genes, the presence of a variant “hotspot” could not 
be determined, since the number of rare variants present in each gene was reduced.  
 
The missense rare variants, similarly to the common variants, also have an impact in 
terms of proteins, since they are variants localized in the gene exons. Therefore, the 
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changes in amino acids that occur as a consequence of those genetic variants are presented 
in Table 16. 
 
Table 16. Functional impact of the missense rare genetic variants. 
Gene 
rs ID or Chr: 
end position 
Ref. amino 
acid 
Alt. amino 
acid 
Change 
position/Protein 
length 
Codon 
change 
STAB1 
rs41292856 Serine Glycine 1089/2570 Agt/Ggt 
rs149944392 Glycine Serine 1529/2570 Ggt/Agt 
Chr 3: 52546850 Glycine Serine 1012/2570 Ggc/Agc 
Chr 3: 52548167 Alanine Threonine 1162/2570 Gcc/Acc 
rs148915659 Threonine Alanine 2116/2570 Act/Gct 
rs143242234 Proline Alanine 2135/2570 Ccc/Gcc 
MMP25 
Chr 16: 3108251 Phenylalanine Serine 359/562 tTc/tCc 
Chr 16: 3108573 Aspartate Glutamate 440/562 gaC/gaA 
CUX1 
Chr 7: 101758496 Lysine Isoleucine 217/676 aAa/aTa 
rs148760130 Arginine Glutamine 558/676 cGg/cAg 
Alt.: altered; Chr: chromosome; Ref.: reference. 
 
The information available regarding the STAB1 protein structure is reduced. Therefore, 
it was only possible to gather that this protein is comprised of 2570 amino acids and 
includes 7 fasciclins I (FAS1), 16 EGF-like repeats, 2 laminin EGF-like and 1 link domain 
near the transmembrane region (207). The FAS1 domains are present in secreted and 
membrane-anchored proteins, being that most of those proteins contain multiple FAS1 
domains, either in tandem or interspersed with other domains. Although the biological 
functions of many of these domains remain to be elucidated, it has been suggested that the 
FAS1 domain represents an evolutionarily ancient cell adhesion domain common to plants 
and eukaryotes (215). The EGF-like domain consists of approximately 40 amino acids 
residues in length and is characterized by a conserved arrangement of 6 cysteines residues 
which form disulfide bonds within the domain (Figure 36).  
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Figure 36. Structure of EGF-like domains (taken from (216)). The numbers represent the cysteine 
residues with the disulfide bonds.  
 
From this domain it is known that the EGF-like repeats of various proteins are involved 
in receptor-ligand interactions; that a common structural folding is shared by all the EGF-
like domains, based on the sequence homologies and dictated by the position of the 
disulfide bonds, and lastly, that this common structure forms three loops, which together 
provide specificity and maximum binding affinity in the proteins with this domain, being 
the recognition sequence located in loop B (216).  
In this gene, the rare variant rs41292856 causes a change from the amino acid serine to 
glycine at the protein position 1089. This change switches a non-essential amino acid with 
a polar side chain (serine) for an also non-essential amino acid but with a nonpolar side 
chain (glycine), in an interspecies conserved region. Based on the information provided by 
UniProtKB, this change occurs in the third FAS1 domain (FAS1 3). Even though this 
change switches an amino acid with a polar side chain for one with a nonpolar, both of the 
amino acids are non-essential. Therefore, theoretically, this change does not provide a 
significant functional impact. In accordance to this is the information obtained from the 
impact prediction programs (PolyPhen-2, SIFT, and CADD), which uniformly classified 
this variant as benign.  
The variants rs149944392 and Chr 3: 52546850, change the amino acid glycine to 
serine at the protein positions 1529 and 1012, respectively. These variants, present in 
interspecies conserved regions, result in the alteration of a non-essential amino acid with a 
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nonpolar side chain (glycine) to an also non-essential amino acid with a polar side chain 
(serine). According to UniProtKB, the variant rs149944392 is located in the twelfth EGF-
like domain and the Chr 3: 52546850 variant is present in the FAS1 3 domain of the 
protein. Although these changes switches an amino acid with a nonpolar side chain for one 
with a polar one, both of the amino acids are non-essential, allowing the speculation that 
maybe this change would not provide a significant functional impact for both variants. 
However, for the variant rs149944392, located in the twelfth EGF-like domain, all of the 
impact prediction programs (PolyPhen-2, SIFT, and CADD) classified this variant as a 
pathogenic one. This could be due to the location of the variant in the protein, affecting an 
important domain, and not due to the amino acid change itself. Regarding the Chr 3: 
52546850 variant, located in the FAS1 3 domain, the information obtained from the 
prediction programs (PolyPhen-2, SIFT, and CADD) is in compliance with the low impact 
amino acid change. All of the programs classified this variant as benign.  
The variant Chr 3: 52548167 results in an exchange from the amino acid alanine for the 
amino acid threonine at the position 1162. This exchange occurs between a non-essential 
amino acid with a nonpolar side chain (alanine) and an essential amino acid with a polar 
side chain (threonine), in an interspecies conserved region. The information obtained in 
UniProtKB localizes this variant in the fourth FAS1 domain (FAS1 4). Based on the amino 
acid change it can be speculated that the functional impact of this variant in terms of 
protein function can be high. This can be justified by the fact that it is the substitution of a 
non-essential amino acid by an essential one, but mainly, because it is a switch between 
amino acids belonging to distinct groups possessing very different characteristic (nonpolar 
side chain amino acid switched for an amino acid with a polar one). The information from 
the prediction programs for this variant is not consistent, since PolyPhen-2 and CADD 
classified the variant as pathogenic while SIFT considers it benign.  
The variant rs148915659 changes a threonine residue for an alanine residue at the 
protein position 2116. This switch occurs in an interspecies conserved region between an 
essential amino acid with a polar side chain (threonine) and a non-essential amino acid 
with a nonpolar side chain (alanine). Regarding protein localization in UniProtKB, the 
exchange takes place in the fifteenth EGF-like domain and can, theoretically, be 
considered a high functional impact exchange. This happens because the amino acid switch 
involves the substitution of an essential amino acid for the organism to a non-essential one. 
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Furthermore, also the groups to which each amino acid belongs are opposed ones (polar vs 
nonpolar). Once more, the prediction programs are not in accordance, being the variant 
considered benign in PolyPhen-2 and CADD, whereas SIFT classifies it as pathogenic, 
more specific deleterious.  
Lastly, the variant rs143242234 leads to the substitution of the proline amino acid for 
alanine at the protein position 2135, an interspecies conserved region. This substitution 
occurs between two non-essential amino acids that present nonpolar side chains and, 
according to UniProtKB, is localized in the sixteenth EGF-like domain. Due to the 
similarity between both amino acids regarding both being non-essential to the organism, as 
well as belonging to the same group and, therefore, sharing the same characteristics, this 
variant functional impact would, theoretically, be considered low. However, the PolyPhen-
2 and CADD programs considered this variant pathogenic, being SIFT the only one that 
considers it as benign. This could be justified by the location of the variant in the protein, 
maybe affecting an important domain, and not due to the amino acid change itself. 
The MMPs are composed of several shared functional domains, such as the signal 
peptide domain, the propeptide domain, the catalytic domain and the hemopexin-like 
domain (73,217). The signal peptide domain, present in the N-terminal of the protein, is the 
domain required for the secretion of MMPs. The propeptide domain contains a cysteine 
(Cys)-switch motif proline-arginine-cysteine-glycine-X-proline-aspartate (PRCGXPD), 
where X is any amino acid. Regarding the catalytic domain, this domain has proteolytic 
activity, in addition to containing a zinc-binding motif. The cysteine residue in this motif 
interacts with the zinc ion, keeping pro-MMPs inactive until the propeptide domain is 
removed. In the C-terminal, the hemopexin-like domain is present, being this domain 
present in almost all MMPs. This domain facilitates protein-protein or lipid-proteins 
interactions and is involved in substrate specificity and in the non-proteolytic functions of 
MMPs (73). The MT-MMPs share this same basic domain organization of most MMPs, 
with the exception of the anchoring region (217). This specific type of MMPs is anchored 
to the cell surface by either a transmembrane domain followed by a short cytoplasmic tail 
or a GPI sequence (73). The MMP25, a MT-MMP GPI-anchored protein, as well as other 
MT-MMPs, regardless of being transmembrane or GPI-anchored proteins, also contain a 
arginine-X-arginine/lysine-arginine (RXR/KR) motif, where X is any amino acid, at the 
end of the propeptide domain (217). This motif serves as a recognition site for pro-
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convertases such as furin, which cleaves the propeptide of inactive precursors, 
consequently activating the MT-MMP zymogen and releasing functional proteins (73,217). 
In Figure 37 the structure of the MMP25 protein is presented. 
 
 
 
 
 
Figure 37. Structure of the MMP25 protein, a MT-MMP GPI-anchored protein (adapted from 
(73)). GPI: glycosylphosphatidylinositol; Zn: zinc ion.  
 
The rare variants accumulated in the MMP25 gene that affect this protein are Chr 16: 
3108251 and Chr 16: 3108573. In Chr 16: 3108251, the change occurs between a 
phenylalanine residue and a serine one in the position 359. This means that an essential 
amino acid with a nonpolar and aromatic side chain (phenylalanine) is substituted for a 
non-essential amino acid with a polar side chain (serine). Regarding the Chr 16: 3108573 
variant, the aspartate is the amino acid switched for glutamate, in the protein position 440. 
Therefore, a non-essential amino acid with a negatively charged side chain (aspartate) is 
substituted for an also non-essential amino acid with a negatively charged side chain 
(glutamate). Furthermore, both of these switches occur in interspecies conserved regions 
and, accordingly to the information obtained by UniProtKB, both rare variant affect the 
hemopexin-like domain. Theoretically, the first variant, Chr 16: 3108251, would present a 
high functional impact, since phenylalanine is an amino acid essential to the organism and 
presents a cyclic group, therefore occupying more space in the protein structure, and is 
replaced by serine, a non-essential amino acid with a very different set of characteristics 
and a plain side chain. In addition to this, the affected domain is also a crucial one, as 
mentioned above, for MMPs to perform their function correctly. Moreover, agreeing with 
the high functional impact theory are all of the impact prediction programs since all of 
them, PolyPhen-2, SIFT, and CADD, classified this variant as a pathogenic one. The 
remaining variant, Chr 16: 3108573, would possibly present a low functional impact. This 
is because the amino acid exchange caused by this variant occurs between two non-
essential amino acids presenting the same type of side chain and, therefore, being very 
similar with each other. However, all of the prediction programs (PolyPhen-2, SIFT, and 
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CADD) classified this variant as pathogenic. This could be due to the fact that, even 
though similar among them, the switch occurs in the hemopexin-like domain and 
consequently can affect the function of the MMPs.    
The CUX1 protein is an evolutionarily conserved protein that contains four DNA-
binding domains (214). The CUX1 protein structural organization consists of an 
autoinhibitory domain present in the N-terminal, followed by a coiled-coil, three Cut 
repeats and a homeodomain, and in the C-terminal region, two active repression domains 
(218,219). Autoinhibitory domains are regions within the proteins that negatively regulate 
the function of other domains via intramolecular interactions. Autoinhibition is a potent 
regulatory mechanism that provides tight "on-site" repression and generates valuable clues 
to how a protein is regulated within a biological context (220). The coiled-coil is a folding 
motif with its most characteristic feature being a heptad repeat pattern of primarily 
nonpolar residues that constitute the oligomer interface. The architecture of this highly 
versatile folding motif determines its oligomerization state, rigidity and ability to function 
as a molecular recognition system (221). The Cut repeats are highly conserved 73 amino 
acid motifs in mammals that share from 52% to 63% amino acid identity with each other. 
Their degree of conservation suggests that they may carry an important biological function, 
and indeed, it has been shown that they bind specifically to DNA, functioning as DNA-
binding domains. These domains exhibit overlapping but distinct sequence specificities, 
possessing a relaxed DNA-binding specificity and being able to recognize a wide range of 
sequences. Following these Cut repeats is the homeodomain. This domain is a 61 amino 
acid DNA-binding domain that harbors a histidine at the ninth amino acid of the third 
helix. That amino acid is responsible for determining the specificity of binding to the two 
bases following the domain TAAT core. Also, alterations within the homeodomain affect 
the DNA-binding specificity. Furthermore, even though Cut repeats can bind to DNA with 
high affinity on their own, the highest DNA-binding affinity and specificity is achieved 
when the protein homeodomain binds to DNA in conjunction with the adjacent DNA-
binding domains (218). The details of the repression domains have not been defined yet. 
However, it is known that active transcriptional repressor proteins such as CUX1, in 
contrast to passive repressors, include independent repression domains and inhibit the 
initiation of transcription directly via the actions of these domains (222). The structure of 
the CUX1 protein is presented in Figure 38. 
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Figure 38. Structure of the CUX1 protein (adapted from (219)). CC: coiled-coil; CR1: Cut repeat 
1; CR2: Cut repeat 2; CR3: Cut repeat 3; HD: homeodomain; In: autoinhibitory domain; R1: 
repression domain 1; R2: repression domain 2.  
 
The rare variant Chr 7: 101758496 in the CUX1 protein cause a change from the lysine 
amino acid to an isoleucine, in the position 217. This alteration results in the substitution of 
an essential amino acid with a positively charged side chain (lysine) for an also essential 
amino acid, but with a nonpolar side chain (isoleucine), in an interspecies conserved region 
of the protein. Based on the information present in UniProtKB, this exchange is located in 
the coiled-coil, and this change possible functional impact can be both high or low. The 
high functional impact hypothesis can be justified by the different side chain characteristics 
of both amino acids, even though they are both essential to the organism. The low impact 
hypothesis can be justified by the fact that the switch leads to the substitution of a 
positively charged amino acid for a nonpolar one, and the coiled-coil is composed of a 
heptad repeat pattern of mainly nonpolar residues. Therefore, this change would not result 
in a significant alteration of the coiled-coil composition. The prediction programs are also 
not in compliance regarding the impact of this variant, with PolyPhen-2 and SIFT 
classifying it as a benign variant, and CADD considering it a pathogenic one.  
The variant rs148760130, leads to an exchange of a non-essential amino acid with 
positively charges side chain (arginine) for an also non-essential amino acid with a polar 
side chain (glutamine) in the interspecies conserved position, 558. In UniProtKB there is 
no information available regarding this position protein domain localization, being only 
possible to affirm that this position is located in a protein region following the coiled-coil. 
However, it can still be speculated that this variant would present a high functional impact, 
since, although they are both non-essential amino acids, there is a significant difference 
between their side chain characteristics. The impact prediction programs for this variant 
are once more not in agreement. PolyPhen-2 and SIFT classified this variant as benign, 
while CADD evaluated it as a pathogenic variant.  
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The splice variants rs371042844, rs199636230 and rs143836348 in the STAB1 gene do 
not possess a protein functional impact. These variants, according to the splice prediction 
programs were considered benign, which suggest that they do not affect the splice region.  
 
4.2. Validation 
 
To validate the genes obtained in the statistical analysis, several validation methods 
were applied to each of the genes accumulating rare variants (Table 17). 
 
Table 17. Validation procedures for each of the rare variants accumulated in the genes relevant to 
diabetic nephropathy. 
Gene 
rs ID or Chr: 
end position 
BAM 
files 
MAF (PT) 
n=19 
Illumina 
microarray 
ASO-PCR 
Sanger 
sequencing 
STAB1 
rs371042844 √ √  √  
rs41292856 √ √  √  
rs149944392 √ √  √  
rs199636230 √ √  √  
rs143836348 √ √  √  
Chr 3: 52546850 √ √  √  
Chr 3: 52548167 √ √  √  
rs148915659 √ √ √   
rs143242234 √ √ √   
MMP25 
Chr 16: 3108251 √ √  √ √ 
Chr 16: 3108573 √ √  √  
CUX1 
Chr 7: 101758496 √ √  √  
rs148760130 √ √ √   
ASO-PCR: allele-specific oligonucleotide polymerase chain reaction; BAM file: binary 
alignment/map file; Chr: chromosome; MAF: minor allele frequency; PT: Portugal.  
 
The first variant validation method was performed by verifying each exome BAM file 
manually for the positions of the rare genetic variants present in that same exome. As 
mentioned in the common variants approach, this verification is an important step for all 
genetic variants, since it allows to distinguish between the real variants that were correctly 
identified in the variant calling step and the variants that were only identified in that step 
due to sequencing errors. An example of a BAM file for a wild-type and a heterozygous 
exome for each rare variant accumulated in the respective gene is presented in Figure 39. 
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Figure 39. BAM file example for a wild-type and a heterozygous exome for each rare variant 
accumulated in the respective gene. In (A) the 9 variants present in STAB1 are reprensented, (B) 
refers to the 2 rare variants present in MMP25 and (C) considers the 2 variants of CUX1. The blue 
reads are the reverse strands and the pink reads represent the forward strands. HT: heterozygous; 
WT: wild-type. 
 
All of the rare variants were checked and validated as real, except for the variant Chr 
16: 3108251. The BAM file visualization of the heterozygous exome for this variant raised 
some doubts regarding the genotype veracity due to the reduced number of reads in the 
forward strand (pink reads) and the fact that, in that reduced number, only one of the reads 
presented the altered allele. 
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The second validation method was the determination of each rare variant MAF in the 
exomes of 19 healthy (without T2D and without diabetic nephropathy) Portuguese 
individuals unrelated to this study. This validation procedure allowed the determination of 
the variants frequency in the Portuguese population and therefore, the verification of the 
variants rarity, as well as their association with diabetic nephropathy. None of the rare 
variants accumulated in the genes obtained by the statistical analysis was present in any of 
the 19 healthy individuals exomes. Therefore, the absence of the variants in the tested 
healthy population confirms that the variants are indeed rare. Moreover, the fact that they 
are only present in type 2 diabetic individuals, regardless of whether they present or not 
diabetic nephropathy, but are not present in healthy individuals, gives emphasis to the 
association between those variants and an increased risk for the development or 
progression of the diabetic complication, as well as protection against it.  
   
Furthermore, 3 rare variants (2 belonging to STAB1 and 1 to CUX1) were also validated 
by the Illumina microarray with the HumanOmniExpressExome. This microarray 
genotyped 4 of the 36 exomes of individuals participating in this study, and the genotypes 
obtained for specific variants in those 4 exomes were then compared to the genotypes 
obtained for the same specific variants in the same exomes using the Ion Proton
TM
 
Sequencer. The genotypes obtained from both techniques were a match, being the tested 
rare variants validated as real. This comparison also allowed the sequencing technology 
validation, with the results obtained by exome sequencing being confirmed for the several 
tested variants. This microarray can only validate variants with rs ID.   
 
The rare variants that were not validated by this latter method were subjected to ASO-
PCR (10 rare variants, 7 in STAB1, 2 in MMP25 and 1 in CUX1). The genetic variants 
were validated for a heterozygous and a wild-type exome for each one of the rare variants 
accumulating in their respective gene. Moreover, negative controls were performed for all 
reactions. The heterozygous and wild-type exomes used in each rare variant are shown in 
Table 18 and the results for each variant and the respective negative controls in Figure 40. 
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Table 18. Heterozygous and wild-type exomes used in ASO-PCR for each of the rare variants 
accumulated in the genes relevant to diabetic nephropathy. 
Gene 
rs ID or Chr: end 
position 
Heterozygous exome Wild-type exome 
STAB1 
rs371042844 134 
21 
rs41292856 47 
rs149944392 4 
rs199636230 142 
rs143836348 158 
Chr 3: 52546850 38 
Chr 3: 52548167 168 
MMP25 
Chr 16: 3108251 132 
Chr 16: 3108573 3 
CUX1 Chr 7: 101758496 34 
Chr: chromosome. 
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Figure 40. Electrophoresis on 1.5% (w/v) agarose gels for the rare variants accumulated in (A) STAB1, (B) MMP25 and (C) CUX1. The molecular marker used was NZYDNA 
Ladder I, being its band size, in base-pairs, represented on the left side of each gel. Above the gels the genetic variant, as well as the optimized temperature for the ASO-PCR of 
each variant are presented and, in the right side of the gels the label for each fragment present can be seen. The alleles, as well as the exome genotype, are presented below each 
agarose gel. C
-
: negative control; HT: heterozygous; WT: wild-type.  
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By the visualization of the electrophoresis gels obtained for the different rare variants, it 
was possible to validate the variants as real, being therefore confirmed the exome 
sequencing results. The exception in this validation procedure was the variant Chr 16: 
3108251 in the MMP25 gene. The results from the exome sequencing showed that exome 
132 had a heterozygous genotype in this variant position. However, at the BAM file 
verification, this genotype had already raised some doubts regarding its veracity.  
Nonetheless, the variant was still subjected to ASO-PCR. Three different sets of primers 
were used to perform this variant ASO-PCR validation, but still, all of those sets originated 
results identical to the one presented in Figure 40 (B – first gel). Those results were 
consistent with a wild-type genotype and not with a heterozygous genotype. Therefore, to 
determine with certainty the exome real genotype, Sanger sequencing was used. 
 
Sanger sequencing was performed for the exome 132, which was supposedly in 
heterozygosity, and for the exome 21, which presented a wild-type genotype. The objective 
of this procedure was to confirm exome 132 genotype. The Sanger sequencing results for 
both the exome 132 and 21 in the rare variant position are in Figure 41. 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Sanger sequencing results for exome 132 and exome 21. The exome 132 was 
supposedly heterozygous (TC) while the exome 21 was a wild-type (TT).  
 
The results from the Sanger sequencing confirmed that the exome 132 genotype, 
obtained from the exome sequencing, in the variant Chr 16: 3108251 position was indeed 
incorrect. Thus, as it can be seen in Figure 35, exome 132 presents a wild-type genotype 
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instead of a heterozygous genotype as originally thought. Furthermore, Sanger sequencing 
also allowed to confirm that exome 21 was definitively a wild-type in this position.      
Exome 132 was the only exome of the 36 which supposedly presented the variant, being 
all others wild-types in this position. However, as the Sanger sequencing confirmed, this 
exome do not exhibit the variant in reality, and therefore, this variant cannot be a part of 
the study. As the MMP25 gene only accumulated two rare variants in the population used 
for this work, and taken into account that this variant can no longer be a part of the study, 
the MMP25 gene no longer accumulates rare variants. Therefore, this gene cannot be 
considered as a valid molecular marker for the development and progression of diabetic 
nephropathy in this work. This situation shows how important it is to verify manually each 
variant in the BAM files, as well as to perform proper validation procedures since exome 
sequencing still presents associated error rates.   
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 4| Conclusion 
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Along with the increase in T2D prevalence, it is expected that the prevalence of the 
complications associated with this condition also rise. Diabetic nephropathy, as well as 
other complications, is still poorly understood and often caught in a late stage. The 
identification of molecular markers for diabetic nephropathy, in addition to the already 
known risk factors, could contribute to a better understanding of this complication 
pathophysiology and also allow an early diagnosis as well as an adequate treatment. 
Although there is no definitive cure solution, diabetic nephropathy early diagnosis and 
early treatment are essential to delay the progression of this complication.  
In this study, the exomes of 36 Portuguese individuals with diagnosed T2D were 
sequenced. From those individuals, 19 did not present diabetic nephropathy, being 
included in the control group, while the 17 individuals that presented the diabetic 
complication formed the case group. Based on the genetic differences between these 
groups, candidate common genetic variants as well as genes accumulating rare genetic 
variants that could explain the increased or reduced risk associated with the development 
and progression of diabetic nephropathy were identified. 
In the search for common variants in the study population, 6 statistically significant (p-
value ≤ 0.05) common variants present in 5 different genes were considered as the most 
biologically relevant ones to the pathogenesis of diabetic nephropathy. Those variants are 
rs1051303 and rs1131620 in the LTBP4 gene, rs660339 in UCP2, rs2589156 in RPTOR, 
rs2304483 in SLC12A3 and lastly rs10169718 present in the ARPC2 gene. In all of these 
variants, the criteria used for their relevance determination was literature review, being all 
of the variants associated with the development or progression of diabetic nephropathy 
based in what is postulated in the literature about their genes biological function. The 
mechanisms in which these variants genes are involved include regulation of TGF-β 
release and activation, oxidative stress, the mTOR signaling pathway as well the RAAS 
pathway, systemic hypertension and the polymerization of actin.  
In the rare variants approach, 2 rare variants accumulating genes, with statistical 
significant (p-value ≤ 0.05), were identified as the ones with a greater potential to be 
relevant to the onset of diabetic nephropathy. The identified genes were STAB1 gene with 
9 accumulated rare variants and the CUX1 gene accumulating 2 genetic variants. Similarly 
to the proceedings in the identification of common variants, in this approach, also the 
relevance of the genes was assessed by literature review of the genes biological function. 
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These genes can be associated with both the development and progression of nephropathy, 
being involved in mechanisms such as the “clearance” of AGEs and the transcriptional 
regulation of collagen I, an ECM protein known to be accumulated in the mesangium of 
individuals with diabetic nephropathy. Based on the mechanisms, it is possible to verify 
that the rare variant accumulating genes are not involved in a specific mechanism, but 
rather spread across different ones. This is consistent with the description of rare variants, 
since they are defined as small effect variants with a strong cumulative biological impact. 
Therefore, subtle alterations throughout different mechanisms may have a cumulative 
effect responsible for the increased risk of developing diabetic nephropathy or its 
progression, as well as increased protection against it. 
Furthermore, all the mechanisms, regardless of being associated with the common 
variants or the genes accumulating rare variants, seem to be implicated in ECM 
accumulation or podocyte disturbances (dysfunction and/or loss), both diabetic 
nephropathy hallmarks. With this, it can be hypothesized that treatments that target 
multiple mechanisms may indeed be more successful than those that target a specific one 
alone. Addittionally, the results obtained from both approachs show that most of the 
identified variants, as well as genes accumulating variants, confer protection against 
diabetic nephropathy.   
Regarding the limitations of this study, there are two of them. The number of studied 
exomes was reduced, being that a higher number of exomes under study translates into a 
more reliable statistical analysis. The other limitation was related to the groups used to 
perform this study. In a case-control study, well-defined groups with similar characteristics 
are the key to ensure that any genetic difference between the groups is associated with the 
disease under study and not due to biased sampling. However, the groups in this study 
were heterogeneous among them for the covariate age, resulting in a statistically 
significant difference (p-value ≤ 0.05) between the control and case groups for this 
covariate. Nonetheless, the statistical analyses performed were adjusted for all the 
covariates, including age.   
As future work, it is proposed, initially, the extension of this study to a larger population 
in order to confirm the results obtained. Furthermore, there is also a need to further explore 
the functional impact of the common variants and rare variants accumulated in the genes 
associated with diabetic nephropathy. For that, the protein structure should be studied, in 
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silico, to verify changes in protein folding and functional studies, in vitro, should be 
performed to prove any protein function changes. 
This work was only an initial study concerning the identification of molecular markers 
possibly associated with the development and progression of diabetic nephropathy (risk 
genetic variants), as well as protection against it (protective genetic variants). However, the 
results obtained by this study can contribute to a deeper understanding of the genetic 
mechanisms associated with this diabetic complication.    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 5| References 
 
 
 
 
 
 
 
 
 129 
 
1. Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol. 2010;204(1):1-11. 
2. Karthikeyan R, Marimuthu G, Spence DW, Pandi-Perumal SR, BaHammam AS, 
Brown GM, Cardinali DP. Should we listen to our clock to prevent type 2 diabetes 
mellitus? Diabetes Res Clin Pract. 2014;106(2):182-190. 
3. Organization WH. Definition, diagnosis and classification of diabetes mellitus and 
its complications. Report of a WHO consultation, part 1: diagnosis and classification of 
diabetes mellitus. Geneva: World Health Organization, 1999. 
4. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of 
pathogenesis and therapy. Lancet. 2005;365(9467):1333-1346. 
5. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. 
Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res 
Clin Pract. 2014;103(2):137-149. 
6. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and 
treatment. Lancet. 2008;371(9631):2153-2156. 
7. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, Saloranta C, 
Tuomi T, Groop L. Genetic prediction of future type 2 diabetes. PLoS Med. 
2005;2(12):1299-1308. 
8. Zimmet P, Arblaster M, Thoma K. The effect of westernization on native 
populations. Studies on a Micronesian community with a high diabetes prevalence. Aust N 
Z J Med. 1978;8(2):141-146. 
9. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 
diabetes mellitus. World J Diabetes. 2014;5(2):128-140. 
10. Das SK, Elbein SC. The Genetic Basis of Type 2 Diabetes. Cellscience. 
2006;2(4):100-131. 
11. Ferrannini E, Mari A. beta-Cell function in type 2 diabetes. Metabolism. 
2014;63(10):1217-1227. 
12. Rorsman P, Braun M. Regulation of insulin secretion in human pancreatic islets. 
Annu Rev Physiol. 2013;75:155-179. 
13. Sam AH, Sleeth ML, Thomas EL, Ismail NA, Mat Daud N, Chambers E, Shojaee-
Moradie F, Umpleby AM, Goldstone AP, Le Roux CW, Bech P, Busbridge M, Laurie R, 
Cuthbertson DJ, Buckley A, Ghatei MA, Bloom SR, Frost GS, Bell JD, Murphy KG. 
 130 
 
Circulating pancreatic polypeptide concentrations predict visceral and liver fat content. J 
Clin Endocrinol Metab. 2014;100(3):1048-1052. 
14. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and 
pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25-53. 
15. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835. 
16. Pierce M, Keen H, Bradley C. Risk of diabetes in offspring of parents with non-
insulin-dependent diabetes. Diabet Med. 1995;12(1):6-13. 
17. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, Ehrnstrom 
BO, Forsen B, Isomaa B, Snickars B, Taskinen MR. Metabolic consequences of a family 
history of NIDDM (The Botnia Study) - Evidence for sex-specific parental effects. 
Diabetes. 1996;45(11):1585-1593. 
18. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 
2010;363(24):2339-2350. 
19. Lohmueller KE, Sparso T, Li Q, Andersson E, Korneliussen T, Albrechtsen A, 
Banasik K, Grarup N, Hallgrimsdottir I, Kiil K, Kilpelainen TO, Krarup NT, Pers TH, 
Sanchez G, Hu Y, Degiorgio M, Jorgensen T, Sandbaek A, Lauritzen T, Brunak S, 
Kristiansen K, Li Y, Hansen T, Wang J, Nielsen R, Pedersen O. Whole-exome sequencing 
of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes. Am J 
Hum Genet. 2013;93(6):1072-1086. 
20. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: worthless 
or valuable? Diabetes Care. 2013;36 Suppl 2:S120-126. 
21. Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2 
diabetes. Trends Endocrinol Metab. 2010;21(4):223-229. 
22. Smyth LJ, McKay GJ, Maxwell AP, McKnight AJ. DNA hypermethylation and 
DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics. 
2014;9(3):366-376. 
23. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, 
Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, 
Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, 
Qi L, Segre AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett 
AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Bengtsson Bostrom K, Bravenboer B, 
 131 
 
Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, 
Doney AS, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, 
Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, 
Isomaa B, Jackson AU, Johnson PR, Jorgensen T, Kao WH, Klopp N, Kong A, Kraft P, 
Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, 
Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JR, 
Petersen AK, Platou C, Proenca C, Prokopenko I, Rathmann W, Rayner NW, Robertson 
NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson 
G, Sparso T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi 
T, van Dam RM, van Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, 
Weedon MN, Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, 
Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso 
M, Mohlke KL, Morris AD, Palmer CN, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, 
Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, 
Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen 
O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir 
U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, 
McCarthy MI. Twelve type 2 diabetes susceptibility loci identified through large-scale 
association analysis. Nat Genet. 2010;42(7):579-589. 
24. Tamayo T, Rosenbauer J, Wild SH, Spijkerman AM, Baan C, Forouhi NG, Herder 
C, Rathmann W. Diabetes in Europe: an update. Diabetes Res Clin Pract. 2014;103(2):206-
217. 
25. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol 
(Lausanne). 2013;4:1-12. 
26. Groop LC, Ferrannini E. Insulin Action and Substrate Competition. Bailliere Clin 
Endoc. 1993;7(4):1007-1032. 
27. Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, Vidal H, 
Rieusset J. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle 
of diet-induced insulin-resistant mice. J Clin Invest. 2008;118(2):789-800. 
28. Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and 
insulin resistance. Front Endocrinol (Lausanne). 2013;4:1-14. 
 132 
 
29. Jewell JL, Oh E, Thurmond DC. Exocytosis mechanisms underlying insulin release 
and glucose uptake: conserved roles for Munc18c and syntaxin 4. Am J Physiol Regul 
Integr Comp Physiol. 2010;298(3):R517-531. 
30. Polonsky KS, Sturis J, Van Cauter E. Temporal profiles and clinical significance of 
pulsatile insulin secretion. Horm Res. 1998;49(3-4):178-184. 
31. Porksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia. 
2002;45(1):3-20. 
32. Perley MJ, Kipnis DM. Plasma Insulin Responses to Oral and Intravenous Glucose 
- Studies in Normal and Diabetic Subjects. Journal of Clinical Investigation. 
1967;46(12):1954-1962. 
33. Lillioja S, Mott DM, Howard BV, Bennett PH, Ykijarvinen H, Freymond D, 
Nyomba BL, Zurlo F, Swinburn B, Bogardus C. Impaired Glucose-Tolerance as a Disorder 
of Insulin Action - Longitudinal and Cross-Sectional Studies in Pima-Indians. New Engl J 
Med. 1988;318(19):1217-1225. 
34. Boden G. Free fatty acids-the link between obesity and insulin resistance. Endocr 
Pract. 2001;7(1):44-51. 
35. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell 
mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10 Suppl 
4:32-42. 
36. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell 
deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 
2003;52(1):102-110. 
37. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin 
secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. 
J Clin Invest. 1999;104(6):787-794. 
38. Weir GC. Non-insulin-dependent diabetes mellitus: interplay between B-cell 
inadequacy and insulin resistance. Am J Med. 1982;73(4):461-464. 
39. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed 
diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150-160. 
40. Alkayyali S, Lyssenko V. Genetics of diabetes complications. Mamm Genome. 
2014;25(9-10):384-400. 
 133 
 
41. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical 
perspective. Endocr Rev. 2001;22(1):36-52. 
42. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic 
nephropathy. Curr Med Chem. 2010;17(34):4256-4269. 
43. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-
Tuduri X, Barrot-De la Puente J, Coll-de Tuero G. Prevalence of chronic kidney disease in 
patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 
2013;14(46):1-8. 
44. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J 
Am Soc Nephrol. 2003;14(5):1358-1373. 
45. Anil Kumar P, Welsh GI, Saleem MA, Menon RK. Molecular and cellular events 
mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front 
Endocrinol (Lausanne). 2014;5:1-10. 
46. Chade AR. Renal vascular structure and rarefaction. Compr Physiol. 
2013;3(2):817-831. 
47. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development 
and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective 
Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-232. 
48. Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: Roles 
of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2015;6(1):3-
15. 
49. Suh JH, Miner JH. The glomerular basement membrane as a barrier to albumin. Nat 
Rev Nephrol. 2013;9(8):470-477. 
50. Brennan E, McEvoy C, Sadlier D, Godson C, Martin F. The genetics of diabetic 
nephropathy. Genes (Basel). 2013;4(4):596-619. 
51. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in 
maturity-onset diabetes. N Engl J Med. 1984;310(6):356-360. 
52. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease 
mortality associated with microalbuminuria and gross proteinuria in persons with older-
onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093-1100. 
53. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current 
treatment on natural history. Curr Diab Rep. 2006;6(6):479-483. 
 134 
 
54. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for 
development of incipient and overt diabetic nephropathy in patients with non-insulin 
dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-
788. 
55. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for 
nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, 
and hyperglycemia. Arch Intern Med. 1998;158(9):998-1004. 
56. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, Gries FA, Keen 
H. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM 
Complications Study. Diabetologia. 1997;40(10):1219-1226. 
57. Association AD. Diabetic Nephropathy (Position Statement). Diabetes Care. 
2002;25(Suppl 1 ):S85-S89. 
58. Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. 
Diabetic nephropathy. Diabetol Metab Syndr. 2009;1(1):1-17. 
59. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. 
Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74(4):1143-
1155. 
60. Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. 
J Histochem Cytochem. 2012;60(12):976-986. 
61. Kimmelstiel P, Wilson C. Intercapillary Lesions in the Glomeruli of the Kidney. 
Am J Pathol. 1936;12(1):83-98. 
62. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy--a review of the 
natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445-
1454. 
63. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental 
diabetes mellitus. Kidney Int. 1981;19(3):410-415. 
64. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the 
initiation and progression of diabetic and other glomerulopathies. Am J Med. 
1982;72(3):375-380. 
65. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-
based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10(2):88-103. 
 135 
 
66. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. 
With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32 Suppl 
2:64-78. 
67. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized 
pericyte. FASEB J. 1987;1(4):272-281. 
68. Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am 
Soc Nephrol. 2009;20(6):1179-1187. 
69. Ghayur MN, Krepinsky JC, Janssen LJ. Contractility of the Renal Glomerulus and 
Mesangial Cells: Lingering Doubts and Strategies for the Future. Med Hypotheses Res. 
2008;4(1):1-9. 
70. Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J Pathol. 
2003;200(4):537-546. 
71. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a 
mechanistic viewpoint. Kidney Int. 2008;74(1):22-36. 
72. Furness PN. Extracellular matrix and the kidney. J Clin Pathol. 1996;49(5):355-
359. 
73. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development 
and disease. Nat Rev Mol Cell Biol. 2014;15(12):786-801. 
74. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827-839. 
75. Xu X, Xiao L, Xiao P, Yang S, Chen G, Liu F, Kanwar YS, Sun L. A glimpse of 
matrix metalloproteinases in diabetic nephropathy. Curr Med Chem. 2014;21(28):3244-
3260. 
76. Lawrence DA. Latent-TGF-beta: an overview. Mol Cell Biochem. 2001;219(1-
2):163-170. 
77. Lee HS. Mechanisms and consequences of TGF-ss overexpression by podocytes in 
progressive podocyte disease. Cell Tissue Res. 2012;347(1):129-140. 
78. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J. Latency, activation, 
and binding proteins of TGF-beta. Microsc Res Tech. 2001;52(4):354-362. 
79. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic 
nephropathy. Kidney Int Suppl. 2000;77:S93-98. 
 136 
 
80. Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Haring HU, Schleicher ED. AP-1 
proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in 
mesangial cells. J Am Soc Nephrol. 2000;11(11):2007-2016. 
81. Weigert C, Brodbeck K, Klopfer K, Haring HU, Schleicher ED. Angiotensin II 
induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. 
Diabetologia. 2002;45(6):890-898. 
82. Hill CS. The Smads. Int J Biochem Cell Biol. 1999;31(11):1249-1254. 
83. Miyazono K, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv 
Immunol. 2000;75:115-157. 
84. Miyazono K. Positive and negative regulation of TGF-beta signaling. J Cell Sci. 
2000;113 ( Pt 7):1101-1109. 
85. Korchynskyi O, ten Dijke P. Identification and functional characterization of 
distinct critically important bone morphogenetic protein-specific response elements in the 
Id1 promoter. J Biol Chem. 2002;277(7):4883-4891. 
86. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall 
toward the center of disease: podocyte injury comes of age in diabetic nephropathy. 
Diabetes. 2005;54(6):1626-1634. 
87. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, 
Moon SJ, Kim DK, Han DS, Kang SW. Podocyte biology in diabetic nephropathy. Kidney 
Int Suppl. 2007;72(106):S36-S42. 
88. Satchell SC. The glomerular endothelium emerges as a key player in diabetic 
nephropathy. Kidney Int. 2012;82(9):949-951. 
89. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and 
mechanisms of proteinuria. N Engl J Med. 2006;354(13):1387-1401. 
90. Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral 
component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 
2009;296(5):F947-F956. 
91. Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler MC, Antignac C. Early 
glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell 
Biol. 2004;24(2):550-560. 
92. George B, Holzman LB. Signaling from the podocyte intercellular junction to the 
actin cytoskeleton. Semin Nephrol. 2012;32(4):307-318. 
 137 
 
93. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc 
Nephrol. 2002;13(12):3005-3015. 
94. Qiu W, Zhou Y, Jiang L, Fang L, Chen L, Su W, Tan R, Zhang CY, Han X, Yang 
J. Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates 
podocyte injury in diabetic mice. PLoS One. 2012;7(7):1-9. 
95. Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte's response to 
stress: the enigma of foot process effacement. Am J Physiol Renal Physiol. 
2013;304(4):F333-F347. 
96. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in the prevention of 
diabetic nephropathy. Pharmacoeconomics. 2004;22(1):9-28. 
97. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-
converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N 
Engl J Med. 1993;329(20):1456-1462. 
98. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril 
to attenuate decline in renal function in normotensive, normoalbuminuric patients with 
type 2 diabetes mellitus - A randomized, controlled trial. Ann Intern Med. 
1998;128(12):982-988. 
99. Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. Economic evaluations of 
angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 
diabetic nephropathy: a systematic review. BMC Nephrol. 2014;15(15):1-17. 
100. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, 
McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, 
Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark 
AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding 
the missing heritability of complex diseases. Nature. 2009;461(7265):747-753. 
101. Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study 
designs and statistical tests. Am J Hum Genet. 2014;95(1):5-23. 
102. Wang Q, Lu Q, Zhao H. A review of study designs and statistical methods for 
genomic epidemiology studies using next generation sequencing. Front Genet. 2015;6:1-
12. 
103. Ku CS, Cooper DN, Polychronakos C, Naidoo N, Wu M, Soong R. Exome 
sequencing: dual role as a discovery and diagnostic tool. Ann Neurol. 2012;71(1):5-14. 
 138 
 
104. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease 
through whole-genome sequencing. Nat Rev Genet. 2010;11(6):415-425. 
105. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation 
sequencing technology. Trends Genet. 2014;30(9):418-426. 
106. Raje N, Soden S, Swanson D, Ciaccio CE, Kingsmore SF, Dinwiddie DL. Utility of 
next generation sequencing in clinical primary immunodeficiencies. Curr Allergy Asthma 
Rep. 2014;14(10):468-489. 
107. Pruitt KD, Harrow J, Harte RA, Wallin C, Diekhans M, Maglott DR, Searle S, 
Farrell CM, Loveland JE, Ruef BJ, Hart E, Suner MM, Landrum MJ, Aken B, Ayling S, 
Baertsch R, Fernandez-Banet J, Cherry JL, Curwen V, Dicuccio M, Kellis M, Lee J, Lin 
MF, Schuster M, Shkeda A, Amid C, Brown G, Dukhanina O, Frankish A, Hart J, Maidak 
BL, Mudge J, Murphy MR, Murphy T, Rajan J, Rajput B, Riddick LD, Snow C, Steward 
C, Webb D, Weber JA, Wilming L, Wu W, Birney E, Haussler D, Hubbard T, Ostell J, 
Durbin R, Lipman D. The consensus coding sequence (CCDS) project: Identifying a 
common protein-coding gene set for the human and mouse genomes. Genome Res. 
2009;19(7):1316-1323. 
108. Wu L, Schaid DJ, Sicotte H, Wieben ED, Li H, Petersen GM. Case-only exome 
sequencing and complex disease susceptibility gene discovery: study design 
considerations. J Med Genet. 2015;52(1):10-16. 
109. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, 
Ozen S, Sanjad S, Nelson-Williams C, Farhi A, Mane S, Lifton RP. Genetic diagnosis by 
whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. 
2009;106(45):19096-19101. 
110. Prada CE, Gonzaga-Jauregui C, Tannenbaum R, Penney S, Lupski JR, Hopkin RJ, 
Sutton VR. Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis. 
Eur J Med Genet. 2014;57(7):339-344. 
111. Anderson MW, Schrijver I. Next generation DNA sequencing and the future of 
genomic medicine. Genes (Basel). 2010;1(1):38-69. 
112. Raffan E, Semple RK. Next generation sequencing--implications for clinical 
practice. Br Med Bull. 2011;99:53-71. 
113. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463-5467. 
 139 
 
114. Maxam AM, Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci U 
S A. 1977;74(2):560-564. 
115. Finishing the euchromatic sequence of the human genome. Nature. 
2004;431(7011):931-945. 
116. Reis-Filho JS. Next-generation sequencing. Breast Cancer Res. 2009;11 Suppl 
3:S12-S19. 
117. Monticone S, Else T, Mulatero P, Williams TA, Rainey WE. Understanding 
primary aldosteronism: Impact of next generation sequencing and expression profiling. 
Mol Cell Endocrinol. 2014;399:311-320. 
118. Mardis ER. The impact of next-generation sequencing technology on genetics. 
Trends Genet. 2008;24(3):133-141. 
119. Frese KS, Katus HA, Meder B. Next-generation sequencing: from understanding 
biology to personalized medicine. Biology (Basel). 2013;2(1):378-398. 
120. Hui P. Next generation sequencing: chemistry, technology and applications. Top 
Curr Chem. 2014;336:1-18. 
121. Zhu P, He L, Li Y, Huang W, Xi F, Lin L, Zhi Q, Zhang W, Tang YT, Geng C, Lu 
Z, Xu X. OTG-snpcaller: an optimized pipeline based on TMAP and GATK for SNP 
calling from ion torrent data. PLoS One. 2014;9(5):1-9. 
122. English AC, Richards S, Han Y, Wang M, Vee V, Qu J, Qin X, Muzny DM, Reid 
JG, Worley KC, Gibbs RA. Mind the gap: upgrading genomes with Pacific Biosciences RS 
long-read sequencing technology. PLoS One. 2012;7(11):1-12. 
123. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, 
Swerdlow HP, Gu Y. A tale of three next generation sequencing platforms: comparison of 
Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 
2012;13:1-13. 
124. Merriman B, Rothberg JM. Progress in ion torrent semiconductor chip based 
sequencing. Electrophoresis. 2012;33(23):3397-3417. 
125. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum 
Genet. 2008;9:387-402. 
126. Dolled-Filhart MP, Lee M, Jr., Ou-Yang CW, Haraksingh RR, Lin JC. 
Computational and bioinformatics frameworks for next-generation whole exome and 
genome sequencing. ScientificWorldJournal. 2013;2013:1-10. 
 140 
 
127. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis 
G, Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 
2009;25(16):2078-2079. 
128. Bromberg Y. Building a genome analysis pipeline to predict disease risk and 
prevent disease. J Mol Biol. 2013;425(21):3993-4005. 
129. Day-Williams AG, Zeggini E. The effect of next-generation sequencing technology 
on complex trait research. Eur J Clin Invest. 2011;41(5):561-567. 
130. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker 
RE, Lunter G, Marth GT, Sherry ST, McVean G, Durbin R. The variant call format and 
VCFtools. Bioinformatics. 2011;27(15):2156-2158. 
131. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and 
survey. Nucleic Acids Res. 2002;30(17):3894-3900. 
132. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense 
mutations. Nat Methods. 2010;7(4):248-249. 
133. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-1081. 
134. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res. 2003;31(13):3812-3814. 
135. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general 
framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 
2014;46(3):310-315. 
136. QIAGEN. DNeasy® Blood & Tissue Handbook. 2006:9-11. 
137. Technologies L. Ion AmpliSeq™ DNA and RNA Library Preparation. 2014:15-34. 
138. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the 
consequences of genomic variants with the Ensembl API and SNP Effect Predictor. 
Bioinformatics. 2010;26(16):2069-2070. 
139. Chen Y, Cunningham F, Rios D, McLaren WM, Smith J, Pritchard B, Spudich GM, 
Brent S, Kulesha E, Marin-Garcia P, Smedley D, Birney E, Flicek P. Ensembl variation 
resources. BMC Genomics. 2010;11:1-16. 
140. Paila U, Chapman BA, Kirchner R, Quinlan AR. GEMINI: integrative exploration 
of genetic variation and genome annotations. PLoS Comput Biol. 2013;9(7):1-8. 
 141 
 
141. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-311. 
142. Consortium TEP. The ENCODE (ENCyclopedia Of DNA Elements) Project. 
Science. 2004;306(5696):636-640. 
143. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott 
DR. ClinVar: public archive of relationships among sequence variation and human 
phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-D985. 
144. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, 
Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 
human genomes. Nature. 2012;491(7422):56-65. 
145. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, 
Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, 
Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, 
Akey JM. Evolution and functional impact of rare coding variation from deep sequencing 
of human exomes. Science. 2012;337(6090):64-69. 
146. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic 
Acids Res. 2000;28(1):27-30. 
147. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A. 
Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 
2005;15(7):901-913. 
148. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan 
S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, 
Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, 
Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, 
Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. Human Protein 
Reference Database--2009 update. Nucleic Acids Res. 2009;37(Database issue):D767-
D772. 
149. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating 
information about genes, proteins and diseases. Trends Genet. 1997;13(4):163. 
150. Smith RN, Aleksic J, Butano D, Carr A, Contrino S, Hu F, Lyne M, Lyne R, 
Kalderimis A, Rutherford K, Stepan R, Sullivan J, Wakeling M, Watkins X, Micklem G. 
 142 
 
InterMine: a flexible data warehouse system for the integration and analysis of 
heterogeneous biological data. Bioinformatics. 2012;28(23):3163-3165. 
151. Lane L, Argoud-Puy G, Britan A, Cusin I, Duek PD, Evalet O, Gateau A, Gaudet P, 
Gleizes A, Masselot A, Zwahlen C, Bairoch A. neXtProt: a knowledge platform for human 
proteins. Nucleic Acids Res. 2012;40(Database issue):D76-D83. 
152. Cooper DN, Stenson PD, Chuzhanova NA. The Human Gene Mutation Database 
(HGMD) and its exploitation in the study of mutational mechanisms. Curr Protoc 
Bioinformatics. 2006;Chapter 1:Unit 1 13. 
153. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, 
Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh 
LS. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2004;32(Database 
issue):D115-D119. 
154. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, 
Eskin E. Variance component model to account for sample structure in genome-wide 
association studies. Nat Genet. 2010;42(4):348-354. 
155. Korbie DJ, Mattick JS. Touchdown PCR for increased specificity and sensitivity in 
PCR amplification. Nat Protoc. 2008;3(9):1452-1456. 
156. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief 
Bioinform. 2002;3(2):146-153. 
157. Mahajan R, Mishra B. Using Glycated Hemoglobin HbA1c for diagnosis of 
Diabetes mellitus: An Indian perspective. Int J Biol Med Res. 2011;2(2):508-512. 
158. Doria A. Genetics of diabetes complications. Curr Diab Rep. 2010;10(6):467-475. 
159. Technologies A. Bioanalyzer Applications for Next-Gen Sequencing: Updates and 
Tips. 2011:4-49. 
160. Sims D, Sudbery I, Ilott NE, Heger A, Ponting CP. Sequencing depth and coverage: 
key considerations in genomic analyses. Nat Rev Genet. 2014;15(2):121-132. 
161. Dogan RI, Getoor L, Wilbur WJ, Mount SM. SplicePort--an interactive splice-site 
analysis tool. Nucleic Acids Res. 2007;35(Web Server issue):W285-W291. 
162. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. 
Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic 
Acids Res. 2009;37(9):1-14. 
 143 
 
163. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in 
Genie. J Comput Biol. 1997;4(3):311-323. 
164. Freund M, Asang C, Kammler S, Konermann C, Krummheuer J, Hipp M, Meyer I, 
Gierling W, Theiss S, Preuss T, Schindler D, Kjems J, Schaal H. A novel approach to 
describe a U1 snRNA binding site. Nucleic Acids Res. 2003;31(23):6963-6975. 
165. Brendel V, Xing L, Zhu W. Gene structure prediction from consensus spliced 
alignment of multiple ESTs matching the same genomic locus. Bioinformatics. 
2004;20(7):1157-1169. 
166. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, Russell GB, Mauer 
M. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system 
and diabetic nephropathy lesions in type 1 diabetes. Diabetes. 2002;51(12):3577-3581. 
167. Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P, Moran JL, Beier DR, Palmer 
AA, McNally EM. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in 
mice. J Clin Invest. 2009;119(12):3703-3712. 
168. van den Bergen JC, Hiller M, Bohringer S, Vijfhuizen L, Ginjaar HB, Chaouch A, 
Bushby K, Straub V, Scoto M, Cirak S, Humbertclaude V, Claustres M, Scotton C, 
Passarelli C, Lochmuller H, Muntoni F, Tuffery-Giraud S, Ferlini A, Aartsma-Rus AM, 
Verschuuren JJ, t Hoen PA, Spitali P. Validation of genetic modifiers for Duchenne 
muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol 
Neurosurg Psychiatry. 2015;86(10):1060-1065. 
169. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the 
pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract. 2008;82 Suppl 1:S42-S45. 
170. Dando I, Fiorini C, Pozza ED, Padroni C, Costanzo C, Palmieri M, Donadelli M. 
UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic 
cell death in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2013;1833(3):672-
679. 
171. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 
2010;107(9):1058-1070. 
172. Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling 
proteins UCP2 and UCP3. Cell Metab. 2005;2(2):85-93. 
173. Souza BM, Michels M, Sortica DA, Boucas AP, Rheinheimer J, Buffon MP, Bauer 
AC, Canani LH, Crispim D. Polymorphisms of the UCP2 Gene Are Associated with 
 144 
 
Glomerular Filtration Rate in Type 2 Diabetic Patients and with Decreased UCP2 Gene 
Expression in Human Kidney. PLoS One. 2015;10(7):1-15. 
174. Lu MK, Gong XG, Guan KL. mTOR in podocyte function: is rapamycin good for 
diabetic nephropathy? Cell Cycle. 2011;10(20):3415-3416. 
175. Yasuda M, Tanaka Y, Kume S, Morita Y, Chin-Kanasaki M, Araki H, Isshiki K, 
Araki S, Koya D, Haneda M, Kashiwagi A, Maegawa H, Uzu T. Fatty acids are novel 
nutrient factors to regulate mTORC1 lysosomal localization and apoptosis in podocytes. 
Biochim Biophys Acta. 2014;1842(7):1097-1108. 
176. Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mor A, 
Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler 
M, Wanke R, Pavenstadt H, Kerjaschki D, Cohen CD, Hall MN, Ruegg MA, Inoki K, 
Walz G, Huber TB. Role of mTOR in podocyte function and diabetic nephropathy in 
humans and mice. J Clin Invest. 2011;121(6):2197-2209. 
177. Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA, Carriere A, Roux 
PP, Ballif BA, Fingar DC. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 
and multisite phosphorylation. J Biol Chem. 2010;285(1):80-94. 
178. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, 
Ruegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, 
Wiggins RC, Guan KL. mTORC1 activation in podocytes is a critical step in the 
development of diabetic nephropathy in mice. J Clin Invest. 2011;121(6):2181-2196. 
179. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 
pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310-322. 
180. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, 
Yonezawa K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced 
inhibition of mTOR function. Genes Cells. 2004;9(4):359-366. 
181. Abu Seman N, He B, Ojala JR, Wan Mohamud WN, Ostenson CG, Brismar K, Gu 
HF. Genetic and biological effects of sodium-chloride cotransporter (SLC12A3) in diabetic 
nephropathy. Am J Nephrol. 2014;40(5):408-416. 
182. Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, Tanaka Y, 
Fujioka T, Kaku K, Kawamori R, Kikkawa R, Iwamoto Y, Nakamura Y, Maeda S. 
Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic 
 145 
 
nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. 
Diabetes. 2003;52(11):2848-2853. 
183. Kim JH, Shin HD, Park BL, Moon MK, Cho YM, Hwang YH, Oh KW, Kim SY, 
Lee HK, Ahn C, Park KS. SLC12A3 (solute carrier family 12 member [sodium/chloride] 
3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. 
Diabetes. 2006;55(3):843-848. 
184. Ng DP, Nurbaya S, Choo S, Koh D, Chia KS, Krolewski AS. Genetic variation at 
the SLC12A3 locus is unlikely to explain risk for advanced diabetic nephropathy in 
Caucasians with type 2 diabetes. Nephrol Dial Transplant. 2008;23(7):2260-2264. 
185. Mathieson PW. The podocyte cytoskeleton in health and in disease. Clin Kidney J. 
2012;5(6):498-501. 
186. Nakatani S, Kakehashi A, Ishimura E, Yamano S, Mori K, Wei M, Inaba M, 
Wanibuchi H. Targeted proteomics of isolated glomeruli from the kidneys of diabetic rats: 
sorbin and SH3 domain containing 2 is a novel protein associated with diabetic 
nephropathy. Exp Diabetes Res. 2011;2011:1-11. 
187. Garg P, Verma R, Nihalani D, Johnstone DB, Holzman LB. Neph1 cooperates with 
nephrin to transduce a signal that induces actin polymerization. Mol Cell Biol. 
2007;27(24):8698-8712. 
188. Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. Nat 
Rev Mol Cell Biol. 2006;7(10):713-726. 
189. Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, Miot A, 
Saulnier PJ, Travert F, Hadjadj S, Marre M, Fumeron F. Association of ADIPOQ genetic 
variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 
diabetes. Nephrol Dial Transplant. 2010;25(7):2231-2237. 
190. Kankova K, Stejskalova A, Pacal L, Tschoplova S, Hertlova M, Krusova D, 
Izakovicova-Holla L, Beranek M, Vasku A, Barral S, Ott J. Genetic risk factors for 
diabetic nephropathy on chromosomes 6p and 7q identified by the set-association 
approach. Diabetologia. 2007;50(5):990-999. 
191. Cooke Bailey JN, Palmer ND, Ng MC, Bonomo JA, Hicks PJ, Hester JM, 
Langefeld CD, Freedman BI, Bowden DW. Analysis of coding variants identified from 
exome sequencing resources for association with diabetic and non-diabetic nephropathy in 
African Americans. Hum Genet. 2014;133(6):769-779. 
 146 
 
192. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, 
McDonough C, Janssen B, Yard BA, van der Woude FJ, Bowden DW. A leucine repeat in 
the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in 
European Americans. Nephrol Dial Transplant. 2007;22(4):1131-1135. 
193. Ahluwalia TS, Lindholm E, Groop LC. Common variants in CNDP1 and CNDP2, 
and risk of nephropathy in type 2 diabetes. Diabetologia. 2011;54(9):2295-2302. 
194. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon 
J, Pearson E, Buehler J, Chen Y, Yu B, Tinkham NH, Zabriskie NA, Zeng J, Luo L, Sun 
JK, Prakash M, Hamam RN, Tonna S, Constantine R, Ronquillo CC, Sadda S, Avery RL, 
Brand JM, London N, Anduze AL, King GL, Bernstein PS, Watkins S, Jorde LB, Li DY, 
Aiello LP, Pollak MR, Zhang K. Promoter polymorphism of the erythropoietin gene in 
severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 
2008;105(19):6998-7003. 
195. Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and 
H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. 
Diabetes Care. 2001;24(7):1187-1191. 
196. Alkayyali S, Lajer M, Deshmukh H, Ahlqvist E, Colhoun H, Isomaa B, Rossing P, 
Groop L, Lyssenko V. Common variant in the HMGA2 gene increases susceptibility to 
nephropathy in patients with type 2 diabetes. Diabetologia. 2013;56(2):323-329. 
197. Buraczynska M, Swatowski A, Buraczynska K, Dragan M, Ksiazek A. Heat-shock 
protein gene polymorphisms and the risk of nephropathy in patients with Type 2 diabetes. 
Clin Sci (Lond). 2009;116(1):81-86. 
198. Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward 
JD, Duff GW. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with 
nephropathy in diabetes mellitus. Hum Genet. 1996;97(3):369-374. 
199. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, Comeau ME, Divers J, 
Langefeld CD, Freedman BI, Bowden DW. Polymorphisms in MYH9 are associated with 
diabetic nephropathy in European Americans. Nephrol Dial Transplant. 2012;27(4):1505-
1511. 
200. Kuricova K, Tanhauserova V, Pacal L, Bartakova V, Brozova L, Jarkovsky J, 
Kankova K. NOS3 894G>T polymorphism is associated with progression of kidney 
 147 
 
disease and cardiovascular morbidity in type 2 diabetic patients: NOS3 as a modifier gene 
for diabetic nephropathy? Kidney Blood Press Res. 2013;38(1):92-98. 
201. McKnight AJ, Currie D, Patterson CC, Maxwell AP, Fogarty DG. Targeted 
genome-wide investigation identifies novel SNPs associated with diabetic nephropathy. 
Hugo J. 2009;3(1-4):77-82. 
202. Neves AL, Mohammedi K, Emery N, Roussel R, Fumeron F, Marre M, Velho G. 
Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular 
morbidity and mortality in type 2 diabetic subjects. Mol Genet Metab. 2012;106(3):359-
365. 
203. Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A. TGF-beta1 and 
TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 
diabetes. Nephron Physiol. 2007;106(4):69-75. 
204. Ahluwalia TS, Lindholm E, Groop L, Melander O. Uromodulin gene variant is 
associated with type 2 diabetic nephropathy. J Hypertens. 2011;29(9):1731-1734. 
205. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing 
for sequencing data with the sequence kernel association test. Am J Hum Genet. 
2011;89(1):82-93. 
206. Vetter SW, Indurthi VS. Moderate glycation of serum albumin affects folding, 
stability, and ligand binding. Clin Chim Acta. 2011;412(23-24):2105-2116. 
207. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita 
S, Iizuka Y, Shimano H, Nagai R, Kimura S, Tsujimoto M, Ishibashi S. FEEL-1 and 
FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem. 
2003;278(15):12613-12617. 
208. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: 
a general overview. Hormones (Athens). 2005;4(1):28-37. 
209. Sourris KC, Harcourt BE, Penfold SA, Yap FY, Morley AL, Morgan PE, Davies 
MJ, Baker ST, Jerums G, Forbes JM. Modulation of the cellular expression of circulating 
advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes 
Res. 2010;2010:1-9. 
210. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation 
end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(8 Suppl 3):S254-S258. 
 148 
 
211. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and 
diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101-108. 
212. English WR, Velasco G, Stracke JO, Knauper V, Murphy G. Catalytic activities of 
membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett. 2001;491(1-2):137-142. 
213. Maeda S, Haneda M, Guo B, Koya D, Hayashi K, Sugimoto T, Isshiki K, Yasuda 
H, Kashiwagi A, Kikkawa R. Dinucleotide repeat polymorphism of matrix 
metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 
2001;60(4):1428-1434. 
214. Fragiadaki M, Ikeda T, Witherden A, Mason RM, Abraham D, Bou-Gharios G. 
High doses of TGF-beta potently suppress type I collagen via the transcription factor 
CUX1. Mol Biol Cell. 2011;22(11):1836-1844. 
215. Clout NJ, Tisi D, Hohenester E. Novel fold revealed by the structure of a FAS1 
domain pair from the insect cell adhesion molecule fasciclin I. Structure. 2003;11(2):197-
203. 
216. Appella E, Weber IT, Blasi F. Structure and function of epidermal growth factor-
like regions in proteins. FEBS Lett. 1988;231(1):1-4. 
217. Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA, Fridman R. MT4-(MMP17) and 
MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: 
properties and expression in cancer. Cancer Metastasis Rev. 2008;27(2):289-302. 
218. Harada R, Berube G, Tamplin OJ, Denis-Larose C, Nepveu A. DNA-binding 
specificity of the cut repeats from the human cut-like protein. Mol Cell Biol. 
1995;15(1):129-140. 
219. Ramdzan ZM, Nepveu A. CUX1, a haploinsufficient tumour suppressor gene 
overexpressed in advanced cancers. Nat Rev Cancer. 2014;14(10):673-682. 
220. Pufall MA, Graves BJ. Autoinhibitory domains: modular effectors of cellular 
regulation. Annu Rev Cell Dev Biol. 2002;18:421-462. 
221. Burkhard P, Stetefeld J, Strelkov SV. Coiled coils: a highly versatile protein folding 
motif. Trends Cell Biol. 2001;11(2):82-88. 
222. Ohta M, Matsui K, Hiratsu K, Shinshi H, Ohme-Takagi M. Repression domains of 
class II ERF transcriptional repressors share an essential motif for active repression. Plant 
Cell. 2001;13(8):1959-1968. 
 
  
 
 
 
 
 
 
 
 
CHAPTER 6| Appendices 
 
 
 
 
 150 
 
Appendix A 
 
Table A1. Type 2 diabetes susceptibility genes (adapted from (9)).  
Gene Chromosome Odds ratio RAF 
Type of 
study 
Function and 
probable 
mechanism 
 
ADAMTS9 
 
3 1.05-1.09 0.68-0.81 MA 
Metalloproteinase/ 
Insulin action 
 
ADCY5 
 
3 1.12 0.78 MA 
Adenylyl  cyclases/ 
Insulin action 
 
ANK1 
 
8 1.09 0.76 MA 
Cell stability/ β-cell 
function 
 
ANKRD55 
 
5 1.08 0.7 MA Insulin action 
 
ANKS1A 
 
6 1.11 0.91 GWAS 
Pathway regulator/ 
Unknown 
ARAP1 11 1.08-1.14 0.81-0.88 GWAS, MA 
Actin cytoskeleton 
modulator/ β-cell 
function 
 
BCAR1 
 
16 1.12 0.89 MA 
Docking protein/ β-
cell function 
 
BCL11A 
 
2 1.08-1.09 0.46 MA 
Zinc finger/ β-cell 
function 
 
BCL2 
 
18 1.09 0.64 GWAS 
Cell death 
regulator/Unknown 
 
CAMK1D 
 
10 1.07-1.11 0.18 LA, MA 
Protein kinase/ β-
cell function 
CAPN10 2 1.09-1.18 0.73-0.96 MA 
Calpain cysteine 
protease/ Insulin 
action 
 
CDKAL1 
 
6 1.10-1.20 0.27-0.31 GWAS, MA β-cell function 
CDKN2A 9 1.19-1.20 0.82-0.83 GWAS 
Cyclin-dependent 
kinase inhibitor/ β-
cell function 
 
 
CENTD2 
 
11 1.08-1.13 0.81-0.88 GWAS β-cell function 
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Gene Chromosome Odds ratio RAF 
Type of 
study 
Function and 
probable 
mechanism 
 
CHCHD9 
 
9 1.11-1.20 0.93 MA Unknown 
 
CILP2 
 
19 1.13 0.08 MA Unknown 
 
DGKB 
 
7 1.04-1.06 0.47-0.54 MA 
Diacylglycerol 
kinase/ Insulin 
action 
 
DUSP9 
 
X 1.09-1.27 0.12-0.77 MA Phosphatase 
FOLH1 11 1.10 0.09 GWAS 
Transmembrane 
glycoprotein/ 
Unknown 
FTO 16 1.06-1.27 0.38-0.41 GWAS, MA 
Metabolic 
regulator/ 
Insulin action 
GATAD2A 19 1.12 0.08 GWAS 
Transcriptional 
repressor/ 
Unknown 
 
GCK 
 
7 1.07 0.20 MA 
Glucokinase/ 
Insulin action 
GCKR 2 1.06-1.09 0.59-0.62 MA 
Glucokinase 
regulator/ 
Insulin action 
GIPR 19 1.10 0.27 GWAS 
G-protein 
coupled 
receptor/ 
Unknown 
 
GRB14 
 
2 1.07 0.60 GCS, MA 
Adapter protein/ 
Insulin action 
HFE 6 1.12 0.29 MA 
Membrane 
protein/ 
Unknown 
HHEX 10 1.12-1.13 0.53-0.60 LA, MA 
Transcriptional 
repressor/ 
Intracellular 
insulin 
degradation/ 
Motor protein 
HMG20A 15 1.08 0.68 GCS, MA 
Chromatin-
associated 
protein/ 
Unknown 
HMGA1 6 1.34-15.8 0.10 GCS 
Transcriptional 
regulator/ 
Insulin action 
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Gene Chromosome Odds ratio RAF 
Type of 
study 
Function and 
probable 
mechanism 
 
HMGA2 
 
12 1.10-1.20 0.09-0.10 MA 
Transcriptional 
regulator 
 
HNF1A 
 
12 1.07-1.14 0.77-0.85 MA 
Pancreatic and liver 
transcriptional 
activator 
 
HNF1B 
 
17 1.08-1.17 0.47-0.51 GCS, MA 
Transcription factor/ 
β-cell function 
 
IGF2BP2 
 
3 1.14 0.29-0.32 GWAS, MA 
Binding protein/ β-
cell function 
 
IRS1 
 
2 1.09-1.12 0.64-0.67 GCS, MA 
Insulin signaling 
element/ Insulin 
action 
 
JAZF1 
 
7 1.10 0.52 MA 
Zing finger/ β-cell 
function 
 
KCNJ11 
 
11 1.09-1.14 0.37-0.47 GCS, MA 
Potassium channel/ 
β-cell function 
 
KCNQ1 
 
11 1.08-1.23 0.44 GWAS 
Potassium channel/ 
β-cell function 
 
KLF14 
 
7 1.07-1.10 0.55 MA 
Transcription 
factor/Insulin action 
 
KLHDC5 
 
12 1.10 0.80 MA 
Mitotic progression 
and 
cytokinesis/Unknown 
 
LAMA1 
 
18 1.13 0.38 GWAS 
Cellular migration 
mediator/Unknown 
 
MC4R 
 
18 1.08 0.27 MA 
G-protein-coupled 
receptor/Unknown 
 
MTNR1B 
 
11 1.05-1.08 0.28-0.30 GWAS, MA 
Melatonin receptor/ 
β-cell function 
 
NOTCH2 
 
1 1.06-1.13 0.10-0.11 MA Membrane receptor 
 
PPARG 
 
3 1.11-1.17 0.85-0.88 GCS, MA 
Nuclear receptor/ 
Insulin action 
 
PRC1 
 
15 1.07-1.10 0.22 MA 
Cytokinesis 
regulador 
PROX1 1 1.07 0.50 MA 
Homeobox 
transcription factor/ 
Insulin action 
 
PTPRD 
 
9 1.57 0.10 GWAS 
Protein tyrosine 
phosphatase 
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Gene Chromosome Odds ratio RAF 
Type of 
study 
Function and 
probable 
mechanism 
 
RBMS1 
 
2 1.08-1.11 0.79-0.83 MA 
DNA modulator/ 
Insulin action 
SLC2A2 3 1.06 0.74 GWAS 
Glucose 
sensor/β-cell 
function 
SLC30A8 8 1.11-1.18 0.65-0.70 GWAS, MA 
Zinc efflux 
transporter/β-cell 
function 
SREBF1 17 1.07 0.38 GWAS 
Lipid 
transcriptional 
regulator/ 
Unknown 
 
SRR 
 
17 1.28 0.69 GWAS Serine racemase 
TCF7L2 10 1.31-1.71 0.26-0.30 
GWAS, LA, 
MA 
Participates in 
the Wnt 
signaling 
pathway/β-cell 
function 
THADA 2 1.15 0.90 MA 
Thyroid 
adenoma-
associated 
protein/β-cell 
function 
 
TH/INS 
 
11 1.14 0.39 GWAS 
Catecholamine 
synthesis/ 
Unknown 
TLE1 9 1.07 0.57 MA 
Transcriptional 
corepressor/ 
Unknown 
 
TP53INP1 
 
8 1.06-1.11 0.48 MA 
Proapoptotic 
protein/Unknown 
TSPAN8 12 1.06-1.09 0.27-0.71 MA 
Cell surface 
glycoprotein/ β-
cell function 
WFS1 4 1.10-1.13 0.60-0.73 GCS 
Transmembrane 
protein/ β-cell 
function 
 
ZBED3 
 
5 1.08-1.16 0.26 MA 
Zinc finger/ β-
cell function 
 
ZFAND6 
 
15 1.01-1.11 0.60-0.72 MA 
Zinc finger/ β-
cell function 
ZMIZ1 10 1.08 0.52 MA 
Transcriptional 
regulator/ 
Unknown 
DNA: deoxyribonucleic acid; GCS: gene candidate studies; GWAS: genome-wide association 
study; LA: linkage analysis; MA: meta-analysis; RAF: risk allele frequency.  
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Appendix B 
 
Table B1. Characterization of the control group.  
Exomes in 
study 
Age (years) 
Disease 
duration (years) 
HbA1c (%) Sex 
21 58 9 14.3 Female 
22 71 22 9.1 Female 
23 63 16 6.5 Female 
29 62 13 7.6 Male 
34 65 24 8.9 Female 
37 64 22 7.7 Male 
38 74 5 10.5 Female 
44 57 33 11.0 Female 
46 62 13 7.7 Female 
47 65 23 10.9 Female 
50 58 15 9.0 Female 
134 67 2 10.6 Male 
136 70 22 8.5 Male 
142 49 2 13.2 Male 
155 64 2 11.2 Male 
158 49 11 8.4 Male 
161 45 3 12.6 Male 
166 75 29 6.8 Female 
168 63 13 8.3 Male 
HbA1c: glycated hemoglobin. 
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Table B2. Characterization of the case group. 
Exomes in 
study 
Age (years) 
Disease 
duration (years) 
HbA1c (%) Sex 
2 70 23 9.3 Male 
3 70 23 8.1 Female 
4 72 14 11.0 Male 
7 70 33 7.1 Female 
16 74 5 5.2 Male 
17 68 17 8.6 Male 
27 77 19 9.8 Female 
39 65 23 8.5 Male 
45 70 20 9.3 Male 
114 57 15 5.7 Male 
116 67 2 12.6 Male 
123 67 12 7.0 Male 
132 56 2 5.4 Female 
140 75 8 13.5 Female 
149 66 32 12.8 Male 
151 62 17 8.6 Male 
164 67 16 6.2 Female 
HbA1c: glycated hemoglobin. 
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Appendix C 
 
Table C1. Coverage analysis for each exome.  
Exomes in study 
Coverage Analysis metrics 
Mapped Reads 
(number) 
Reads on Target 
(%) 
Mean Depth  
(x) 
Uniformity  
(%) 
2 40,259,514 93.96 111.30 67.52 
3 29,810,924 93.00 75.33 68.34 
4 18,516,510 91.97 46.17 68.69 
7 40,455,509 92.12 107.90 61.78 
16 47,570,535 94.50 138.70 91.87 
17 39,713,195 94.35 115.20 92.34 
21 42,355,561 94.97 124.30 93.21 
22 45,374,642 94.77 132.80 92.92 
23 42,919,052 94.57 123.70 92.99 
27 37,295,987 93.52 105.60 90.32 
29 42,658,040 95.00 124.70 91.93 
34 60,004,978 93.78 168.40 93.10 
37 49,030,450 96.22 152.30 93.68 
38 41,249,229 95.20 120.70 92.38 
39 39,685,963 95.25 116.60 92.36 
44 41,630,753 95.21 121.30 92.87 
45 41,059,571 95.28 119.40 92.79 
46 40,323,607 95.57 118.90 91.95 
47 43,292,335 95.33 127.20 93.30 
50 38,643,370 95.24 110.30 91.92 
114 31,222,625 95.44 83.14 87.90 
116 27,080,919 95.74 72.44 90.33 
123 37,021,319 95.49 99.20 85.67 
132 27,478,730 96.31 80.32 87.55 
134 48,586,140 96.67 152.90 93.65 
136 47,905,254 96.35 149.90 91.88 
140 47,762,220 96.43 150.30 93.00 
142 47,476,003 96.13 147.20 92.19 
149 46,238,152 95.90 144.30 92.79 
151 47,599,369 96.08 147.10 89.40 
155 49,609,805 96.67 148.70 92.07 
158 47,531,704 96.09 140.70 92.26 
161 42,348,690 96.54 132.60 92.41 
164 45,105,472 96.31 139.90 89.62 
166 32,978,117 96.85 103.70 58.15 
168 41,626,664 96.52 130.00 56.66 
 
 157 
 
Table C2. Total of genetic variants by type and number of homozygous and heterozygous for each 
variant type by exome. 
Exomes 
in 
study 
SNP INS DEL MNP 
HM HT Total HM HT Total HM HT Total HM HT Total 
2 14,481 34,946 49,427 405 2,136 2,541 483 2,962 3,445 15 426 441 
3 12,912 34,312 47,224 379 4,224 4,603 476 4,402 4,878 16 422 438 
4 12,754 29,188 41,942 303 1,937 2,240 906 3,431 4,337 13 287 300 
7 14,275 31,840 46,115 471 2,878 3,349 725 2,780 3,505 2 19 21 
16 18,787 29,765 48,552 490 798 1,288 636 1,355 1,991 19 42 61 
17 18,411 30,718 49,129 572 834 1,406 537 1,291 1,828 14 31 45 
21 18,782 29,907 48,689 524 801 1,325 582 1,260 1,842 16 22 38 
22 18,365 30,974 49,339 495 863 1,358 672 1,361 2,033 16 41 57 
23 18,131 31,260 49,391 517 855 1,372 582 1,494 2,076 11 38 49 
27 18,193 30,098 48,291 498 822 1,320 580 1,321 1,901 16 32 48 
29 18,382 30,644 49,026 547 864 1,411 569 1,387 1,956 13 54 67 
34 18,149 31,580 49,729 592 976 1,568 568 1,695 2,263 27 98 125 
37 18,644 31,319 49,963 609 1,033 1,642 520 1,124 1,644 155 354 509 
38 18,732 30,525 49,257 493 794 1,287 683 1,390 2,073 11 34 45 
39 17,946 31,413 49,359 489 770 1,259 615 1,401 2,016 14 28 42 
44 18,349 30,928 49,277 488 842 1,330 547 1,330 1,877 23 32 55 
45 18,550 30,380 48,930 556 916 1,472 549 1,435 1,984 21 59 80 
46 18,182 31,045 49,227 549 858 1,407 536 1,199 1,735 10 47 57 
47 18,478 30,946 49,424 518 799 1,317 629 1,324 1,953 18 41 59 
50 17,979 30,667 48,646 517 907 1,424 516 1,396 1,912 16 53 69 
114 17,052 28,486 45,538 630 1,325 1,955 786 1,763 2,549 87 242 329 
116 16,984 29,006 45,990 639 1,259 1,898 841 1,730 2,571 91 258 349 
123 17,442 28,309 45,751 610 1,284 1,894 861 1,672 2,533 114 228 342 
132 19,237 25,579 44,816 541 872 1,413 515 878 1,393 151 396 547 
134 18,792 31,196 49,988 580 1,002 1,582 478 1,158 1,636 152 368 520 
136 18,851 30,825 49,676 552 969 1,521 535 1,151 1,686 145 359 504 
140 18,712 31,407 50,119 605 1,028 1,633 510 1,124 1,634 144 342 486 
142 18,839 30,744 49,583 593 1,046 1,639 491 1,077 1,568 149 361 510 
149 18,664 31,446 50,110 580 1,033 1,613 512 1,104 1,616 156 351 507 
151 19,996 27,767 47,763 578 926 1,504 547 994 1,541 152 366 518 
155 18,794 31,175 49,969 625 1,005 1,630 488 1,239 1,727 150 410 560 
158 18,469 31,582 50,051 618 1,070 1,688 518 1,135 1,653 157 387 544 
161 18,735 30,747 49,482 568 945 1,513 533 1,159 1,692 148 393 541 
164 18,162 31,706 49,868 582 960 1,542 494 1,150 1,644 144 392 536 
166 13,801 21,241 35,042 387 645 1,032 351 631 982 124 298 422 
168 13,524 21,971 35,495 386 704 1,090 337 668 1,005 125 300 425 
DEL: deletion; HM: homozygouss; HT: heterozygous; INS: insertion; MNP: multiple nucleotide 
polymorphism; SNP: single nucleotide polymorphism.  
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Appendix D 
 
Table D1. List of the filtered common genetic variants obtained in the statistical analysis of the 36 
exomes.  
Gene rs ID Ref. allele Alt. allele Type of variant 
ABCC11 rs61739606 T A Missense 
ACTRT2 rs3795263 G A Missense 
ADAM8 rs3008326 G A Missense 
AIM1L rs11247919 C T Splice 
AMDHD1 rs7955450 A G Missense 
ARHGEF26 rs13096373 T C Missense 
ARPC2 rs10169718 A G Splice 
ASB16-AS1 rs7220138 C G Splice 
ASMTL None T C Splice 
ASTN2 rs72765708 C T Missense 
BACE1 rs490460 C A Splice 
BFAR rs11546303 T G Missense 
C3 rs1047286 G A Missense 
C17orf53 rs227584 A C Missense 
C17orf102 rs58529418 C G Missense 
CCNB1IP1 rs1132644 G T Splice 
CD207 rs10489990 G A Missense 
CDH4 rs6142884 A G Missense 
CEP44 rs4695918 G A Missense 
CEP89 rs10411735 C T Splice 
CKMT2 rs545 G A 3’-UTR 
CLEC7A None A C Stop gained 
CNN2 rs2304260 G A Missense 
COL17A1 rs17116350 T C Missense 
CYBRD1 rs10455 G A Missense 
DENND2A rs2293177, rs386564002 C T Missense 
DHX35 rs3752302 C T Missense 
DNAJB13 rs72982975 G A Missense 
EIF2AK3 rs867529 G C Missense 
EPB41 rs12070152 A G Intron 
ERCC2 
rs13181 T G Missense 
rs1799793 C T Missense 
FAHD1 rs3743853 G A Missense 
FAM86A rs12928528 G C Missense 
FAM179A rs11127202 A G Missense 
FANCI 
rs17803620 C T Missense 
rs2283432 G C Missense 
FBXO39 rs4796555 C T Missense 
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Gene rs ID Ref. allele Alt. allele Type of variant 
FIGLA rs7566476 C G Missense 
GABRR1 rs1186902 T C Missense 
GALNT14 rs2288101, rs386563728 G T Missense 
GGT5 rs762276 G A Missense 
GPR98 
rs2366777 G T Missense 
rs4916684 G A Missense 
rs2247870 G A Missense 
GREB1 rs2304402 G A Missense 
HEATR4 rs8014577 T C Splice 
HNRNPC rs8016099 A C Intron 
IFNL1 rs30461, rs386578910 A G Missense 
IL15 rs2857261 A G Splice 
INMT rs4720015 T G Missense 
IRF6 rs7552506 G C Splice 
ITGA10 rs2274616 G A Missense 
ITIH4 rs13072536 A T Missense 
JSRP1 rs80043033 C G Missense 
KRT3 rs3887954 G C Missense 
KRTAP10-6 rs233303 G T Stop gained 
LAMTOR4 rs3736591 A G Splice 
LDHAL6B rs3825937, rs386587320 T C Missense 
LGALS9 rs361497 G A Missense 
LMO7 rs7986131 T C Missense 
LTBP4 
rs1051303 A G Missense 
rs1131620 A G Missense 
MERTK 
rs7604639 G A Missense 
rs2230515 A G Missense 
MESDC2 rs56314660 G A Intron 
MFSD6 rs386624005, rs9646748 A G Missense 
MLN rs2281820 A G Missense 
MYO16 rs157024 A G Missense 
NACA2 
rs17531723 C T Missense 
rs61739273 G C Missense 
NAV2 rs6483617 G A Missense 
NCKAP5 
rs12611515 C T Missense 
rs12691830 A G Missense 
OBSCN 
rs453140 C T Missense 
rs1188697 G A Missense 
rs11810627 C T Missense 
rs435776 G A Missense 
rs437129 G A Missense 
rs1188710 C G Missense 
OR2T3 rs139993642 C T Missense 
OR4N4 
rs62006710 A G Missense 
rs62006708 G C Missense 
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Gene rs ID Ref. allele Alt. allele Type of variant 
OR7C1 rs73004304 C G Missense 
OR10R2 rs3820678 G A Missense 
OR10V1 rs499033 T C Missense 
OR51F1 rs17324812 T C Missense 
P2RX3 rs2276038 C T Missense 
PBXIP1 rs2061690 C T Missense 
PCGF2 rs1138349 G A Stop gained 
PKHD1L1 rs1673408 C A Missense 
PRSS56 rs2853447 A G Splice 
RAET1E rs9383583 C T Missense 
RAPGEF3 rs2074533 T C Splice 
RP1L1 rs55642448 C T Missense 
RP5-966M1.6 rs2071041 T G Splice 
RPF1 rs2292191 A G Missense 
RPTOR rs2589156 G A Splice 
SEPT9 rs34587622 C T Missense 
SERPINB8 rs3826616 A G Missense 
SIGLEC10 rs9304711 G A Missense 
SLC12A3 rs2304483 T C Splice 
SLC12A7 rs11951420 G A Splice 
SLC22A1 rs628031 A G Missense 
SLCO2A1 rs34550074 C T Missense 
SPHKAP rs16824284 T C Intron 
SRRM2 rs16824284 C A Missense 
STAC 
rs112766131 G A 5’-UTR 
rs113135397 C T 5’-UTR 
STARD3 rs16824284 G A Missense 
SULF2 rs56218501 C T Missense 
SYT6 rs72690087 G T Intron 
TAF4B rs74947492 G C Missense 
TAS1R2 
rs34447754 G C Missense 
rs35874116 T C Missense 
TCOF1 
rs15251 C T Missense 
rs1136103 C G Missense 
TEC rs2271173 G A Splice 
TMC6 rs2613522 A G Splice 
TMPRSS4 rs2276122 A G Splice 
TUBB6 rs11267036 G C Splice 
UBASH3B rs12790613 G A Missense 
UBE3B rs7298565 G A Missense 
UBR4 rs3762396 A G Splice 
UCP2 rs660339 G A Missense 
UNC79 rs4905081 G A Missense 
VANGL1 rs4839469 G A Missense 
 
 161 
 
Gene rs ID Ref. allele Alt. allele Type of variant 
VN1R4 rs112711591, rs74429916 G A Missense 
WDYHV1 rs4416808 T A Splice 
ZFR2 
rs2240231 G A Splice 
rs2240235 G A Missense 
ZMYM5 
rs41292167 T C Missense 
rs9579718 T C Missense 
ZNF419 rs1135692, rs8108040 G C Splice 
ZNF860 rs13087612 T C Missense 
Alt.: altered; Ref.: reference; UTR: untranslated region. 
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Table D2. Impact prediction for the splice region variants in the common variants approach. 
Prediction Tool 
Reference Sequence > Sequence with the variant 
rs2589156  
(RPTOR) 
rs2304483  
(SLC12A3) 
rs10169718  
(ARPC2) 
SplicePort: An 
Interactive Splice Site 
Analysis Tool (161)* 
1.97 > loss of the 
splice region 
0.04 > - 0.17 0.46 > - 0.14 
HSF (162)** 91.61 > 62.66 87.98 > 88.59 65.74 > 65.91 
Analyzer Splice 
Tool*** 
95.04 > 83.12 79.19 > 77.24 
The variant is outside 
of the region 
analyzed by the 
prediction tool 
NNSplice (163)**** 0.99 > 0.89 
The prediction tool 
does not recognize the 
region as a splice 
region 
0.99 > 0.99 
HBond Score Web-
Interface  
(164)***** 
19.90 > 14.70 
The variant is outside 
of the region analyzed 
by the prediction tool 
17.20 > 15.30 
USD SplicePredictor 
Online Service 
(165)****** 
0.99 > 0.94 
The prediction tool 
does not recognize the 
region as a splice 
region 
0.90 > loss of the 
splice region 
*spliceport.cbcb.umd.edu 
**www.umd.be/HSF3/index.html 
***ibis.tau.ac.il/ssat/SpliceSiteFrame.htm 
****www.fruitfly.org/seq_tools/splice.html 
*****www.uni-duesseldorf.de/rna/html/hbond_score.php 
******bioservices.usd.edu/splicepredictor/ 
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Table D3. List of diabetic nephropathy candidate genes and respective genetic variants for 
European type 2 diabetic individuals. 
Gene Genetic variant ID Reference 
ADIPOQ 
rs17300539 
(189) 
rs2241766 
AGER 2184A>G (190) 
APOL2 rs7285167 (191) 
CNDP1 
5-5 leucine repeat, also termed CNDP1 Mannheim (192) 
rs2346061 (193) 
CNDP2 rs7577 (193) 
EPO rs1617640 (194) 
HFE rs1799945 (195) 
HMGA2 rs1531343 (196) 
HSPA1A 
rs1008438 
(197) 
rs1043618 
IL1RN 86 bp variable number tandem repeat polymorphism in intron 2 (198) 
LIMK2 
rs61098917 
(191) 
rs3747154 
MYH9 
rs4821480 
(199) 
rs4281481 
rs2032487 
rs3752462 
NOS3 894G>T (200) 
OR2AK2 rs4478844 (191) 
PLXND1 
rs2285372 
(201) 
rs2301572 
RAET1L rs1543547 (201) 
SOD1 rs1041740 (202) 
TGFB1 869T>C (203) 
UMOD rs13333226 (204) 
bp: base-pairs. 
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Appendix E 
 
Table E1. List of the statistically significant genes accumulating rare variants in the 36 exomes.   
Gene 
Number of rare variants 
accumulated 
Number of individuals with the 
accumulated rare variants 
ABCC6 3 2 
ADAMTS8 3 6 
ADD1 2 2 
AMH 2 2 
ANKAR 2 2 
APOA4 3 3 
APOC4 2 2 
APPBP2 1 2 
ARFGEF2 2 2 
ARHGAP44 2 2 
ASCC2 3 3 
BPG116M5.17 2 4 
BPIFC 2 3 
BRCA2 2 2 
C1orf129 3 3 
C6orf1321 1 2 
C16orf7 1 2 
C17orf64 1 2 
CAST 2 2 
CCDC64B 2 2 
CD93 2 2 
CECR2 5 4 
CELSR1 3 4 
CENPE 2 2 
CERCAM 4 3 
CFB 2 4 
CFH 3 4 
CLCN2 2 2 
CNTNAP5 1 2 
COL6A2 2 2 
CUX1 2 2 
CYP2W1 2 2 
DDX60 1 2 
DENND1C 3 3 
DNAH2 17 13 
DNAI1 5 5 
DOK3 2 2 
DOPEY1 3 4 
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Gene 
Number of rare variants 
accumulated 
Number of individuals with the 
accumulated rare variants 
EYS 3 3 
FAM65A 3 3 
FAM129C 2 2 
FAM160A1 5 4 
FAM193A 4 3 
FBN3 11 12 
FBRSL1 4 5 
FCRL1 3 4 
FUT11 2 2 
GANAB 2 2 
GBGT1 4 4 
GRN 1 2 
GTF2F1 1 2 
HABP2 4 6 
HIRA 1 2 
HOXC6 1 3 
HUWE1 2 2 
IDI2 1 3 
IGSF21 2 2 
ITGA9 2 2 
ITGB7 4 4 
IQCE 2 2 
KCNH5 2 2 
KCNQ5 2 2 
KIAA0195 2 2 
KIAA1244 1 2 
LRRC37A3 4 4 
LTK 3 4 
METRNL 2 2 
MMP25 2 2 
NEU4 3 4 
NFYA 2 2 
NRAP 4 4 
NT5DC2 5 5 
OBP2A 2 2 
OR11A1 3 4 
OSGIN1 3 3 
OTUD7A 2 2 
PAM 2 2 
PARP10 2 2 
PC 2 2 
PDIA2 6 7 
PEG3 5 7 
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Gene 
Number of rare variants 
accumulated 
Number of individuals with the 
accumulated rare variants 
PGBD2 2 1 
PI15 2 2 
PIK3C2A 3 3 
PIK3C2B 3 3 
PKD1 14 12 
PLA1A 2 2 
PLOD2 2 2 
PMS1 2 3 
POLD1 4 5 
PTPN13 4 4 
RAPGEF2 2 2 
RELN 4 5 
REV3L 2 2 
RPL36 1 2 
SDHD 2 2 
SLC22A13 3 3 
SLITRK5 2 2 
SPG7 1 2 
SRD5A1 2 2 
ST7 1 2 
STAB1 9 10 
TANC1 3 3 
TARM1 2 2 
TBCC 2 2 
TCHH 2 2 
TEX14 2 2 
TMC3 3 3 
TMEM43 1 2 
TMEM173 3 3 
TMPRSS7 5 3 
TOP3A 1 3 
TP53I13 2 2 
TXNDC16 3 3 
VPS8 2 2 
VWA5B1 4 4 
WDR25 2 3 
WDR36 3 3 
YLPM1 4 4 
ZNF134 2 2 
ZNF197 2 2 
ZNF208 7 4 
ZNF280B 3 4 
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Gene 
Number of rare variants 
accumulated 
Number of individuals with the 
accumulated rare variants 
ZNF343 2 3 
ZNF407 4 3 
ZNF416 2 2 
ZNF680 1 2 
ZNF844 3 3 
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Table E2. Impact prediction for the splice region variants accumulated in the genes obtained from 
the rare variants approach. 
Prediction Tool 
Reference Sequence > Sequence with the variant 
STAB1 
(rs371042844) 
STAB1 
(rs199636230) 
STAB1 
(rs143836348) 
SplicePort: An 
Interactive Splice 
Site Analysis Tool 
(161)* 
2.38 > 2.54 
The prediction tool 
does not recognize the 
region as a splice 
region 
0.31 > 0.11 
HSF (162)** 
The prediction tool 
does not recognize the 
region as a splice 
region 
85.60 > 77.92 67.90 > 66.05 
Analyzer Splice 
Tool*** 
The variant is outside 
of the region analyzed 
by the prediction tool 
81.48 > 75.89  
The variant is 
outside of the region 
analyzed by the 
prediction tool 
NNSplice (163)**** 1.00 > 0.99 0.57 > 0.69 0.94 > 0.91 
HBond Score Web-
Interface  
(164)***** 
17.10 > 17.10 
The variant is outside 
of the region analyzed 
by the prediction tool 
The variant is 
outside of the region 
analyzed by the 
prediction tool 
USD SplicePredictor 
Online Service 
(165)****** 
1.00 > 1.00 0.86 > 0.92 
The prediction tool 
does not recognize 
the region as a 
splice region 
*spliceport.cbcb.umd.edu 
**www.umd.be/HSF3/index.html 
***ibis.tau.ac.il/ssat/SpliceSiteFrame.htm 
****www.fruitfly.org/seq_tools/splice.html 
*****www.uni-duesseldorf.de/rna/html/hbond_score.php 
******bioservices.usd.edu/splicepredictor/ 
 
 
 
